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Abstract
Tuberculosis (TB) accounts for over 1 million deaths each year, despite
effective treatment regimens being available. Improving the treatment of
TB will require new regimens, each of which will need to be put through
expensive and lengthy clinical trials, with no guarantee of success. The
ability to predict which of many novel regimens to progress through the
clinical trial stages would be an important tool to TB research. as current
models are constrained in their ability to reflect the whole spectrum of
pathophysiology, particularly as there remains uncertainty around the
events that occur.
This thesis explores the use of computational techniques to model a
pulmonary human TB infection. We introduce the first in silico model
of TB occurring over the whole lung that incorporates both the environ-
mental heterogeneity that is exhibited within different spatial regions of
the organ, and the different bacterial dissemination routes, in order to
understand how bacteria move during infection and why post-primary
disease is typically localised towards the apices of the lung.
Our results show that including environmental heterogeneity within
the lung can have profound effects on the results of an infection, by
creating a region towards the apex which is preferential for bacterial
proliferation. We also present a further iteration of the model, whereby
the environment is made more granular to better understand the regions
which are afflicted during infection, and show how sensitivity analysis
can determine the factors that contribute most to disease outcomes.
We show that in order to simulate TB disease within a human lung
with sufficient accuracy, better understanding of the dynamics is required.
The model presented in this thesis is intended to provide insight into
these complicated dynamics, and thus make progress towards an end
goal of a virtual clinical trial, consisting of a heterogeneous population of
synthetic virtual patients.
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1ChapterOneIntroduction
In which the motivation behind the thesis is explored, mechanistic modelling is
discussed and research questions and thesis structure are outlined
1.1 Motivation
This thesis explores the ways in which computational models of disease
can contribute to the understanding of observed pathology, and create
insights to guide future medical exploration and treatment development.
We look at one disease in particular: tuberculosis (TB).
1.1.1 The eradication of TB
TB is a bacterial-based infectious disease. Infection may be naturally
resolved by the host’s immune system but can also be fatal, and TB is
classified by the World Health Organization (WHO) as the leading cause
of death from a single infectious agent, with an estimated 10 million
people contracting TB in 2017 and over 1.4 million deaths being attributed
to the disease [245]. It is estimated that approximately one quarter of the
world’s population is infected with some form of the disease, often in a
latent, asymptomatic form [115]. TB has been present in human societies
for thousands of years [53] and has claimed an incalculable number of
lives. Since the introduction of the first vaccine for TB in the 1920s and
the first anti-tuberculous drug, streptomycin, in the 1940s, TB incidence
has declined rapidly in developed regions such as western Europe, Japan
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and North America [76], to the point where it is often considered, in
those regions, to be eradicated and an ‘ancient’ disease. But this does not
reflect the current global situation, with high prevalence levels occurring
in India, China and sub-Saharan Africa.
The WHO recommends a standard treatment regimen that can be used
to treat drug-susceptible forms of TB, which make up the majority of
cases worldwide [246]. When correctly adhered to, this regimen should
eliminate the bacteria within the patient and thus cure them, which raises
what seems like a fairly obvious question:
If we have an effective treatment regimen that works to cure
TB, why has the disease not been eradicated globally?
The answer is not straightforward. One aspect that contributes to the
continuing global burden of TB prevalence and mortality is adherence.
The standard regimen requires the patient to commit to 6 months of daily
chemotherapy using multiple drugs, all of which have adverse side-effects.
This duration is very long but also necessary - shorter regimens have
been shown to have an unacceptable relapse rate [79]. It is believed that
this long time-frame is necessary in order to kill the entire population of
Mycobacterium tuberculosis (M. tuberculosis) bacteria which cause infection,
as these mycobacteria are better able to withstand chemotherapy due to
them becoming metabolically dormant [142]. The combination of a long
duration and toxic side-effects can contribute to patient non-adherence,
with patients being overwhelmed by the multiple drugs or discouraged
by the negative side-effects from completing treatment [58]. Furthermore,
patients may start to feel better before treatment has concluded and thus
not complete the full regimen as they believe they are completely cured.
Non-adherence has serious implications. At the individual level, failure
to complete treatment may result in some bacteria remaining alive in
the patient, even in the absence of any outward symptoms of infection;
these bacteria then act as a reservoir for future relapse and further dis-
ease. Further compounding this is the phenomenon of drug resistance:
exposure to insufficient quantities of a drug can lead to the remaining
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organisms (i.e. those not destroyed by it) developing resistance to that
drug [89], and some bacteria may become multiple-drug resistant [61,
253]. This emergence of resistance is a danger to the patient as it increases
the chance of relapse and of treatment failure. But, far worse than this,
drug-resistant strains of disease pose a major threat to the global control
of TB [89, 175], as they are harder to treat and require the use of more ex-
pensive and more toxic second-line drugs. Improving patient adherence
is, therefore, of paramount importance but efforts to improve adherence
through direct observation of patients taking medicine have been shown
to have no impact on clinical results [129]. It has been proposed that
rather than trying to force adherence to the standard regimen, it may be
more sensible to make the standard regimen easier to adhere to. This
could possibly be done by reducing the length [64, 253], which would
require new regimens involving different drugs than the current gold
standards.
1.1.2 Creating shorter treatment regimens
Creating new treatment regimens for any disease is a difficult and expens-
ive process. For TB, many new possible regimens exist [253], but these
must all be evaluated in extensive (and costly) clinical trials in order to
prove their effectiveness, with no guarantee of a successful result: three
recent phase III clinical trials, attempting to shorten treatment time to
four months, proved unsuccessful [90, 127, 162].
The ability to predict in advance which of many multiple possible new
regimens is most likely to be successful when put to clinical trial would
be of great benefit to the TB research community. Current models used
to do this are typically either in vitro laboratory experiments and in vivo
animal experiments. These models are key to identifying potentially
useful agents prior to human administration, but it is important to ac-
knowledge that the benefit of these analyses is dependent on how closely
the experimental model approximates the pathophysiological conditions
of human disease: in vitro laboratory models only offer a narrow view
of a single aspect of the complex inter-play of dynamics of bacteria and
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immune cells that occur during infection, and whilst a number of in vivo
animal models exist, including mice, zebrafish and non-human primates
(NHPs) [99], each of these models either does not accurately reflect the
pathophysiology found in humans and/or has ethical concerns [98].
Statistical models of TB are also involved in the clinical trials process,
often predicting individual treatment response based on the rate of bac-
terial clearance in the patient, based on data collected from sputum
samples. Whilst these models are a crucial part of this process, they are
constrained by the data upon which they are built, especially if the data
available are sparse or do not appropriately reflect the full conditions of
the disease. The analytical outputs of TB statistical models have never
been robustly validated as predictors of long-term clinical outcome. For
example, the relationship between sputum culture conversion and final
patient outcome is imperfect and becomes unreliable when looking at
data from individual patients. The REMoxTB phase III trial unsuccess-
fully trialled a new 4-month regimen containing moxifloxacin [90], and
a recent analysis of this demonstrated that there was a small sub-set of
patients who relapsed after treatment even though their sputum samples
rapidly became culture-negative, indicating that the clinical outcome
could not be based solely on this data [189].
It is possible that the M. tuberculosis cells which are critical for defin-
ing patient relapse may not actually be present in the sputum [188]. They
may in fact be sequestered in isolated sites within the lung [122] such as
the closed lesions described by Canetti [30], and thus be undetectable in
sputum samples. Understanding where bacteria reside during infection
is important: recent work has suggested that heterogeneous penetration
by components of drug regimens into pathological TB lesions can result
in insufficient levels of some drugs to reach the minimum inhibitory
concentration (MIC) for bacterial elimination [196]. This may have con-
tributed to relapse in the experimental arms of the REMoxTB trial.
M. tuberculosis can exist in a state where many of its metabolic pro-
cesses are down-regulated and this is often associated with the presence
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of lipid body in the mycobacterial cell [83, 104, 171]. These cells are
postulated as a cause of relapse in treated patients [142, 189] as the
presence of lipid inclusions is associated with a significant increase in
the amount of antibiotic needed to destroy the bacteria, meaning the
they are more likely to survive the treatment process and go on to cause
future relapse [92, 104]. Many possible influencing factors have been
postulated as the driving force behind this switch to ‘dormancy’, but
the exact determinants are uncertain [104, 142]. As current TB statistical
models are typically based only on standard drug susceptibility tests
that measure lipid-poor cells that are phenotypically more susceptible
to antibiotics, they do not account for the whole spectrum of bacterial
phenotypes.
Therefore, in order to build more effective statistical models, we require
mechanisms that capture the biological processes and environmental
conditions within the host which have the greatest influence on disease
progression. Mechanistic models can provide this detail.
1.1.3 Mechanistic modelling of disease
Mechanistic modelling involves the simulation of events as they occur
in the real world, through mathematical or computational means. The
overall system is broken down into constituent parts, each of which is
simulated: the overall system behaviour emerges as a result of the com-
bination of interactions of the individual components. In this manner,
complex systems such as those seen in nature can be achieved through
describing just the simplistic individual events that comprise them [243].
Although these models represent an abstracted view of the complexity
involved in the real-world systems they simulate, they can still provide
insight into those events and parameters which influence important out-
comes. This abstraction affords us the power to describe events even in
cases where laboratory diagnostic tools or treatment monitoring tools are
unable to measure them.
As seen in Figure 1.1, mechanistic model development is typically an
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iterative process [25]. An initial model is created based on a theoretical
description of the underlying real-world dynamics. This model then
enters a period of iterative refinement along with testing against available
data until the model is deemed to adequately describe the data. Once
this has been achieved, the predictions created by the model are then
validated against independent experiments or trials. If the predictions are
validated, the model’s parameters and dynamics may provide important
insights that further our understanding of the real-world phenomena of
the system being studied, advancing our understanding. These advances
can be fed into further models or can direct future experiments or trials
(or both).
Mechanistic models are inexpensive to produce compared to a clinical
trial or in vitro experiment, fast (obtaining results in hours rather than
weeks or years), and easily adaptable to account for new data [98]. Fur-
thermore, the development of the mechanistic model can be as important
to furthering our understanding as the predictive outcomes which the
model provides. Each parameter of the model must have a biological
basis and the process of parameterising these models can identify import-
ant knowledge gaps, thus serving as a guide to direct new research.
In silico models have long been applied to the study of TB, but these have
predominantly focused on the spread of TB epidemics [229]. Whilst these
models are essential in determining effective intervention strategies [111,
140, 170], epidemic modelling alone will not be enough if we wish to
reduce TB mortality worldwide as it only allows the reduction in trans-
mission, not the removal of the source of infection. TB in silico modelling
needs greater focus on the in-host dynamics in order to make the gains
seen within other fields such as cancer research [103]. This is a relatively
new concept for TB and has only recently started to gain momentum (see
[132] for a comprehensive review of in-host TB modelling efforts).
Simulation of within-host TB dynamics could occur at many scales.
Lesional level models simulate the interactions between host and bacteria
on a small-scale, looking at the individual factors that impact the devel-
opment and progression of a single lesion of infection. At a larger scale,
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Figure 1.1: The iterative process of mechanistic model development.
Laboratory experiments provide patient demographic and clinical data,
as well as furthering our understanding of the real-world system. Our
current understanding provides the system dynamics of the model and
quantifiable real-world data provide the parameters. The model may
be refined, and this process of development may highlight any missing
knowledge, which then guides further experiments or trials to collect
the relevant data. Once simulation predictions are obtained, they must
be validated against independent results. If the predictions cannot be
validated, the model must be refined. If predictions are validated, the
dynamics of the model provide insight into the processes driving the
observations and thus furthers our knowledge (adapted with permission
from [25]).
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whole-organ or whole-body models can explore how variance of biology
within and between hosts can impact both the disease and its treatment.
Currently, most mechanistic modelling of in-host TB dynamics has fo-
cused on a lesional scale and has provided valuable insights into the
factors that contribute to individual lesions. However, during an infec-
tion, many lesions can develop in a variety of spatial locations within the
lung. Therefore, larger scale models looking at the whole lung and whole
body are needed, investigating how individual lesions form in specific
locations within the lung and later coalesce to form cavities for bacterial
dissemination between people.
1.2 Research questions
In this work, we seek to answer the following research questions:
• To what extent can we use computational models of whole organ
scale to provide insight into the dynamics that occur during TB
infection within the lungs?
• What environmental factors within the lung contribute to the spe-
cific localisations of TB during different stages of the disease?
1.3 Contributions
This thesis makes the following contributions to the field in order to
answer the research questions in section 1.2:
• A framework for the creation of networked metapopulation models
which incorporate environmental heterogeneity
• A whole organ model of a pulmonary TB infection that incorpor-
ates the environmental heterogeneity found within the lung to
determine the role it plays upon disease progression
• A software framework to efficiently perform sensitivity and uncer-
tainty analysis
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• Insight into biological factors that contribute to TB progression
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population software model applied to the simulation of a pulmon-
ary tuberculosis infection’. In: Applied Network Science 3.1 (Dec.
2018), p. 33. issn: 2364-8228. doi: 10.1007/s41109-018-0091-
2 (comprised of the work detailed in Chapters 3 and 4)
The following publication is in pre-print:
• M. J. Pitcher et al. ‘Modelling the effects of environmental hetero-
geneity within the lung on the tuberculosis life-cycle’. In: bioRxiv
(2019). doi: 10.1101/2019.12.12.871269
1.5 Thesis structure
This thesis is structured as follows:
• Chapter 2 provides an overview of the biology, pathology, immuno-
logy and therapeutics of TB which are relevant to this thesis, paying
particular attention to the distinct localisations that occur during
different stages of TB infection.
• Chapter 3 describes the development of a framework for the creation
of networked metapopulation models. This framework allows for a
network of connected patched with heterogeneous environmental
attributes to be created, along with a systems of dynamics that
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occur at different rates depending on these attributes. This chapter
also details the verification tests performed to ensure accuracy of
the system.
• Chapter 4 describes the creation of a whole-lung model of TB,
TBMetapopPy, using the framework of the previous chapter, that
incorporates the environmental heterogeneity within the lung that
is believed to contribute to the distinct apical localisation during
post-primary disease. Here, we present the results of our initial
simulations to show how differentials in environment within the
lung can lead to the creation of regions of preferential bacterial
growth.
• Chapter 5 details the creation of a secondary iteration of the TB-
MetapopPy model that incorporates a more granular network. This
chapter describes the development of a space-filling tree algorithm
used to create a network with a much greater number of patches,
which is then combined with the known lung heterogeneities to
create a new, granular landscape where differentials are based
on vertical position. This model is extended to also include post-
primary dynamics, thus making it whole life-cycle model of TB.
Here, present our results from this model, showing how environ-
mental conditions affect the disease at all stages of the life-cycle.
• Chapter 6 explores the concepts of uncertainty and sensitivity ana-
lysis as used for mathematical and computational models. It de-
scribes the creation of a framework designed to allow for easy
computation of the parameter samples required for these analyses,
as well as the automatic model evaluation using these samples in
parallel on a remote compute cluster. It presents the results of
sensitivity analyses run against the TBMetapopPy model, showing
how uncertainty in the model outcomes can be attribute to specific
model parameters.
• Chapter 7 summarises the content of the thesis, and describes how
the contributions made by this work answer our research questions.
10
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We also outline the limitations, both in terms of mechanistic mod-
elling in general and those specific to our work. It also proposes
avenues of possible future research arising from the work presented
here.
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2Chapter TwoBackground ontuberculosis
In which we review the history of tuberculosis, the pathology of the disease
(paying particular attention to the differences in localisation during disease
stages), and its treatment
2.1 History of TB
TB is an ancient disease, also known throughout history as ’pthisis’ and
’consumption’ (due to the disease seeming to ’consume’ the host from
the inside). A progenitor to the bacteria that currently cause infection has
been shown to have existed over 3 million years ago [100]. There is evid-
ence of TB infection stretching back to ancient Egypt (around 1550–1080
BC) [178], and it is believed to have been spread to the Americas over
10,000 years ago with migration from Asia, many years before colonisa-
tion by European explorers [54]. Like many other infectious diseases,
TB incidence has surged and then receded in a repeating cycle, albeit
with time scales much larger than other diseases [53], on the scale of one
hundred to several hundred years [21].
By the 1800s, TB had reached epidemic proportions throughout Europe
and America. It was during this century that the pathology was first
described by René Laennec in 1819, whilst Robert Koch first identified
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and described the bacteria causing TB in 1881. Increased scientific study
and advancements in medicine and public health systems lead to major
progress in fighting the disease and a general reduction of TB incidence in
Europe throughout the 20th century, albeit with a sharp increase during
the First World War. In 1921, the Bacillus Calmette–Guérin (BCG) vaccine
was first trialled on humans, with the vaccine successfully conferring im-
munity to TB on child recipients. In 1943, streptomycin, the first anti-TB
drug, was discovered and further drugs were developed in the following
years.
In the twentieth century, the number of cases and deaths rapidly de-
clined in most developed countries, including western Europe, Japan
and North America [76], caused by the introduction of new treatments
and preventions and a range of complex social and economic changes
[95]. However, incidence and mortality have not seen such declines in
less-developed countries.
2.2 Current epidemiology and global burden
of TB
Despite effective treatments having existed for decades, TB still remains
a global health threat today. In 2017, an estimated 10 million people
contracted TB, with over 1 million deaths being attributed to the disease
[245]. It is estimated that approximately one quarter of the world’s popu-
lation is infected with the disease in a latent form [115].
The distribution of the disease worldwide is uneven, with far greater
prevalence in developing countries than in developed countries. Over
half of all new cases of TB in 2017 occurred in just five countries (Figure
2.1), while India alone accounted for more than a quarter of the global
incidence. Figures 2.2 and 2.3 show the incidence and mortality, respect-
ively, of TB per 100,000 members of the population for every country in
2017. Sub-Saharan Africa and south-east Asia show significantly higher
incidence densities than the rest of the world, while sub-Saharan Africa
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has a higher rate of mortality per population. There are many sociopol-
itical causes of this uneven distribution, including poverty levels and
human immunodeficiency virus (HIV) rates [43].
Figure 2.1: Distribution of global incidence of TB in 2017 (top 5 countries
with highest values listed). Data taken from [239]
Figure 2.2: Estimated incidence of TB per 100,000 population, by country
in 2017. Data taken from [239].
Approximately 9% of the incident TB cases in 2017 came from those co-
infected with HIV, with African countries having the highest proportion,
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Figure 2.3: Estimated mortality of TB cases (all forms) per 100,000 popu-
lation by country in 2017. Data taken from [239].
exceeding 50% in parts of southern Africa. The risk of developing TB for
those already infected HIV was roughly 20 times greater than the risk
for those without HIV [245]. Figure 2.4 shows the positive correlation
between HIV rates per population and TB incidence rates per population
for 2017, with higher prevalence of HIV resulting in an increase in the
number of new cases of TB.
2.3 Cause
TB disease can be found in both humans and animals, and is caused
by mycobacteria from the Mycobacterium tuberculosis complex. Members
of this complex include M. tuberculosis, which causes TB exclusively in
humans, Mycobacterium bovis (M. bovis), which can infect humans as well
as animals such as cattle and badgers, and Mycobacterium africanum (M.
africanum), a less virulent bacterium similar to M. tuberculosis [69]. Myco-
bacteria are slender, non-motile bacteria and are often highly resistant to
antibiotics due to their unusual cell structure and the low permeability
of their cell walls [27].
M. tuberculosis, the major cause of TB in humans, is a relatively-slow
growing bacterium, with a replication rate of at least 12 hours (for com-
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Figure 2.4: HIV cases per 100k population plotted against TB incidence
per 100k for year 2017 for every country where HIV data exists. Red line
is linear regression performed on data sets (p=1.142e-13). TB data taken
from [239], HIV data taken from [238].
parison, Staphylococcus aureus has a doubling time of around 42 minutes).
M. tuberculosis are believed to be able to enter a ’dormant’ state, associ-
ated with the presence of lipid bodies accumulated by the bacteria [104],
whereby they reduce their metabolic activity (lowering their replication
rate) and become increasingly resistant to antimicrobial agents [142]. Bac-
teria in this state can survive within the host for decades [44]. It has been
shown that a ’dormant’ state can be achieved in a laboratory setting by
subjecting the bacteria to stresses such as hypoxia [232] (M. tuberculosis
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is an aerobic bacteria and thus requires oxygen in order to replicate),
nutrient deficiency [144], acidity [216], and antibiotics [117].
2.4 Transmission and initial infection
TB is transmitted between humans primarily through the inhalation of
bacteria expelled from the lungs of an infectious individual, although
TB can be zoonotic and M. bovis strains may be contracted through
consumption of unpasteurised cow’s milk [50]. Infection can be spread
from an infectious person through coughing, talking or other vocal
actions, which generate aerosols containing droplets to be expelled from
the lower respiratory tract. These droplets are of such a size that they
may be immediately respired by other individuals in close proximity,
and each droplet may contain bacteria [74], with only a small number of
bacteria needing to be inhaled to initiate an infection [33]. Once inhaled,
the bacteria pass through the lower respiratory tract eventually landing
in the alveoli, where they attempt to establish an infection.
2.5 Disease life-cycle and clinical disease
expressions
Once TB infection begins within the lungs, a long series of complex inter-
actions occur between the invading bacteria and the host immune system.
Figure 2.5 shows an overview of the TB life-cycle within an individual.
Initial exposure is either naturally cleared by the host’s defence system
or an infection is established within the lung. In approximately 10% of
those infected [2], the immune system is incapable of suppressing the
bacteria and the infection develops and causes active disease. This is
known as ’primary TB’ as it originates from the initial infection.
In the majority of cases, the protective immune response is sufficient to
keep the infection contained. In a further 10% of cases [2], this eradic-
ates the bacteria from the lungs, but most of those infected will instead
become latently infected - whereby the infection remains in the body
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Exposure
Clearance Infection
Limited
bacterial
growth
Bacteria
eliminated
10%
Latent TB
Clearance Post-
primary TB
5-15%
90%
90%
Primary TB
10%
Figure 2.5: Overview of the clinical outcomes of tuberculosis infection.
Adapted from [2], values from [2, 245]. Red boxes indicate active, symp-
tomatic infection.
asymptomatically, neither being eradicated nor causing damage and be-
coming capable of transmission. This period of latency can last for years
or decades. Latent infection poses the risk of future active disease, with
around 5 to 15% of those latently infected going on to develop active
disease in the form of ’post-primary’ infection. The exact causes for this
re-emergence of disease remain controversial, occurring either due to
endogenous re-activation (as the immune system becomes compromised
due to old age or co-infection) or due to exogenous re-infection (see
section 2.5.4).
Here, we overview the main clinical disease expressions of a TB infection.
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2.5.1 Clearance
In rare cases, the innate immune response is strong enough, and the
bacterial load is small enough, to completely eradicate infection before an
adaptive immune response is established. The evidence that a clearance
scenario exists comes from studies that show close exposure to infectious
patients does not always lead to a positive tuberculin skin test (TST),
indicating that an adaptive immune response has not been triggered, and
thus it can be assumed that the immune system has cleared the infection
without need of an advanced immune response. [227].
2.5.2 Primary TB
In a small number of cases (approximately 10% [2]) where an infection
is established, the immune system is unable to contain the infection
and the bacteria present are able to overwhelm the immune cells and
cause tissue damage. As progression of TB is heavily dependent on
the host immunity, any condition that causes the immune system to
become compromised (such as HIV) increases the risk of primary TB
[165]. This explains the correlation seen in Figure 2.4, with greater HIV
rates increasing the incidence of TB.
2.5.3 Latent TB
In the majority of cases of those infected with M. tuberculosis (approx-
imately 90% [2]), the immune system is strong enough to contain, but
not eradicate the bacteria, within the granulomas, and thus latent TB is
established. Latent TB was defined by Amberson as "the presence of any
tuberculous lesion which fails to produce symptoms of its presence" [8].
The definition of latent TB relies solely on the basis of lack of evidence
of clinical symptoms, and as such may actually cover a wide variety of
patients with differing internal conditions, none of whom display any
outward effects of infection [14]. Bacteria within the patient may have
entered a dormant phase and thus have reduced replication, or they may
be actively replicating but kept at sub-clinical levels. Therefore, latency
may be viewed as a ’spectrum’ [251].
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The classical view of TB pathology is that primary infection typically re-
solves to latency, with the bacteria numbers contained but not eradicated,
and with the initial lesion releasing small numbers of bacteria that are
disseminated across the lung via the bronchial tree and the bloodstream,
eventually seeding other lesions in the lung [34] (see section 2.8 for more
detail on the means of dissemination). This state persists for years or
decades, with the bacteria present in the body acting as a reservoir for
possible future disease in the form of post-primary TB.
2.5.4 Post-primary TB
Post-primary, or ‘secondary’, TB accounts for 80% of all clinical TB dis-
ease and almost 100% of disease transmission [121]. It can be classified
as any form of TB disease that arises after a state of immunity has been
established from the initial infection [124]. Thus, post-primary TB must
always follow latency.
There are believed to be two routes through which this can occur [13, 69]:
• Reactivation - where infection occurs endogenously, through the
reactivation of dormant disease in the lung originating from the
initial infection
• Reinfection - where infection occurs exogenously, through the in-
halation of new bacteria into the lung
There remains controversy around which of these two causes accounts
for the majority of post-primary TB incidence [201].
2.6 Pathogenesis
In this section, we detail the bacteriological, immunological and patholo-
gical processes that contribute to the clinical disease expressions outlined
above.
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2.6.1 Innate and adaptive immune responses
Within the lung, multiple immune cells are present to detect and remove
foreign bodies that may interfere with the lung function. The main bulk
of these are macrophages, phagocytes which act as sentries: patrolling
the environment and ingesting and destroying any invading entities they
encounter. When a particle is ingested, it is stored inside the macrophage
in a phagosome, a vacuole within the macrophage cell membrane. The
macrophage also contains a lysosome, an organelle containing degradat-
ive enzymes. During normal function, these two chambers are merged
together into a single one called a phagolysosome, exposing any material
in the phagosome to the destructive enzymes of the lysosome and thus
destroying the material. Whilst M. tuberculosis are ingested in this man-
ner, the bacterium has evolved a number of mechanisms to counter its
destruction within the macrophage, including prevention of the phago-
some–lysosome fusion [161]. By doing so, the bacteria remain present
within the macrophage, absorbing nutrients such as iron directly from
the immune cell [47], and they begin replicating intracellularly. Excessive
replication within the macrophage can cause the immune cell to rupture
or ’burst’, destroying the cell and releasing its interior bacterial load back
into the extracellular space [62], thus allowing for a new cycle of cell
infection. Further macrophages are recruited to the site of infection in
response to cytokines given off by infected and activated cells there [93].
Rather than allow the bacteria to proliferate within the cell and eventually
cause necrosis, the body can trigger apoptosis: the programmed death of
the cell [7]. The cell is ordered to destroy itself in an organised manner
[136], which is believed to destroy some or all of the intracellular bacteria,
as apoptosis of macrophages is associated with a reduction in bacillary
viability [183]. Macrophages can also become ’activated’ in response to
signals from their local environment, with a wide spectrum of possible
triggers contributing to this [169]. Activation increases the bactericidal
functions of macrophages, allowing them to successfully destroy M. tuber-
culosis bacteria.
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Dendritic cells (DCs) also reside in the lung, and these cells also phago-
cytose bacteria, although they are even less proficient at mycobacterial
destruction than macrophages [22]. Instead, the purpose of these cells is
to act as a signal to initiate an adaptive immune response [12]. DCs that
come into contact with bacteria may maturate, either through contact
with antigens (molecules derived from the bacteria) released by necrotic
cells or bacteria, or via ingestion of whole bacteria [119]. These cells then
migrate from the lung tissue to the adjacent lymph nodes [226] - it has
also been shown that macrophages may perform the same migratory
function [130].
At the lymph nodes, these antigen-presenting cells (APCs) function by
presenting antigens on their surface. Naïve T cells survey these APCs and
recognise the presented antigens, which cause the T cells to be primed
and convert into an activated state [23]. Once activated, these T cells
may migrate back to the lungs, using chemokine signals and homing
pathways in order to determine which tissues to migrate towards [9].
There are wide variety of T cells, each of which performs different func-
tions at the site of infection, including activation of resting macrophages
and enhancing apoptosis of infected ones. The end result of this is the
creation of a cell-mediated immune response, with increased immune
activity in the lung intending to suppress infection before it can cause
tissue damage. This adaptive immune response takes around 5 to 6
weeks to be initiated, a much longer time-frame than other microbial
diseases, possibly caused by M. tuberculosis inhibiting the ability of DCs
to migrate to the lymph nodes [202].
2.6.2 The granuloma
At the sites of infection, the cell-mediated immune response results in
the formation of structures known as granulomas - organised, dynamic
arrangements of immune cells designed to contain infection [98] (see
Figure 2.6). Infected macrophages compose the centre of the granuloma,
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and these are surrounded by layers of infected cells and then non-infected
cells and lymphocytes such as T cells. Granulomas consist of a wide
variety of cells and are thus extremely heterogeneous [231]. In some
cases, the centre of the granuloma may contain a cheese-like substance
known as caseum, formed from the necrosis of infected immune cells.
The initial lesion formed by TB infection is known as the ‘Ghon focus’,
with a combination of this lesion and an infected lymph node known
as the ‘Ghon complex’. Whilst it is believed granulomas are a necessity
for the host to constrain infection, it is also possible that these structures
are actually beneficial for the bacteria, allowing them to persist for long
periods of time [204, 217]. The granulomas involved in latent TB often
Figure 2.6: Diagram of a granuloma (from [199])
become fibrous in nature, with a fibrotic cuff surrounding the cells and
physically isolating infected tissue to prevent disease spread [231]. The
exact processes that follow remain controversial. In many cases, the
caseum that makes up the centre of the lesion begins to calcify [38]. The
majority of these calcified lesions destroy any bacteria contained within
them [31].
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2.7 Differences between primary and
post-primary disease
Whilst a number of contemporary sources view primary and post-primary
forms of TB as being similar, grouping them together under a simple label
of ’active’ disease, it is important for our purposes to make the distinction
between the two, as each has differing manifestations of pathophysiology,
immunology and localisation.
2.7.1 Differences in localisation
A classical paradigm of TB pathogenesis [29] is that primary infection
forms a granuloma that caseates but stabilises, and this granuloma then
remains in a quiescent state, holding the bacteria at bay until a weakening
of the immune system (e.g. through old-age or contraction of HIV) causes
the structure to break down, releasing bacteria and thus allowing them to
replicate, causing post-primary TB. This would suggest that both forms
of TB occur at the same location. But there is a wealth of evidence to
contradict this.
Primary lesions are found in the lower regions of the lung and the
surrounding lymph nodes. Post-primary TB is always associated with
cavitation [30], and these cavities are found within the apical regions of
the lung [20, 67, 122]. This suggests that if primary and post-primary
disease originate from a granuloma, then these entry and exit granulomas
must be distinct as they occur in different regions of the lung. This would
imply a dissemination event - whereby some of the bacteria that make
up the initial infection are able to migrate from the lower regions to the
apex in order to establish an infection in that location [11].
2.7.2 Differences in pathophysiology
Cavity formation is an important event in the TB life-cycle as the presence
of cavities within the lung of the host greatly increases the chances of
transmission to another person [250]. The general consensus within the
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literature on cavitary TB is that a cavity arises when the caseous necrosis
present in the centre of a TB granuloma (originating from the death
of immune cells and destruction of surrounding tissue) enlarges and
liquefies [35, 55–57, 106, 137, 250]. This liquefied caseum then empties
out of the alveoli space, leaving behind an empty region. In this region,
remaining bacteria are able to replicate in great numbers, possibly due
to the sudden increase in availability of oxygen, as the cavity is in direct
communication with the bronchial tree [96]. Bacteria are believed to be
able replicate much better in liquefied caseum [96, 250], and coughing
may distribute this bacteria-laden liquid caseum into other regions of the
lung, or out of the body and into the air, to be inhaled by other people
and transmit TB infection. However, there is evidence to suggest that the
pathophysiology of post-primary TB differs significantly from primary
TB. Whilst the caseating granuloma is a hallmark of primary TB, the
classical paradigm that cavities are formed from a caseating granuloma
eroding into an airway has been challenged [120–124, 159], due to evid-
ence from the pre-antibiotic era where necropsies of post-primary TB
patients displayed pneumonia [160].
Regardless of the actual events that occur during post-primary TB, the
difference in localisation during primary and post-primary stages raises
important questions relating to TB pathogenesis viewed over the whole
of the lung:
• Assuming all bacteria land in the basal regions initially, how do
bacteria disseminate across the lung from their initial location at
the basal lung regions to establish post-primary infection at apical
lung regions?
• Why is post-primary disease confined to the apex of the lung? What
heterogeneous factors of anatomy occur within the lung to create a
region at the apex that is preferential for TB proliferation?
These two questions are addressed in the following two Sections, 2.8 and
2.9, respectively.
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2.8 Bacterial dissemination
Dissemination of M. tuberculosis bacteria can occur through a variety of
methods [195], including:
• Local progression
• Lymphogenous progression
• Lymphohaematogenous progression
• Bronchogenic progression
• Haematogenous progression
Local progression occurs when TB disease expands directly through
tissue [195]. This can occur through the creation of cavities or when
neighbouring lesions expand and coalesce [38].
Primary TB infections often include a secondary infectious focus within
the lymphatic system [15, 16]. Thus, it is assumed that bacteria are able
to disseminate from the primary lung focus to the regional lymph nodes
via the lymphatics [42]. The formation of the adaptive immune response
necessary to contain pulmonary infections requires migration of immune
cells from the primary focus in the lung to regional lymph nodes (Section
2.6.1). But doing so provides a route of dissemination for lung pathogens:
as APCs migrate to the lymph nodes, they also traffic with them any
pathogens that remain alive inside them [130].
The lymphatic system has multiple important functions within the hu-
man body, including the reclamation of blood plasma, blood filtration
and initiating an adaptive immune response. It is a one-way system, with
two terminal ducts: the right thoracic duct drains the right arm, upper
right torso and head, while the thoracic duct drains the remainder of
the body. These ducts empty into the right and left subclavian veins,
respectively [66]. Doing so allows any immune cells produced by the
lymphatic system to enter the bloodstream and reach their intended
targets.
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Therefore, by being transported to the lymphatic system, M. tuberculosis
is provided with access to the bloodstream. The blood in the subclavian
veins is deoxygenated, and is sent (via the heart) back into the lungs
to be re-oxygenated before returning first to the heart and then to the
remainder of the body. Any bacteria that pass through the entirety of
the lymphatic system enter this blood and are sent back to the lungs,
allowing for re-seeding in previously uninfected areas, or may infect the
rest of the body. In the lung, lesions formed by this spread are termed
‘Simon’ foci [195].
Bronchogenic progression occurs when a TB lesion erodes into an airway,
usually into a bronchus but also into the trachea. Soft caseous material
expelled from the lesion is usually removed from the lungs as sputum
by coughing, but some of this material may be aspirated and thus seed a
new part of the lung. In this case, the new lesions that are formed are
usually clustered together and may be of varying sizes [195].
Not to be confused with lymphohaematogeneous progression, haemato-
genous progression occurs when a lesion within the lung erodes directly
into the bloodstream [195]. This allows for a larger number of bacteria to
be disseminated through the blood to all areas of the body, and the term
‘miliary’ TB1 is used to define all forms of haematogenous spreading of
TB [163]. Cases where the bacteria establish infection in organs other
than the lungs are defined as ‘extrapulmonary’ TB. This is not contagious,
unless the person also has pulmonary infection or the disease has spread
to the oral cavity [41].
2.9 Impact of physiology on TB
TB pathology occurs in different regions of the lung during different
stages, and it is important to note that the physiology of the lung is not
homogeneous within an individual. All human lungs display significant
1The term ‘miliary’ derives from the resemblance of the lesions to millet seeds
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heterogeneity throughout, in the form of size, shape and function.
2.9.1 Ventilation
The main purpose of the lungs is oxygen exchange: air is breathed in
and passes through the trachea and bronchi and eventually reaches the
alveoli, where the oxygen in the air is exchanged for carbon dioxide
released from the blood, which is then exhaled. The delivery of the air to
the bronchi is heterogeneous: more air is delivered to the lower regions
of the lung than to the apices, due to factors such as gravity [236] and
asymmetrical branching anatomy [81] (see Figure 2.7, blue line).
Figure 2.7: Distribution of ventilation (V) and perfusion (Q) in the lung,
and differential in ventilation-perfusion ratio (V/Q). Both V and Q are
higher at the base than the apex, but the differential in Q is much greater
than the differential in V, resulting in a V/Q imbalance, such that V/Q is
much higher at the apex than the base (taken from [237]).
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Differentials in ventilation impact on TB pathology, particularly in its
conception: a greater distribution of air towards the lower regions results
in a greater deposition of inhaled particles at those regions. This explains
the propensity for primary TB to occur towards the base of the lung, as
this is the region where more of the aerosols containing M. tuberculosis
bacteria land when breathed in.
2.9.2 Perfusion
Oxygen exchange requires de-oxygenated blood to be supplied to the
lungs, and similarly to ventilation (Section 2.9.1), this supply of blood (of-
ten labelled as ’perfusion’) also varies in the lung, with greater perfusion
occurring at the lower regions than the apices. This occurs due to gravity
[166], hydrostatic pressure differences [234] and anatomical effects [81]
(see Figure 2.7, green line).
The rate of blood flowing to a region of the lung impacts on the body’s
ability to establish an efficient immune response there, as immune cells
are recruited to sites of infection through the blood. This may explain,
in some part, the apical localisation of post-primary TB: at the apices,
the perfusion rate is at its lowest and thus the immune response there
is expected to be lower than in other regions. Therefore, M. tuberculosis
bacteria may favour the apex due to the lack of intervention from the
immune system restricting bacterial growth.
2.9.3 Oxygen tension
Oxygen exchange within the body is imperfect due to the differences in
scales between ventilation and perfusion (see Figure 2.7). Both ventilation
and perfusion exhibit linear differential scales whereby they increase
travelling down the lung, but the scale of increase is much higher for
perfusion than for ventilation. Thus the apex of the lung has almost no
perfusion, whilst the base of the lung is over-perfused. The result of this
is that although more air is sent to the base of the lung, all oxygen within
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the air there is transferred to the blood; whilst at the apex of the lung,
the lack of perfusion means that some oxygen remains in the air before it
is exhaled. Air that is inhaled but does not take part in oxygen exchange
is termed ’alveolar dead space’. The physiology creates a differential in
oxygen tension: the apex of the lung has a high oxygen tension whilst
the basal regions have low values.
As noted in Section 2.3, M. tuberculosis is aerobic, and thus the high
oxygen tension at the apex may make it a preferential environment for
the bacteria, allowing them the oxygen they require to replicate excess-
ively. The high oxygen tension at the apex is often cited as the cause of
post-primary TB localisation at the apex, although the reality may be a
combination of this and other factors.
2.9.4 Drainage
The drainage of immune cells from the lung tissue to the lymphatics is an
important part of fighting an infection, both enabling the activation of an
adaptive immune response, and clearing the lung tissue of pathogens and
transporting them to the lymph nodes, where an abundance of lympho-
cytes allows easier destruction of the pathogen. During breathing, the
lung expands and contracts, and this movement acts as a pump to push
immune cells into the lymphatics. The movement is different throughout
the lung, with the uppermost ribs moving the least and thus creating less
drainage than at the lower regions [94].
This drainage differential could also impact TB progression, with the
inability of the body to sufficiently drain cells at the apex possibly con-
tributing to the accumulation of infection there.
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Drug Properties Months
Isoniazid (H) • Highly bactericidal against
replicating bacteria
1-6
Rifampicin (R) • Bactericidal against bacteria in
both intracellular and extracellu-
lar locations
1-6
• Greater sterilising potency
against dormant bacteria than
isoniazid
Pyrazinamide (Z) • Potent sterilisation effect at
high pH locations
1-2
Ethambutol (E) • Works synergistically with
other drugs to delay or prevent
emergence of drug resistance
1-2
Table 2.1: First line drugs used for TB treatment, showing properties and
their usage in particular months of the standard regimen [3, 244, 246,
249].
2.10 Treatment
2.10.1 Current treatment
Treatment of active TB typically requires multiple antibiotics over a
sustained period of time. The WHO recommends a variety of regimens
depending on the status of the patient. For patients with known drug-
susceptible strains of the disease who have not received prior treatment, a
standard regimen of 6 months is recommended, known as 2HRZE/4HR
[246]. This requires an initial 2 month intensive period consisting of
4 drugs taken simultaneously on a daily basis, followed by a 4 month
sterilising period of 2 drugs. The initial intensive phase is designed
to destroy all bacteria that are in a replicating phenotype, whilst the
sterilising phase eradicates any bacteria that are dormant (and thus more
resistant). Table 2.1 lists all drugs used in the standard regimen, their
individual purposes and their months they are prescribed for. Different
regimens are recommended for other forms of disease, including latency
[252] and patients with antibiotic resistance [84].
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2.10.2 Antibiotic resistance
One of the major threats to global control of TB is the emergence of
drug resistance [175]. This phenomenon is caused by mutation of the
bacteria during cell division [89], and was discovered in M. tuberculosis
shortly after the discovery of the first anti-TB drug, streptomycin [52].
Combination therapy (the use of more than one antibiotic in the treatment
regimen) was subsequently shown to prevent resistance emerging [89].
Drug-resistant strains of TB are classified by the drugs that they are
resistant to. Strains that are resistant to both isoniazid and rifampicin
are classified as Multidrug-resistant tuberculosis (MDR-TB) [186]. The
emergence of MDR-TB has serious implications, as these two drugs make
up the continuation phase of the standard treatment regimen. Resist-
ance to either one of these can be combatted by extending the standard
regimen and using other standard first-line drugs (Table 2.1), but resist-
ance to both requires the use of more toxic second-line drugs, such as
fluoroquinolones [186]. Further resistance to second-line drugs has even
greater consequences. Extensively drug-resistant tuberculosis (XDR-TB)
is classified as resistance of the bacteria to at least isoniazid, rifampicin,
any fluoroquinolone, and at least one of three injectable second-line drugs
[126].
2.10.3 New treatments
Delivering a clinical trial of a new treatment, for any disease, is a long
and complicated process with no guarantee of success. The trials take
a long time to complete, involving lengthy time periods between treat-
ment and follow-up [184]. This is particularly the case in TB, where the
slow-growing and resistant nature of the M. tuberculosis bacillus requires
a lengthy treatment phase. Furthermore, in order to make any significant
conclusions trials require large sample sizes of patients. The total cost of
running a clinical trial can be very high, reaching up to USD$600 million
[70]. One form of clinical trial that is gaining more momentum with
TB research is non-inferiority trials. These typically involve a trade-off,
a new regimen is trialled which, whilst perhaps less efficacious than
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the current standard, has other benefits, perhaps in duration or less
side-effects [220]. A new regimen can be implemented if it is shown
to be as effective (i.e. not inferior) or better than the current standard
regimen, based on some pre-defined metric and margin of non-inferiority.
The standard regimen for TB requires patients to take daily doses of
chemotherapeutic drugs for a period of 6 months. This can be difficult
for patients to adhere to [5, 253], and non-adherence can have serious com-
plications, both for the patient (due to relapse) and the wider community
(due to the risk of antibiotic resistance emerging). Thus shortening the
duration of treatment regimens is seen as a priority, as a regimen of, for
example, 4 months is expected to improve patient adherence and lower
costs [90]. To this end, regimens utilising drugs outside of the current
gold standard have been trialled, aiming to show a shorter regimen is
non-inferior to the current standard. Moxifloxacin is a drug with prom-
ising bactericidal activity against M. tuberculosis in in vitro studies, and
this drug was used in clinical trials (REMoxTB) to test whether utilising
it in place of one of the current standard drugs could reduce treatment
time to 4 months. The trials were unable to prove non-inferiority [90],
possibly due to the inability of the drug to penetrate into caseum within
lesions [196].
The drug development process for TB is thus long and complex and
in dire need of streamlining [180]. Whilst changes could be made to
improve the quality of non-inferiority test end-points and margins [184],
these changes will only be able to improve the quality of results of regi-
mens put to trial: they will not be able to mitigate against the risk that
the regimen will not be successful. One way to make improvements in
the length of the drug development process would be to improve the
prioritisation mechanisms by which regimens are chosen.
Consider the drug development process shown in Figure 2.8. A novel
treatment regimen is conceptualised, and then experiments (typically
in vitro lab experiments or in vivo animal experiments) can be used to
determine the likelihood of success. The regimen can be put to trial, and
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Figure 2.8: The drug development process
if the trial is successful, approval can be granted and the drug can be
administered to patients globally. One of the key bottlenecks here is the
experimentation stage - the lack of a suitable animal model that accur-
ately reflects human pathophysiology hinders the predictive capability
at this stage. Therefore, improvements at the experimental stage could
lead to better predictions and thus reduce the risk that an expensive
development stage producing a negative result.
2.11 Conclusion
In this chapter, we have outlined some of the major elements concerning
TB, including the history, transmission, immunology, pathology and
treatment of the disease. In particular, we have explained how different
stages of the disease have distinct localisations within the lung, and
have outlined the biological factors which are believed to contribute to
these. We have explained how the standard treatment regimen is long
and difficult to adhere to, and how efforts to reduce this treatment time
have been unsuccessful. We have described the inherent costs in terms
of time and money associated with clinical trials, and have shown how
improvement in the discovery stage with regard to make predictions
over the likelihood of efficacy of a new regimen could reduce these costs.
In the next chapter, we look at how in silico models could contribute in
terms of improving predictions at the discovery stage.
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3Chapter ThreeNetworkedmetapopulationframework
In which we provide an overview of concepts relating to metapopulation and
mechanistic modelling, present MetapopPy, a framework for creating networked
metapopulation models with heterogeneous environments, and detail our
verification testing of it against published models.
3.1 Introduction
As discussed in the previous chapter, TB pathology within the human
lung involves a complex series of dynamics and interactions. The envir-
onmental heterogeneity present within the lung is believed to impact on
the distinct localisations seen during different stages of infection, but the
exact contributions it has on disease progression are poorly understood.
Mechanistic modelling of real-world process can allow us to explore the
dynamics of a system, helping us to shed light on these complexities and
improve our knowledge, thus guiding us in our decisions regarding the
direction and scope of future research.
In this chapter, we provide an overview of the current state of in silico
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models of within-host TB dynamics, showing that most models to date
have focused on small scales, modelling single lesions. Those that have
taken a larger view of disease over the whole lung have not yet incorpor-
ated the environmental heterogeneity that is believed to be a crucial part
of the disease pathology. We show how models can be built incorporat-
ing environmental heterogeneity, creating a metapopulation of spatially
distinct sub-populations, with the local environment of each patch being
assigned different environmental attributes, thus creating differentials of
resources across the landscape. We overview some modelling processes
that are relevant to this thesis, outlining the process for simulating time
using the Gillespie algorithm.
We then present a framework for creating a networked metapopula-
tion, written in Python, which allows a population to spread across
distinct patches, each of which may be assigned its own values for envir-
onmental attributes. These attributes may then affect the event dynamics,
modelled using the Gillespie algorithm, that occur across the network of
patches and edges, where members interact within a patch or translocate
between patches. Thus the heterogeneity of the environment affects the
dynamics occurring upon it, an important factor when modelling TB
across the lung. Finally, we outline verification testing performed on
the model against existing epidemic models at both a single-patch and
multiple-patch scale to demonstrate the validity of MetapopPy as a means
of simulating dynamics upon a heterogeneous environment.
3.2 Background
3.2.1 In silico models of within-host TB
Mathematical and computational models within TB research have focused
on three main aspects of the disease [132]:
• The epidemiology of the disease, studying the spread of TB over
populations of people [229].
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• The bacteriology of the disease, particularly studying the growth,
drug-resistance and latency phenomena of the M. tuberculosis bac-
teria.
• The pathology, immunology and treatment of the disease, exploring
the complex interactions and dynamics that occur within the host
during infection.
In this section, we review the latter, detailing some of the in silico models
of TB within-host dynamics (see [132] and [36] for comprehensive reviews
on this subject).
3.2.1.1 Lesional-scale models
The first models exploring the evolution of a single lesion within the lung
were agent-based models (ABMs), in which the cells and bacteria which
constitute the system are represented as individual components with
their own rules (‘agents’) and a lesion forms as an emergent behaviour
from the combination of the interactions of these agents [200, 213]. These
models were able to study the formation of a granuloma by taking into
account the spatial factors, such as overcrowding mechanics and the
spatial location of T cells [213] which impact the disease dynamics, which
had been impossible to do through mathematical differential equation
models. Other methods such as partial differential equations (PDEs) [73]
and metapopulations [82] have also been used to study lesion progression.
Segovia-Juarez et al [213], described a model (later named GranSim)
which would form the basis of many future models of TB lesions. The
environment modelled is a 2D portion of alveolar tissue, 2mm by 2mm
in size, divided into a lattice of micro-compartments. Each compart-
ment may contain a ’source’ (whereby immune cells enter the system),
extracellular bacteria or immune cells. Cells are able to move and may
come into contact with bacteria, and thus ingest them. The bacteria then
become intracellular and may replicate within the immune cell. Whilst
this model is an ABM, it also incorporates some elements of cellular
automata. A chemokine gradient occurs whereby immune cells secrete
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chemokines and these diffuse between micro-compartments. This is
achieved through a cellular-automaton like process, where the chemokine
value at a micro-compartment changes over time based on the values in
the micro-compartments adjacent to it. Time is modelled synchronously,
with each time-step possibly involving multiple events.
Further models extended the initial GranSim model by creating a multi-
scale model examining dynamics at tissue, cellular and molecular scales
by including ordinary differential equations (ODEs) and PDEs to model
cytokine molecules [72]. Inclusion of pharmacokinetic (PK) and phar-
macodynamic (PD) effects into the GranSim model showed that antibiotics
can reach insufficient quantities within the granuloma between dosages,
with antibiotic gradients occurring within the lesion [190].
Models by other groups were produced, including those exploring the
effects of oxygen and nutrient starvation, whereby the structure of the
granuloma contributes to the bacteria being deprived of access to these
important resources [59, 214]. ABM models have also been used to study
the effects of spatial distribution of oxygen upon bacterial cell state [26].
This model showed that regions of the tissue may be preferable for bac-
terial proliferation, as they are located far enough away from important
blood vessels that an immune response cannot be triggered fast enough
and chemotherapeutic concentrations are too weak to destroy the bacteria.
Importantly, this model also incorporates the notion of ’dormant’ bacteria,
with bacteria becoming dormant due to oxygen differentials within the
lesional environment. These findings indicate the importance of spatial
structure to the progression of a TB lesion.
3.2.1.2 Inclusion of the lymphatics
Primary infection with TB often includes infection of the lymph nodes,
and transfer of immune cells (and possibly bacteria) between the lung
and the lymphatics is an important part of the disease process for TB. As
such, models have been created which include this translocation of cells
and thus create a two-organ model. A two-compartment mathematical
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model [151, 153] depicts the transfer of immune cells between the lung
and lymph nodes. In the lung compartment, differential equations de-
scribe the growth of bacteria and their interactions with immune cells,
and DCs are permitted to transfer to the lymph compartment, whereby
they interact with naïve T cells and cause T cell activation. The activated
T cells may then move to the lung compartment and influence dynam-
ics there. This model demonstrated the importance of transfer of both
DCs and T cells between these sites. A further model constructed from
this two-compartment model also included bacterial infection within the
lymphatics [154, 174] and macrophage infection there, showing how cy-
tokines balance the macrophage phenotypes present in each environment.
In [152], the GranSim model was combined with the ODE model that
described the priming of T cells by cells migrating out of the lung. Thus,
the ABM of the lung tissue simulates the initial infection and the cell
actions, with the number of infected cells serving as a proxy to determine
the number of APCs that will be present in the lymphatics and this
provides appropriate values to the equations. This model showed that
the spectrum of infection outcomes (active, latency, clearance, etc.) can
be regulated by key immune cell migration rates.
3.2.1.3 Modelling infection over the whole lung
Whilst the models described in section 3.2.1.1 explore a single lesion in
the lung, there exist models that have explored TB development over a lar-
ger, whole-organ scale. Most of the whole-lung models of within-host TB
dynamics are ODE and PDE models, exploring M. tuberculosis densities
during infection [10, 148], the factors which regulate the immune sys-
tem [147, 219, 240] and the effects of co-infection of TB with HIV [17, 131].
Whilst these models are scaled to explore dynamics, it is important
to note that none of these contain any spatial dimensions within the lung.
In each, the lung is treated as a single entity: a homogeneous, well-mixed
environment and thus the location where infection occurs is irrelevant.
For example, in [148], the effects of environmental factors such as oxygen
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and nutrient starvation on bacterial states (active, dormant and latent)
over time is modelled to create states of active, latent and re-activation
TB. But there is no indication that the actual environment where these
disease states are occurring may be different, as described in the previous
chapter.
3.2.2 Metapopulations
Many early population models, such as those used in ecology modelling,
made an assumption that the entire population was well-mixed, with all
members of the system able to interact with each other and the entire
environment assumed to be homogeneous in nature. Whilst this is appro-
priate in some scenarios, in scenarios where a heterogeneous environment
exists (such as the internal conditions within the lung as explained in
Chapter 2) this paradigm can be too restrictive. In order to allow the
differential spatial attributes of the environment to impact the simula-
tion dynamics that occur, a paradigm which incorporates space is needed.
One such paradigm is that of metapopulations. A metapopulation is a
population in which the members are divided based on their spatial loca-
tion. In the original Levins model [139], the environment is divided into
spatially distinct sites, commonly referred to as ‘patches’. Each patch is
either inhabited by a population (‘occupied’) or the population is extinct
at said patch (‘unoccupied’) (see Figure 3.1A). Thus, local dynamics are
ignored: if a patch is inhabited, it is assumed that the carrying capacity of
the patch is reached. All patches contain the same extinction probability,
and an unoccupied patch can become inhabited by migration from an
occupied patch [105]1. The Levins model can be used to predict the
threshold at which a population will survive or become extinct.
The Levins model incorporates space in as much as sub-populations are
spatially distinct and cannot interact with one another, but it does not
include the environmental heterogeneity found in many real-world sys-
1These dynamics can be seen as analagous to a networked SIS epidemic model, with
migration reflecting infection and extinction reflecting recovery.
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Figure 3.1: Examples of different types of metapopulation models (each
with 3 patches). A) Levins model of occupied/unoccupied patches. B)
Gyllenberg model whereby patches are assigned a quality value. C)
Epidemic SIS model of Susceptible and Infectious members.
tems, as each patch contains the exact same dynamics as all other patches.
Later metapopulation models incorporated heterogeneous environments
by including patch ‘quality’ - the better the quality of a patch, the less
likely the species is to become locally extinct there (see Figure 3.1B) [101].
The models described thus far have examined a single species, but meta-
population modelling can be used to study systems whereby multiple
species interact with one another. These are of particular use in epi-
demiology, with each species (or ‘compartment’) representing a disease
state [247]. Examples of these include Susceptible-Infectious-Susceptible
(SIS) (shown in Figure 3.1C), Susceptible-Infectious-Recovered (SIR) and
Susceptible-Exposed-Infectious-Recovered (SEIR) models, where each
compartment represents a recognised state of the given disease, and
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members pass between compartments as their disease progresses. Rather
than a single set of equations defining the rate of change of disease states
of the whole population, each patch may contain its own set of equa-
tions, and movement between patches (hereby termed ’translocation’) is
included within these equations, either impacting the chances of infection
(due to short term migration) [143], or by the movement of members
between patches (due to long-term or permanent migration) [46].
3.2.3 Time modelling
All simulation of real-world event systems requires us to consider tem-
poral factors - at what point and what order do events occur? There
are two main forms of event modelling: synchronous and asynchronous
modelling [39, 207, 212].
3.2.3.1 Synchronous
In synchronous modelling, the simulated time is considered discrete and
is broken up into slots, with all events in one time slot considered to
occur at the same time. One such implementation of a synchronous time
modelling paradigm is shown in Figure 3.2. Here, all events chosen in
the time-step occur at the exact same time, i.e. between t and t + τ.
3.2.3.2 Asynchronous
In asynchronous modelling, events are performed one-at-a-time, with
no overlap between when events occur. In this case, the time difference
between event occurrences can be infinitesimally small.
The Gillespie algorithm, sometimes known as the Stochastic Simula-
tion algorithm, provides a means to model events asynchronously. In its
initial description, the algorithm is used to describe molecular species in-
teracting through chemical reactions [87, 88]. However, the principles can
apply to any system where interactions occur between sub-populations,
and this has been used in a variety of scenarios, particularly in epidemic
modelling [97, 228], with the species representing disease states. For
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t = 0
Model is inspected
Events chosen
to perform
Events performed,
model updated
t = t + τ
t > TMax
End simulation
Yes
No
Figure 3.2: Example of synchronous time modelling. A time-step, τ, is
determined before simulation as is the maximum time TMax. Simulation
begins with t=0, and an iterative loop continues whereby the state of the
model determines all events to occur in the time-step. Simulation ends
when the maximum time is exceeded.
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the purposes of describing the algorithm in this thesis, we use a more
generalised description: exploring the algorithm through the lens of
elements of the system interacting through events. Here, we describe the
algorithm for a system occurring in a single spatial location (description
adapted from [32, 87, 88]):
Consider the set of N elements {S1,S2, . . . ,SN}. These elements may
participate in a series of M events, {E1, E2, . . . , EM}. The state of the sys-
tem at time t is described by the vector X(t) = {X1(t), X2(t), . . . , XN(t)},
where Xi(t) is the value of element Si in the system at time t. It is as-
sumed that the system is well-mixed (i.e. all elements of the system can
interact with all other elements)2.
Each event, Ej, must define the following:
i) A reaction parameter, cj, which gives the average probability that one
Ej event will occur in the next infinitesimal time interval [t, t + dt).
ii) A state variable function, hj(X(t)), which takes the current state of
the system and determines the possible number of occurrences of
event Ej.
iii) A state change vector, νj = {v1,v2, . . . ,vN}, where vi describes the
changes that occur to the value of element Si when event Ej is
performed.
Using these, each event can calculate its ‘rate’, rj(t), at time t as per
equation 3.1, which can be defined as the probability, to first order in τ,
that an Ej event will occur in the next time interval τ.
rj(t) = hj(X(t)) ∗ cj (3.1)
2It is important to note that the term ‘element’ here is left deliberately vague: events
may involve interaction between a variety of different objects within the system. One
conceptual view, which we utilise later in the MetapopPy framework, is that the modelled
environment contains a subpopulation of species, as well as attributes defining the
nature of the environment in the system at the location being modelled. Both of these
may impact on the rate at which events occur. Thus, the elements of the system are
a set of both discrete, non-negative integer counts of members of various species and
continuous positive or negative values for environmental attributes.
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An iteration similar to that described in 3.2.3.1 occurs, but instead of
incrementing by the same time-step iteration, a time-step, τ(t), is calcu-
lated dynamically based on the sum of all rates, R(t), at time t, calculated
in equation 3.2.
R(t) =
M
∑
j=1
rj(t) (3.2)
This value is then used to calculate τ(t) as per equation 3.3, where q is a
pseudo-random number generated for each simulation timestep in the
interval [0,1) (see [87] (Appendix: The Inversion Generating Method) for
the derivation of this formula from the appropriate probability density
function).
τ(t) =
1
R(t)
∗ ln
(
1
q
)
(3.3)
The iteration for the Gillespie Algorithm proceeds as follows:
1. Simulated time starts at zero, i.e. t = 0
2. All events calculate their rates as per equation 3.1, giving a rate
vector {r1(t),r2(t), . . . ,rM(t)}.
3. R(t) is calculated as per equation 3.2 and τ(t) is likewise calculated
as per equation 3.3.
4. An event, Ej, is chosen probabilistically based on values of the rate
vector, with a greater rate indicating a greater likelihood of being
chosen.
5. The state change vector, νj associated with Ej is used to update the
state of the system.
6. Time is incremented, such that t = t + τ(t).
7. Steps 2 to 6 repeat until a time limit is reached.
3.2.3.3 Comparison of synchronous and asynchronous methods
Whilst synchronous and asynchronous methods can be used to model
the same scenarios, the choice of time modelling paradigm can lead
to significantly different dynamics [212], and the choice of updating
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t = 0
Model is inspected
Events define rates
Event chosen
to perform
Event performed,
model updated
Calculate τ(R(t))
t = t + τ(t)
t > TMax
End simulation
Yes
No
Figure 3.3: Example of asynchronous time modelling. Contrasting with
synchronous time-modelling, only a single event is performed per loop,
and the time-step, τ, is now a function of the event rates R(t) and is
determined each loop.
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method should depend on the real-world system being modelled [39].
Asynchronous methods are efficient in sparse situations: when not many
interactions occur, no time is wasted by simulating time-steps where no
events happen [228]. Furthermore, asynchronous modelling avoids any
issues around conflicting events - as events occur one-by-one, there is no
scenario where two mutually-exclusive events could both occur (as may
happen in a synchronous system), which would lead to a paradoxical
outcome, and it has been argued that asynchronous methods present a
more realistic approximation of real continuous time [39, 49, 212] and
we therefore chose to use an asynchronous updating method within our
modelling framework.
3.3 Methods
In this section, we detail the creation of a networked metapopulation
framework, name MetapopPy. This framework, written as a Python lib-
rary, is abstract in nature and allows for the creation of a metapopulation
consisting of patches connected together with edges, which signify trans-
location of member between patches. Event dynamics can be created, and
a Gillespie Algorithm implementation is used to simulate these dynamics
occurring over the network. In order to create this heterogeneous envir-
onment, we chose a networked metapopulation paradigm. As shown in
section 3.2.2, using a metapopulation allows for the spatial discretisation
of the entire landscape, creating distinct regions, each of which can be
positioned within the larger environment and given environmental at-
tributes that are appropriate for that position. Whilst metapopulations
have been used extensively for modelling populations of people, we used
this paradigm to model cellular-level interactions within the lung during
TB infection, a process which has only been done rarely [82] and never
at the scale of a whole lung including the environmental heterogeneity
discussed above.
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3.3.1 Existing software
The MetapopPy Python library builds upon already existing Python lib-
raries. Firstly, epyc [63] serves as the foundation upon which MetapopPy
is built. epyc is a Python module designed to automate the control of
long-running experiments with multiple repetitions. This module sep-
arates the logic of a single experiment from the processes required to
run multiple simulations of that experiment with varying parameters,
which proved to be ideal for our own framework. As such, the base
Dynamics class of MetapopPy is a subclass of the Experiment class of
epyc, and so can be plugged efficiently into epyc experiment combinators
to allow various parameter spaces to be explored, allowing us to focus
on the development of creating a metapopulation framework without the
concern of how to implement modules to run simulations.
In epyc, the parameter space can be explored as follows:
1. An instance of the Lab class is created and assigned a set of para-
meters, with each parameter having either a single value or a range
of values.
2. A parameter space is created from the parameter values, with the
default being the cross-product of all possible parameter values.
3. A parameter sample is taken from the space. This is then passed to
a given experiment (an instance of the Experiment class).
4. The experiment calls its configure method to prepare for the
simulation. This occurs once for every parameter sample.
5. For each parameter sample, a number of experiment repetitions
may be run (through the RepeatedExperiment class). For each
repetition, the setUp method the experiment is called. This may
be used to initialise the experiment for the given repetition.
6. The actual mechanics of the Experiment instance occur using the
do method, and results are recorded.
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Dynamics
Events Environment
Figure 3.4: Overview of the modules within the MetapopPy framework
Thus, the configure and setUp methods are used to initialise the
model (for a parameter sample and a repetition, respectively), and the
run function performs the actual experiment. These functions are used
within the MetapopPy framework, as described in Section 3.3.2.3.
The metapopulation network of our framework is created by using the
NetworkX library [102], which is used to create and manipulate com-
plex network structures of nodes and edges. Subclassing the Graph
class of NetworkX provided us with a network with useful manipulation
interfaces with which to add and remove nodes and edges.
3.3.2 Framework description
MetapopPy consists of three main modules (see Figure 3.4):
• Environment - the environment upon which the populations be-
ing modelled reside, which will be altered by the events
• Events - the individual actions and occurrences that alter the state
of the system
• Dynamics - the combination of the events and the environment
In this section, we briefly overview each module to explain how the
framework is used.
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3.3.2.1 Environment
The Environment class of MetapopPy is a subclass of the Graph class of
NetworkX, and thus takes the form of a network of patches and edges3
which may be altered dynamically. At initialisation, the following must
be provided to the Environment class:
i) A list of population compartments, reflecting the divisions within
the overall population (by species, status etc.).
ii) A list of patch attributes, reflecting the environmental conditions at
a patch.
iii) A list of edge attributes, reflecting the environmental conditions at
an edge.
When a simulation is started, the environment automatically assigns
dictionaries of compartments and patch attributes to each patch of the
network, and a dictionary of edge attributes to each edge. The de-
fault position is that all patches contain the same compartments within
their populations and the same types of patch attributes, and all edges
contain the same types of edge attributes. We provide a subclass,
TypedEnvironment, that assigns a ‘patch type’ to each patch, in order
to make an easier distinction between different parts of the environment
(e.g. between different organs within the body), and each patch of a given
type is assigned only the patch attributes that are relevant to that type.
3.3.2.2 Events
Following the Gillespie algorithm (see section 3.2.3.2), each subclass of
the abstract Event class of MetapopPy must:
i) provide a reaction parameter value when declared. This value rep-
resents the probability of a single instance of the event occurring
in the given unit time. For the initial framework, this was a static
value fixed at the start of simulation.
3 NetworkX describes its network in terms of ’nodes’ and ’edges’, as is common
in the Complex Network literature. Metapopulation literature typically describes the
environment in terms of ’patches’ and ’edges’, and we choose to use this nomenclature
as the framework is concerned with creating metapopulations.
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ii) provide a function for calculating the state variable. This function
will take the current state of a single patch of the network and return
a float value, representing the number of possible occurrences of
the event at the current time. The rate is automatically calculated
by multiplying the reaction parameter by the state variable.
iii) provide a perform function. This can be seen as analagous to the state
change vector described in 3.2.3.2, and is a function that updates the
network when given a patch on which the event is to be performed.
It should be noted that events may update more than one patch, as
in the case of translocation of members from one patch to another.
3.3.2.3 Dynamics
The Dynamics class is a subclass of the ‘Experiment’ class of the epyc
library. Therefore, this class forms the base of a single experiment - a
range of values can be provided for parameters, and the parameter space
can be explored by performing simulations using different combinations
of parameter values. The Dynamics class of MetapopPy requires the
following:
i) an instance of the MetapopPy Environment class. This instance
may already have a network structure, or otherwise may create the
network structure dynamically at simulation execution-time based
on the parameter values assigned.
ii) a function to create the events that will occur over the network.
These events are then stored within the Dynamics instance.
iii) functions to determine the initial conditions of the network. These
are expected to take the parameter values being explored and
return a dictionary of the appropriate seedings of compartments
and attributes at the beginning of the simulation.
The MetapopPy Dynamics class overrides the methods present in the epyc
Experiment class to perform its necessary functionality:
• At the configure stage (i.e. when a new parameter sample has
been selected), the Dynamics class checks to see if a network has
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been provided. If not, then one is created (using a user-defined
process and the given parameter sample). Update handlers are
attached to the network. These are lambda functions4 and will fire if
a change is made to the network, informing the Dynamics instance
that a change has occurred and rate values must be recalculated.
An initial seeding for all patches and edges is calculated based on
the parameter sample (using a user-defined process).
• At the setUp stage (i.e. at the start of each of the repetitions for a
parameter sample), the network is reset to an empty state (as it may
have been altered by previous repetitions) and then updated with
values from the seeding.
• At the do stage (i.e. the actual repetition itself), the start time is
set, as is the maximum time that will be simulated. A rate table
is created, with rows representing the patches of the network, and
columns representing the events. Thus, every patch-row combina-
tion has a value, the rate of the event at that patch.5 The following
loop iteration then occurs repeatedly until the simulated time ex-
ceeds the maximum:
1. A time-step value, τ, is calculated using the sum of all values
in this rate table, following equation 3.3.
2. An event and patch combination is chosen probabilistically
using the individual rate values in the table.
3. The perform function of the event is called using the patch
as an argument. The event then performs the necessary ac-
tions. Where the event changes values on the network, this
triggers the update handler functions which returns a list of
the patch(es) and compartment(s) and attribute(s) that have
4A lambda function in the context of the Python programming language is an
anonymous function that can be passed and called by another function. These are
used within MetapopPy as they allow the Environment object to update the Dynamics
object without having to see its internal functions and/or structure.
5For the case of translocation events moving members between patches, we assume
that the event occurs at the patch where the member originally resides
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been changed to the dynamics. The dynamics then updates
the rate table for events occurring at the altered patches.
4. Time is incremented by τ.
3.3.2.4 Mechanics to improve efficiency
Whilst the above is sufficient to run experiments, the following function-
ality was also added to improve performance:
• Patches may be considered ‘active’ or ‘inactive’. Only when a patch
becomes ‘active’ is it added to the rate table. When ‘inactive’, no
event dynamics may occur at a patch. This can be used to focus
simulation only on the areas of interest in the network. As such,
a patch is only seeded with values when it becomes active. The
default option is that all patches are always considered ‘active’, but
this may be overridden with user-defined functions.
• In order to reduce computational overhead when updating the rate
table, each event must list the compartments, patch attributes and
edge attributes it is dependent on to calculate its state variable.
Then, when an update occurs, only the events which are dependent
on the changed items are called on to recalculate their state variable
(and thus also recalculate their rate).
• A time-step is defined by the user as to when to record the state of
the network. Once the simulated time exceeds a multiple of this
time-step, the state of the network is recorded to the results. This
avoids recording excessive amounts of data where only minimal
changes have occurred.
• In the case where a TypedEnvironment instance has been used,
the patch type may be used to drive the model dynamics, such that
events can be restricted to occurring only at a given patch type. This
is done with a PatchTypeEvent class, which is initialised with a
patch type, and returns a zero value for its state variable function if
the supplied patch is not of the same patch type.
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3.4 Verification testing
In order to ensure that the MetapopPy framework was suitable for mod-
elling dynamics over heterogeneous environments, we examined the
literature on epidemics to find models which could be used for com-
parison tests. We chose this field as metapopulation paradigms have
been used extensively to simulate epidemic spreading (as opposed to,
for example, within-host disease progression, for which few models ex-
ist). We used the MetapopPy framework to recreate the models within
these sources and verify that the framework creates suitably accurate
results compared to deterministic mathematical models. In this section,
we review models at single-patch and multi-patch scales and compare
the results from those sources against our own reproductions. We also
describe the construction of the MetapopPy model used in each instance,
in order to demonstrate how a conceptual model can be turned into the
necessary class instances within MetapopPy.
3.4.1 Single patch epidemics
Most early epidemic models are essentially single-patch models: the en-
tire population is constrained to a single location and it is assumed that
the population is well-mixed. These models have been used extensively
for TB modelling, with the dynamics often presented as a form of SEIR
model, with the Exposed compartment representing the latent stage of
the disease.
For the first verification test, we used MetapopPy to recreate a single
patch infection model of TB, as described by Herrera et al [110]. This
model was created to investigate TB dynamics in semi-closed communit-
ies (communities with some departure and recruitment but which have
the potential for sustained daily contact between members over periods
of weeks, months and years). This model contains 5 compartments:
Susceptible (S), Exposed (E), Infected and infectious (II), Infected and
Non-infectious (IN) and Recovered (R). Firstly, we recreated the graph
present in the original paper (Fig 5 of [110]) using the differential equa-
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Figure 3.5: Side-by-side comparison of results of a single-patch epidemic
model created by A) differential equations and B) MetapopPy. The equa-
tions for the model in A were taken from [110]. These were converted
into the necessary events for a MetapopPy model. B) shows results from
200 MetapopPy simulations: solid line is mean value, shading is error.
tions described by the authors, the results of which can be seen in Figure
3.5A.
We then converted the equations of the Herrera model into Events within
a MetapopPy model. Figure 3.6 shows the transition between compart-
ments within the original Herrera model. Each arrow, representing a
member leaving and/or entering a compartment, can be seen as a unique
event, thus needing an instance of the Event class in MetapopPy.
Any event that moves members from one compartment to another would
require two corresponding terms in the equations of an equation-based
model (a term for the compartment the member is originally in to remove
the member, and a term in the new compartment to add the member).
However, in MetapopPy, this type of event only requires a single event,
defining the rate at which the event occurs and the impact it has on
the system. As an example, consider the infection events of the Herrera
model. S members come into contact with II members and become
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Figure 3.6: Flowchart of the movement of members between compart-
ments in the Herrera model (taken from [110]).
infected. Of these newly infected members, a proportion, p, become
actively infected, whilst the remainder, 1− p, become latently infected
(E). Of those actively infected, a proportion, f , become infectious and can
transmit disease (II), and the remainder (1− f ) become non-infectious
(IN). Thus 4 terms are needed:
• −βSII in dSdt to describe members becoming infected and leaving
the S compartment
• (1− p)βSII in dEdt to describe members becoming latently infected
and joining the E compartment
• p f βSII in
dII
dt to describe members becoming actively infected and
infectious, joining the II compartment
• p(1− f )βSII in dINdt to describe members becoming actively infected
but non- infectious, joining the IN compartment
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This can be implemented in at least 2 ways within MetapopPy:
1. A single event which occurs at rate βSII . This represents all infec-
tion routes. Then, the perform function can be set to probabilist-
ically choose a compartment to place the newly-infected member
into, with probabilities of (1− p), p f and (1− f )p for E, II and IN
respectively.
2. Three separate events, one each for conversion to E, II and IN . These
will occur at rates (1− p)βSII , p f βSII and p(1− f )βSII respect-
ively, and thus the reaction parameters set to use the appropriate
parameters for each (this method was chosen for our model).
Having created the events, we created an Environment instance which
consisted of a single patch which we seeded with the appropriate values
(4980 S members and 20 I members) at the beginning of simulation. 200
simulations were run, and the averaged results with standard deviation
can be seen in Figure 3.5B. As shown, MetapopPy provides a reasonable
approximation of the same model created using differential equations.
3.4.2 Multi-patch epidemics
In order to verify that MetapopPy works as an approximation for model-
ling metapopulations, we proceeded to compare results against a model
that included multiple patches in a heterogeneous environment. In [157],
the authors define a model for studying a SIR disease occurring over
multiple patches, each of which has different parameter values for events
such as infection and recovery6 and with migration of members between
each patch. The equations that compose this model are similar to those of
a single-patch model, but each include terms to alter the subpopulations
based on the counts of same-compartment members in other patches.
In this model, migration is driven by the number of connections on the
network - the more edges a patch has, the greater the rate of migration
of members out of the patch (and similarly, the more influx of members
from other patches.) Figure 3.7A, C and E show the results taken from
6In an epidemic context, variable rates could occur for a variety of reasons, such as
due to regional/national differences in healthcare or poverty.
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Figure 3.7: Side-by-side comparison of results of a multi-patch epidemic
model created by differential equations from [157] (A, C and E) and
MetapopPy (B, D and F). A and B show Susceptible population, C and D
show Infectious population, E and F show Recovered population. Green
plots are Patch 1, Red are Patch 2 and Blue are Patch 3. B, D and F show
results from 500 MetapopPy simulations.
the equations of that model (a recreation of Figure 10 of [157], with plots
grouped by compartment). The model is evenly coupled (all patches are
connected are rate of movement is the same in both directions of each
edge), and the differential parameters at each patch result in differing
outcomes: the epidemic reaches a higher equilibrium in patch 1 than in
patches 2 and 3.
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In order to recreate this model in MetapopPy, a model-specific envir-
onment was created whereby each patch is defined with spatial attributes
equivalent to the variable parameter rates (e.g. local birth rate, local
death rate, local infection rate, etc.). Then, events were created which
calculated their state variable using these environmental attributes. To
demonstrate this, consider the infection event. In [157], this occurs at rate
Sj Ij
λj
Nj
at patch j. Sj, Ij and Nj are the Susceptible, Infectious and total
populations at patch j, whilst λj is an infection rate specific to patch j. In
MetapopPy, Sj, Ij and Nj are calculated dynamically during simulation
(as they are constantly changing), whilst λj is a patch attribute. Thus
assigning different values to the patch attributes creates different rates of
infection across the environment7.
The results from 500 simulations of the MetapopPy model are show in
3.7B, D and F. Again, we see that the results from a MetapopPy model
are a suitable approximation of the results obtained from a deterministic
equation-based model of the same scenario.
3.5 Conclusions
In this chapter, we have detailed the creation of a networked meta-
population framework, MetapopPy, designed to aid in the creation of
metapopulation based models that include environmental heterogeneity.
The framework provides the user with the underlying network data
structure and event dynamics mechanisms, requiring the user only to
define how the environment and events are described, without concern
for the event and time processing algorithms. By extending epyc, we
allow for experiments to be run across the model using a variety of
parameter ranges, again removing the need for the user to define the
experimental control mechanisms. We have verified our framework by
recreating models from already-published sources and confirming that
7In order to make the rates valid, the reaction parameter for these events was set
to 1. Another valid approach to this would be to set a reaction parameter equal to a
standard infection rate and use patch attributes as a means of scaling the rates based on
this value.
61
3. Networked metapopulation framework
the output is similar. This framework then forms the basis of our TB
whole-lung model, as described in the next chapter.
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4Chapter FourWhole lung modelof TB
In which we present TBMetapopPy, a novel whole-lung model of TB that
incorporates environmental heterogeneity within the lung that impacts on the
immunology and pathology of the disease dynamics, and present our results
from the initial simulations.
4.1 Introduction
In previous chapters, we have explained how TB disease exhibits distinct
localisations within the lung during different stages of disease, which is
hypothesised to be caused by environmental heterogeneity within the
lung. We have also shown that, to date, there are few computational
models that explore TB disease occurring over the whole lung, and of
those that do, none explore these differences in localisations or incorpor-
ate this concept of environmental heterogeneity within the lung which
impacts on disease dynamics. In this chapter, we outline what we believe
to be the first in silico model that simulates TB within an environmentally
heterogeneous lung, in which the dynamics are influenced by differ-
entials in environmental attributes such as ventilation, perfusion and
oxygen tension, thus creating regions in the lung which are preferential
or disadvantageous to bacterial proliferation.
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We begin by providing an overview of anatomical and immunological
concepts that are relevant to the creation of the model. We then outline the
model, explaining how a differential environment is created by assigning
values for environmental attributes based on each patch’s position within
the lung. We detail all of the events within the model, explaining their
state variable calculations and the impact they have on the model and
show how the environment influences the rates of some of these events.
We then show the results of simulations using the model, demonstrating
how the incorporation of environmental heterogeneity in a whole-lung
model of TB can have significant impact on the outcome, with far greater
bacterial proliferation occurring in a heterogeneous model due to the
creation of regions at the apex whereby reduced immune activity and
increased oxygen aid the cause of the bacteria.
4.2 Model description
We extended the MetapopPy framework presented in Chapter 3 to create
TBMetapopPy, a model that simulates a TB infection over the whole lung,
incorporating environmental heterogeneity and bacterial dissemination
in order to understand the influences these factors have upon the progres-
sion of disease. As an extension of MetapopPy, TBMetapopPy follows the
same class structure of Environment, Events and Dynamics. We discuss
each of these in turn in the following subsections.
4.2.1 Environment
The lung is the main pulmonary organ of the human body. Air that is
inhaled is directed into the lung through the trachea. This splits into
two main bronchi, each supplying one lung. The right lung is larger in
size than the left (as the left lung has to accommodate the heart within
the chest cavity) and thus the main right bronchus is larger than the left.
Each main bronchus divides into lobar bronchi, which each supply a
lobe of the lung. The tissue of the lobes of the lung are separated by
fissures. Due to size differences, the right lung contains 3 lobes whilst
the left contains 2 [138]. Each of these lobes are also further subdivided
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Figure 4.1: Diagram of the bronchopulmonary segments and lobes within
the human lungs (taken from [24]). In the left lung, braces denote
common fusions between segments.
into bronchopulmonary segment, with 10 bronchopulmonary segments
in the right lung and 10 in the left, although in the left lung some fuse
together [66]. It should be noted that lung anatomy is not constant, and
differences in the number, size and shape of bronchopulmonary segment
may occur between people. Each of these segments is supplied by its
own segmental bronchus, branching off from the lobar bronchus (see
Figure 4.1). A bronchopulmonary segment is the smallest functionally
independent region of the lung [66].
Within each bronchopulmonary segment, the segmental bronchus splits
(typically into no more than 2 subsequent airways) continuously, until
the airways terminate at the alveolar sacs.
Our spatial domain for TBMetapopPy is a single lung and associated
lymphatics and thus our model consists of two interlinked environments:
65
4. Whole lung model of TB
the alveolar tissue of the lung (LungPatch) and the lung-associated lymph-
atics (LymphPatch). Within the lung, the alveolar tissue is the region
where most infection occurs, due to initial particle deposition there [37].
The average number of alveoli in an adult human lung is estimated to
be in the range of 274–790 million [182], and these make up a combined
surface area of approximately 70m2 [51]. We chose to model only a single
lung for the initial model, and chose the right lung, as particle deposition
(and thus TB primary disease) tends to occur more frequently in the right
lung than the left, due to the size and angle of the main bronchi and
lower airways [66].
The lymph nodes that serve the lung were chosen as they are neces-
sary to trigger an adaptive immune response during infection [12], often
show signs of disease during infection [16, 167] and are postulated as
the means by which bacteria may disseminate to uninfected areas of the
body [20, 119]. Thus, we used a ‘TypedEnvironment’ instance from the
MetapopPy library, with patch types of ‘LungPatch’ and ‘LymphPatch’ to
differentiate between the two organs.
4.2.1.1 Patch environmental attributes
In order to allow for a heterogeneous environment within the lung, each
of the lung patches was assigned environmental attributes shown in Table
4.1. We chose attributes that have either been proven to impact on TB
pathology or are assumed to do so (see section 2.9 for explanations on
how each of these attributes impacts TB).
We made the assumption that these attributes, and only these attributes,
have impact on TB progression. This included the following assumptions:
• The distribution of ventilation within the lung is linear, based on
the patch’s vertical position. Ventilation affects particle deposition,
with lower patches more likely to receive an incoming particle than
those higher up.
• The distribution of perfusion within the lung is also linear, and also
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Label Attribute Description
V Ventilation The amount of inhaled air that is
directed to the patch of alveolar tis-
sue
Q Perfusion The amount of blood that is direc-
ted to the patch of alveolar tissue
for oxygen exchange
O Oxygen tension The amount of oxygen remaining
in the air within the lung after oxy-
gen exchange has occurred
G Drainage The rate at which migratory cells
within the lung translocate to the
lymphatic system
Table 4.1: Environmental attributes included within the lung patches of
TBMetapopPy
based on the patch’s vertical position. Immune cell recruitment to
the lung occurs through the blood used for oxygen exchange, and
thus patches with a lower perfusion (towards the apices) will have
lower levels of cell recruitment.
• The oxygen tension distribution is a direct result of the differentials
for both ventilation and perfusion. Oxygen availability affects the
replication capabilities of bacteria in the lung.
• Differentials in drainage are also linear in the lung, and also based
on the patch’s vertical position. Patches in a higher vertical position
will have reduced rates of drainage than those towards the base.
Values for V, Q and G were defined at the beginning of simulation. The
value for O was calculated automatically from these values, according to
equation 4.1.
O =
V
Q
(4.1)
The lymph patch was not assigned any environmental attributes as we
are unaware of any environmental heterogeneity within the lymphatics
that would impact TB pathophysiology.
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Label Compartment
BER Bacterium extracellular - replicating
BED Bacterium extracellular - dormant
BID Bacterium intracellular - dendritic
BIM Bacterium intracellular - macrophage
DI Immature dendritic cell
DM Mature dendritic cell
MR Resting macrophage
MI Infected macrophage
MA Activated macrophage
TN Naïve T cell
TA Activated T cell
Table 4.2: Population compartments within TBMetapopPy
4.2.1.2 Patch population compartments
All patches were assigned populations divided into compartments, each
of which represented the species and status of immune cells or bacteria,
as described in Table 4.2.
We modelled 4 types of bacteria, based on their location and/or rep-
lication rate. Bacteria that are present on the tissue surface were ‘extracel-
lular’. M. tuberculosis has been shown to exhibit ‘dormancy’, associated
with the accumulation of lipid bodies, whereby it reduces its replication
rate but becomes more resistant to antibiotics [104, 142]. Thus we mod-
elled this dormancy by allowing bacteria to switch between a ‘replicating’
(BER) and a ‘dormant’ (BED) state when extracellular, dependent on oxy-
gen availability. M. tuberculosis has evolved to suppress the destructive
mechanism of immune cells by preventing phagolysosome biogenesis,
and thus is able to reside within the intracellular matrix of host cells [206,
225, 241]. We defined two types of intracellular bacteria - those within
dendritic cells (BID) and those inside macrophages (BIM), as both of these
cells have been shown to become infected by M. tuberculosis [86]. We did
not make the distinction between replicating and dormant when intra-
cellular: we assumed that dendritic cells are too small to permit internal
bacterial replication, and that the internal environment within a mac-
rophage is hostile and thus forces the bacteria into a slower-replicating
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state regardless of replication rate when ingested.
We modelled 3 types of immune cells: dendritic cells, macrophages
and T cells. The primary role of dendritic cells in the model is antigen-
presentation: the immature dendritic cells (DI) resident in the lung
encounter and ingest bacteria, causing the dendritic cell to convert to
a mature state (DM). These mature cells can then trigger an adaptive
immune response by transferring to the lymphatics and activating T cells
there.
Macrophages play a similar role in the model, as they can also encounter
and ingest bacteria and transfer to the lymphatics, but we assumed that
macrophages are less mobile than dendritic cells and have a greater in-
ternal capacity - they are more likely to remain in the lung and attempt
to eliminate bacteria there. Thus, macrophages were given ‘resting’ (MR)
and ‘infected’ (MI) states. We also included an ’activated’ state (MA),
whereby the macrophage’s bactericidal ability is improved during an
adaptive immune response [75].
Naïve T cells (TN) are present within the lymphatic system and may
be activated by antigen-presenting cells (DM and MI). Multiple varieties
of activated T cells exist within the lungs with varying different functions
[78, 141]. For simplicity, we did not make a distinction between the
different roles and include just one type of activated T cell (TA) to serve
as a representation for all real-world types.
4.2.1.3 Network topology
For our initial model, we chose to use a simple network in order to
demonstrate that even a model with coarse environmental heterogeneity
will exhibit profoundly different dynamics than one with a homogeneous
domain. We chose to model the right lung (as this is where initial infection
more often occurs) and base each of our patches on a bronchopulmonary
segment: thus, the model contained 10 patches within the lung, and a
single patch to model the adjacent lymph nodes. We used a single lymph
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Figure 4.2: Translocation within the initial TBMetapopPy model.
patch to model the entire lymphatic system associated with the lungs.
The network is connected with edges, both between patches in the
lung, and between lung patches and the lymph patch. Figure 4.2 shows
the translocation opportunities within the network and the patch or edge
attributes that affect translocation. Movement from a LungPatch to a
LymphPatch is dependent on the G value of the LungPatch, whilst trans-
location from a LymphPatch to a LungPatch is dependent on the Q value
of the LungPatch1. Doing so allows for a differential T cell response: T
cells in the LymphPatch can transfer into the lung, with a greater rate
translocating to patches with a higher Q value.
We fully connected all patches within the lung, using the fact that the
internal structure of the lung is a tree to assume that all areas are connec-
ted and any bacteria in one area will be able to transfer bronchogenically
(see section 2.8) to any other area. We assigned a weight (W) value to
each edge. We assumed that patches within each lobe are closer on the
bronchial tree than those in other patches, and thus the W value is higher
within-lobe than between-lobe.
The overall topology of the network can be seen in whole in Figure 4.3.
1In order to achieve this, the Q value of the LungPatch was also assigned to the edge
connecting the LungPatch and LymphPatch, thus allowing events at the LymphPatch to
view the perfusion value and calculate state variables using it
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Figure 4.3: Network topology for initial TBMetapopPy model.
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The 10 patches of the lung (based on bronchopulmonary segments) are
placed into lobes based anatomically, with the upper lobe containing 3
patches, the middle lobe containing 2 patches. and the lower lobe contain-
ing 5 patches. In order to define values for environmental heterogeneity,
we separate the lung into 3 regions: apical, middle and base (blue, yellow
and red, respectively, in Figure 4.3). [233], defined three distinct zones
within the lung based on magnitudes of pulmonary arterial, venous and
alveolar blood pressures, and the zones in our model can be seen as ana-
logous to these zones. All patches within the same zone were assumed
to have the same values for ventilation and perfusion (and thus oxygen).
4.2.2 Events
Here, we describe the events that occur within the initial TBMetapopPy
model. We describe each event in terms of its action (i.e. the changes
made by its perform function) and its rate (i.e. its reaction parameter
multiplied by its state variable). Figure 4.4 shows a schematic of how
events move members between compartments and a list of all parameters
can be found in Tables 4.3, 4.4, 4.5, and 4.6.
4.2.2.1 Innate immune response
MR cells are initially present in both the lung and lymphatic system.
These cells die naturally at a rate of µMR and are replaced through re-
cruitment, which occurs at rate QαML in the lung and αMY in the lymph.
DI cells are also present in the lung at simulation start; these die at rate
µDI and are replaced through recruitment at rate QαD. In the lymphatics,
naïve T cells are present at the beginning of simulation; these die at rate
µTN and are replaced through recruited cells at rate αT.
The bacteria in the lung are initially extracellular and are able to replicate
freely, with BER replicating at rate λRBER and BED replicating at rate
λDBED. In order to model the effects of hypoxia on bacterial replication,
we include an event to switch bacteria from BER to BED with increased
likelihood in an oxygen-poor environment, with rate ξBER
(
O−σξ
O−σξ+θξ
−σξ
)
,
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Figure 4.4: Schematic showing the movement of members between popu-
lations (and patches) within the preliminary TBMetapopPy model. Trans-
location of extracellular bacteria between LungPatch instances is also
included in the model (not shown here).
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Parameter Description Value Ref
φ Bacterial carrying capacity of a
macrophage
50 [153]
σλ Intracellular bacteria replication
sigmoid
2 [153]
λR Replication rate of BER 0.25 [240]
λD Replication rate of BED 0.005 [240]
λI Replication rate of BIM 0.005 Estimated
κBR Destruction rate of BER and BED
by MR
1.25E-8 [153]
κBA Destruction rate of BER and BED
by MA
1.25E-4 Estimated
ξ Rate of conversion between BED
and BER
1 Estimated
θξ Half-sat value of O for conver-
sion between BER and BED
1 Estimated
σξ Sigmoid value for conversion
between BER and BED
1 Estimated
τBL Rate of translocation of BER and
BED along LungEdge (within
lung)
0.001 Estimated
τBY Rate of translocation of BED
along BloodEdge (lymph to
lung)
0.05 Estimated
Table 4.3: Bacterial event parameters used for experiments in the prelim-
inary TBMetapopPy model. All value units are per day.
whereby σξ > 0. We also include the reverse event, with BED convert-
ing to BER when presented with an oxygenated area, with rate equal to
ξBED
(
Oσξ
Oσξ+θξ
σξ
)
.
The resident phagocytes (MR and DI) within the lung may encounter the
extracellular bacteria and ingest them. For dendritic cells, we assumed
that a dendritic cell is incapable of destroying a bacteria and can only
uptake them. This occurs at rate γDDI
BE
BE+θγD
, where BE = BER + BED.
When performed, an extracellular bacteria is probabilistically chosen to be
ingested based on current levels. For macrophages, we modelled M. tuber-
culosis’s ability to avoid destruction through two events: one where the
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Parameter Description Value Ref
µDI Rate of death of DI 0.01 [153]
µDM Rate of death of DM 0.02 [153]
γD Rate of uptake of BER and BED
by DI , causing maturation
1E-7 [153]
αD Standard recruitment rate of DI
into lung
500 [153]
βD Enhanced recruitment rate of DI
into lung caused by BED and BER
0.02 [153]
θβD Half-sat for enhanced recruit-
ment rate of DI into lung caused
by BED and BER
6.5E5 [153]
τD Rate of translocation of DM
along LymphEdge (lung to
lymph)
0.5 [153]
Table 4.4: Dendritic cell event parameters used for experiments in the
preliminary TBMetapopPy model. All value units are per day.
bacteria is destroyed upon contact, occurring at rate κBRMRBE, and one
where the macrophage becomes infected, occurring at rate piMR
BE
BE+θpi
.
For both these events, the bacterium is chosen probabilistically based
on current extracellular levels of BER and BED. We assumed that the
different replication phenotypes (BER or BED) have the same chances of
survival when encountered by macrophages.
If a bacteria survives the ingestion process, it converts to an intracel-
lular state (BIM or BID for phagocytosis by MR or DI respectively) and
the cell converts to an infected state (MR convert to MI , DI convert to
DM). MI and DM both die naturally, at rates µMI MI and µDMDM re-
spectively, and this may return some of the internal bacteria back into
extracellular compartment BED (we assume that the internal conditions
within a macrophage are stressful to bacteria and thus they have been
forced into a dormant state, which they remain in once released). For
DM death, we assumed the single internal BID is always released, whilst
for MI death, we assumed a percentage of the bacteria inside the macro-
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Parameter Description Value Ref
eMT Rate of activation/deactivation
of MR by TA
0.3 [153]
θeMT Half-sat value for activation of
MR by TA
5E2 Estimated
pi Rate of macrophage infection by
BER and BED
0.4 [153]
θpi Half-sat value for macrophage
infection
1E6 [153]
µMR Death rate of MR 0.01 [153]
µMA Death rate of MA 0.01 [153]
µMI Standard death rate of MI 0.01 [153]
ζ Rate of bursting of MI due to
BIM
0.25 [153]
αML Standard rate of recruitment of
MR into lung
400 [240]
αMY Standard rate of recruitment of
MR into lymph
53.465 [154]
βMLI Enhanced rate of recruitment of
MR by MI
0.0056 [153]
βMLA Enhanced rate of recruitment of
MR by MA
0.04 [153]
τM Rate of translocation of MI along
LymphEdge (lung to lymph)
0.25 Estimated
Table 4.5: Macrophage event parameters used for experiments in the
preliminary TBMetapopPy model. All value units are per day.
phage (ψµ
BIM
MI
) are destroyed with the remainder ((1−ψµ)BIMMI ) released.2
Once in the internal environment of the immune cell, bacteria can replic-
ate [197]. We allow replication of BIM to occur, constrained by the internal
capacity of the cell. BIM may replicate at rate λI BIM
(
1− (BIM)σλ
(BIM)σλ+(φMI)σλ
)
.
Thus the rate of replication decreases as the levels of bacteria approach
the total carrying capacity of all infected macrophages (φMI). As mac-
rophages start to fill with bacteria, they may ’burst’, rupturing their
outer wall and releasing bacteria [62]. The rate of occurrence for this
2These values in TBMetapopPy (and all other compartment values where fractions
are calculated) are rounded to whole numbers in order to comply with MetapopPy rules
that compartment values must be integers.
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Parameter Description Value Ref
κM Rate of destruction of MI by TA 1.3 [153]
θκM Half-sat value for destruction of
MI by TA
0.5 [153]
eT Rate of T-cell activation by anti-
gen presentation by MI and DM
1E-5 [153]
µTN Rate of death of TN 0.102 [153]
µTA Rate of death of TA 0.3333 [153]
αT Standard rate of recruitment of
TN into lymph
1000 [153]
βT Enhanced rate of recruitment of
TN into lymph due to DM and
MI
0.1 Estimated
τT Rate of translocation of TA along
BloodEdge (lymph to lung)
0.6 [153]
Table 4.6: T-cell event parameters used for experiments in the preliminary
TBMetapopPy model. All value units are per day.
in TBMetapopPy is inverse to replication, i.e. it increases as the bacterial
level approaches capacity, with rate βMI
(
(BIM)σλ
(BIM)σλ+(φMI)σλ
)
. When this
occurs, the internal bacterial contents of the macrophage are return to the
extracellular compartment, which is calculated as BIMMI members switching
from BIM to BED. We assume DI cells are too small to permit bacterial
replication within themselves and thus their internal bacteria, BID, do
not replicate.
Extracellular bacteria may translocate: bacteria present in a LungPatch
may translocate along the air (via LungEdge instances) at rate τBLBER and
τBLBED for BER and BED respectively. The choice of edge depends on the
weighting value of the edge, with greater probability along edges with
greater W values. Extracellular bacteria in a LymphPatch may translocate
along a BloodEdge back into the lung at rate τBYBED, with the edge to
move along chosen probabilistically based on the Q value.
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4.2.2.2 Adaptive response
In response to infection, the body increases the supply of immune cells
to the lung to assist within containment [93]. This is modelled in TBMeta-
popPy by separate events for each resident immune cell and trigger cell
type at each location. We assume that signalling cytokines are expressed
by MI and MA cells, with enhanced recruited of macrophages due to
each cell occurring at rates βMLI MI and βMLAMA respectively in both
the lung and lymph patches. In the lung, dendritic cell recruitment
is enhanced by bacterial presence at rate βD
BE
BE+θβD
. In the lymphatics,
enhanced T cell recruitment is dependent on APCs and is increased at
rate βT(DM + MI).
Both dendritic cells [6, 164] and macrophages [130] have been shown to
transfer to the lymphatics during infection in order to present antigens
and trigger an adaptive immune response. We treat both DI and MI as
antigen-presenting cells and we model their transfer to the lymphatics
as two separate events: with DI translocating at rate τDGDI and MI
translocating at rate τMGMI , thereby creating different rates of clear-
ance at different regions, based on G. This transfer, whilst necessary
for establishing an adaptive immune response, also carries the risk of
spreading infection, as any internalised bacteria are also transferred to
the lymphatics. The transfer of bacteria to the lymph nodes may be
a necessity for establishing an adaptive immune response [242]. Thus
in our model, transfer of MI also causes the transfer of BIM members
(calculated as the average number of BIM per MI ,
BIM
MI
), and transfer of a
DM member also transfers a single BID.
Antigen-presenting cells in the lymphatics can cause activation of T cells
from a naïve to an activated state. This occurs at rate eTTN(MI + DM),
and results in TN changing to TA. Once activated, these T cells migrate to
the sources of infection to enhance the immune response and contain the
bacteria. The rate of translocation is τTTA. When choosing a LungPatch
to translocate to, the Q values of each patch serve as a means of probab-
ilistically choosing a patch: patches with a greater perfusion value are
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more likely to be chosen and thus a greater T cell response is initiated at
patches with greater perfusion.
Activated T cells perform two primary functions in the model. The
first is to cause activation of macrophages, converting MR into MA, oc-
curring at rate eMT MR
TA
TA+θeMT
. The second function of TA is to causes
apoptosis - the controlled destruction of infected cells. This is modelled by
allowing TA members to destroy MI members at rate κM MI
TA/MI
(TA/MI)+θκM
.
We assumed that the destuction of the macrophage also destroyed the
internal bacteria, calculated as BIMMI , which are removed from the BIM
compartment. TA members naturally die at rate µTATA
Activated macrophages can destroy bacteria in the same manner as MR,
with rate κBAMABE, but in our model MA cannot become infected and
thus the bacteria ingested are always destroyed, simulating the increased
bactericidal effects of macrophage activation. MA cells die naturally at
rate µMAMA.
4.2.3 Dynamics
A TBModel class (an extension of the Dynamics class of MetapopPy)
combines the pulmonary environment and TB events.
4.2.3.1 Initial conditions
The lung topology is initialised and seeded with values for resident
immune cells (MR and DI in the LungPatches, MR and TN in the Lymph-
Patch) based on the recruitment and death values to calculate average
equilibrium levels of these cells. A population of bacteria are seeded,
either in a defined location or probabilistically based on Q values. The
simulation proceeds as per the MetapopPy framework until a simulated
time limit is reached.
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4.3 Results
4.3.1 Set-up
In order to demonstrate the effects of environmental heterogeneity upon
TB infection within the lungs, we performed experiments against two
distinct topologies of the TBMetapopPy model. In the first, topology A,
the lung is modelled as a whole homogeneous unit, consisting of just one
LungPatch coupled to a LymphPatch which models the lymphatics. A
LymphEdge and a BloodEdge allow movement of cells between the two.
The second, topology B, is the setup as described in section 4.2.1.3. wed
defined attribute values for each zone as per Table 4.7.
V Q O
Apical 0.6 0.5 1.2
Middle 0.8 0.8 1.0
Basal 1.2 1.3 0.923
Table 4.7: Values for attributes of West Zones used in simulations of
multi-patch topology model. V = Ventilation, Q = Perfusion, O = Oxygen
tension.
As the model is stochastic in nature, all experiments are run over 30
repetitions, with the mean counts of members (and standard deviations)
of each compartment over these repetitions calculated at each time-step.
For experiments involving topology B, 5 BER members were placed into
one of the basal regions at the start of simulation. In topology A models,
they are placed in the single lung patch.
We are interested in overall bacterial growth, and our marker for this
is the combined total of the BER, BED, BIM and BID compartments in
each patch of the lung.
4.3.2 Topology A: Homogeneous systems require
significant reduction in immune activity in order
to establish infection
Figure 4.5a) shows the overall bacterial growth over time for the model us-
ing topology A and parameters as per Tables 4.3, 4.4, 4.5 and 4.6. For this
80
4.3. Results
model, we set the V and Q values of the patch to 9.0 and 9.1 respectively,
chosen in order to match the sum of the total ventilation and perfusion
over an entire lung as seen in topology B. Bacterial growth is severely
limited, as the bacteria population is overwhelmed by the numbers of
immune cells, and the entire population of bacteria is eradicated within
750 days.
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Figure 4.5: The overall bacterial growth (BER, BED, BIM and BID) within
a single patch topology (Topology A). Line is mean, shading is standard
deviation. a) shows results using event parameters as described in Tables
4.3, 4.4, 4.5 and 4.6. Infection is contained quickly and virtually eradicated.
b) shows the effects of a minimal reduction in cell recruitment (RD =
50, RM_lung = 40) and c) shows the effects of a major reduction in cell
recruitment (RD = 25, RM_lung = 20). As recruitment is reduced, the
spike of initial infection (at around 50 days) increases massively. In both
cases, the infection is contained and remains at a reasonably steady state
thereafter (latency).
We then investigated the conditions necessary to establish a bacterial
presence. In order to do this, we reduced the recruitment rates of dend-
ritic cells and macrophages (αD and αML respectively) by arbitrary factors
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of 10 (shown in Figure 4.5B) and then 20 (shown in Figure 4.5C). This
severe weakening of the immune system recruitment throughout the
course of infection is enough to allow TB to establish a presence within
the lungs.
This was explored further by instead reducing the Q value of the
lung patch in topology A. This has the effect of also weakening the
adaptive immune response, which requires perfusion in order to increase
macrophage and dendritic cell numbers and allow T cells to access the
lung. Figures 4.6A and B show the effects of reducing the Q value of the
single patch to 4.5 and 1.3 respectively. Reducing perfusion allows the
establishment of a bacterial presence, with a higher bacterial load being
established with perfusion reduced to very low levels. In Figure 4.6c),
perfusion of the whole lung is reduced to levels used in the apical regions
of topology B (i.e. 0.5). Here, a bacterial presence is firmly established.
This suggests that lack of perfusion may be the main cause for bacterial
growth as low-perfused patches experience high bacterial growth in both
topologies.
4.3.3 Topology B: Spatial heterogeneity increases
overall bacterial load
In order to explore the effects of environmental heterogeneity (both in
the separation of the overall lung population into discrete patches and
the variation of resources within those patches) and translocation on
these disease dynamics, we ran simulations over the spatially separated
network of topology B. Figure 4.7a) shows the results of simulation runs
where no attribute heterogeneity exists (all patch values are set equal).
From this, we see that the separation into distinct spatial regions results
in much greater initial bacteria growth, due to the limitations on the
number of immune cells that can encounter the bacteria during the early
stages on infection. An adaptive immune response begins to quell the
infection, but in doing so it results in transfer of the bacteria to other
areas of the lung. An oscillating process of bacterial growth occurs, with
bacteria numbers increasing and decreasing over time, but never reaching
the levels of the initial growth explosion. This can be seen as a latent
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Figure 4.6: The overall bacterial growth (BER, BED, BIM and BID) within
a single patch topology (Topology A) when perfusion is reduced to a)
4.5, b) 1.3, c) 0.5. Line is mean, shading is standard deviation. Reducing
perfusion allows a bacterial presence to be established. In a) no major
initial infection takes place and the infection level remains fairly constant
throughout. In b) a pattern similar to the reduced recruitment rate in
Figure 4.5 is seen. In c), the reduced perfusion results in a saw-tooth
pattern, whereby latency now involves an oscillating, rather than constant,
level of bacteria.
form of TB: the bacteria levels are contained but not eradicated. As all
patches contain the same values for their attributes, the bacteria levels at
each patch remain approximately the same. The bacterial levels here far
outweigh those seen in the single-patch model, except in the case where
perfusion is drastically reduced.
We then introduced spatial heterogeneity to the different zones, with
values as per Table 4.7, the results of which are shown in Figure 4.7b). As
per the previous experiment, bacterial growth occurs in the initial patch
until the introduction of an adaptive immune response, which brings the
bacterial levels under control but at the consequence of spreading bacteria
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Figure 4.7: The overall bacterial growth (BER, BED, BIM and BID) upon a
multiple patch topology. Patches are grouped by spatial location (base,
middle and apex). Line is mean, shading is standard deviation. All
simulations use event parameters as per Tables 4.3, 4.4, 4.5 and 4.6. a)
shows the results of a network that includes no spatial heterogeneity -
initial infection spikes in the initial, basal patch and spreads to other
patches, where infection is established at consistent levels throughout. b)
shows the effects of introducing heterogeneity (with values as per Table
4.7). Infection spreads to other patches, with the bacterial load dependent
on the spatial location.
to other regions. However, in this scenario the bacteria have access to the
oxygen-rich, immune-poor regions at the lung apices, and once there the
population explodes dramatically, reaching levels far higher than it did
at the basal regions during initial infection. Again, the adaptive immune
response is able to bring the bacterial levels down and reach an oscillating
equilibrium. But in this scenario, we show that the levels of bacteria
at latency are different for each region, with far higher levels being
established at the apical regions than at the basal and middle regions.
Figure 4.8 shows the levels of replicating and dormant bacteria in each
region of the multi-patch network. We see that there are similar levels
of replicating and dormant bacteria, with a slight majority to replicating
bacteria in all patches.
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Figure 4.8: The bacterial levels of BER and BED in a) apical patches, b)
middle patches and c) basal patches. Line is mean, shading is standard
deviation. All three regions show similar levels between replicating (blue)
and dormant (red) bacteria, with a slight majority to replicating bacteria
in all.
4.3.4 Bacterial translocation
To investigate the effects that translocation within the lung had on bac-
terial growth, we ran experiments using different weight (W) values on
the LungEdges connecting the patches within topology B. Figure 4.7b)
shows the effects of no translocation within the lung (all W values set
to 0), whilst Figure 4.7c) shows the effects with translocation allowed
between patches which reside in the same lobe (W attribute of edges
between patches in the same lobe is set to 1.0, and 0.0 for all other edges).
Figure 4.7d) shows the effects of allowing translocation between all areas
of the lung. W values are set as per Table 4.8.
In Figure 4.9, we tested the effects of removing a) long-scale inter-
lung transmission b) all inter-lung transmission and c) bloodstream
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superior middle inferior
superior 1.0 0.5 0.25
middle - 1.0 0.5
inferior - - 1.0
Table 4.8: WEIGHT values for edges between patches in different lobes
transmission from the lymphatics to the lung. In all cases, the overall
pattern of bacterial growth in the lungs remains fairly robust, with
minor changes in the amplitude of the resulting oscillations of bacteria
levels. These findings suggest that the means of translocation across the
pulmonary system are not as important as the heterogeneity therein. So
long as bacteria can reach the favourable apical locations in some manner,
they will be able to proliferate and establish a greater infection there.
4.4 Analysis
4.4.1 The need for environmental heterogeneity when
modelling TB
It is believed that the environmental heterogeneities present in the lung
are responsible for the apical localisation seen during the post-primary
stage of disease [67], and the results from our preliminary model would
seem to validate this hypothesis. By including differentials within the
lung for attributes such as ventilation, perfusion and oxygen tension that
mirror those evidenced in human anatomy, our model created regions of
the lung at the apex that were preferential for bacterial growth. At these
regions, the bacterial numbers far exceeded the numbers that occurred in
a similar model without environmental heterogeneity. This could explain
the localisation at the apex during post-primary disease: when latency
is established, the lesions at the apical regions contain greater bacilliary
loads, and thus under a weakening of the immune system, it is reasonable
to assume that these lesions would be the first to degrade and experience
bacterial proliferation on a rapid scale. This hypothesis is tested in later
chapters of this thesis.
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Figure 4.9: The overall bacterial growth (BER, BED, BIM and BID) upon a
multiple patch topology with different routes of bacterial dissemination.
Patches are grouped by spatial location (base, middle and apex). Line is
mean, shading is standard deviation. All simulations use event paramet-
ers as per Tables 4.3, 4.4, 4.5 and 4.6. a) shows the results of a network
where translocation within the lung can only occur within the same lobe
(i.e. small-distance translocation). b) shows the effects of completing
removing translocation within the lung. c) shows the effects of removing
translocation of bacteria via the lymphatics and bloodstream back to the
lung. In all cases, removing options of translocation results in a similar
pattern of growth to when all methods are viable (as per Figure 4.7).
The differences in routes of bacterial translocation across the pulmonary
system appear to have little effect on the disease outcome; so long as
bacteria have some means of reaching the preferential apical regions (i.e.
through dissemination in the blood after establishing lymphatic disease
or via direct transfer within the air of the lung), this will be enough to
cause an enhanced population growth of bacteria in the region due to its
favourable environment.
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Figure 4.8 indicates that the bacterial population in all regions is com-
posed of both replicating and dormant bacteria in almost equal measure.
Whilst it is believed that a latent form of infection involves the host main-
taining a population of dormant, non-replicating bacteria [181], there is
evidence that some bacterial replication occurs during latency [116, 128],
which may explain the presence of a population of BER bacteria after
initial infection and the oscillating bacteria levels in our model.
With the results presented in this chapter, we have demonstrated the ne-
cessity of in silico modelling of TB infections to take a broader view of the
disease as it occurs within the lung than is done currently: environmental
factors play an important role in determining the scale of infection before
latency is established. Developing new treatment regimens requires a
better understanding of exactly which environments bacteria persist in
within the lungs - computational models such as the one introduced here
can help shed light on these niches.
4.4.2 Limitations
This model is a highly abstracted representation of the actual conditions
found during a TB infection, but it is nevertheless based on gross-scale
real world pathology. These abstractions are necessitated by the current
lack of understanding of how the disease pathology is influenced by its
surroundings. We have shown that the introduction of a small amount of
heterogeneity, by dividing the lung into a network consisting of 10 nodes,
can have significant impact on the results of simulations in contrast with
models that treat the lung as a homogeneous environment.
The purpose of this model is not, presently, to be predictive; it serves to
provide insight into the complex factors that drive TB infections to their
apical localisation. This insight can provide the basis for models which
can build on this work to further study the impact of lung environment
on TB. We have identified some parameters whose spatial heterogeneity is
significant to apical localisation (such as reduced perfusion at the apices),
but others may exist. Where possible, we have used parameters taken
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directly from the scientific literature.
The model presented in this chapter uses the environmental oxygen
level of the patch as the only influence on the switch between replication
and dormancy - in reality, a wide range of factors are believed to initiate
dormancy, including oxygen deficiency, nutrient deficiency, hyper-acidity
and antibiotics [142]. These stresses may drive bacteria to dormancy all
over the lung, with the oxygen availability at the apices then providing
the ideal environment for future reactivation.
The pathophysiology of TB is a complex process involving many and
various interactions between the bacteria and a large number and variety
of immune cells. In this model, we have simulated just three types of
immune cells with a small number of states. In reality, there are many
more immune cells involved in the progression of the disease, including
neutrophils [71, 168], which are believed to play a significant role in the
pathogenesis of TB as they are one of the first cells to encounter bacteria
[145]; and B cells [1, 146]. For this iteration of the model, the cells we have
included are sufficient to show that heterogeneity in the lungs can impact
immune response and thus also disease pathology, but future iterations
that intend to fully explore the immune response should incorporate
these types of cells.
This preliminary TBMetapopPy model is an approximation of two stages
of the TB life-cycle: primary infection and latency. In order to better
understand how environmental factors contribute to disease, the model
would need to incorporate factors appropriate to post-primary disease, as
this is the stage that results in disease transmission and patient mortality.
This is explored in the following chapter.
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In which we present the second iteration of TBMetapopPy, where a space-filling
tree algorithm is used to create a more granular network, and present our results
from simulations of this model, showing how position in the lung affects lesion
development.
5.1 Introduction
As noted in the previous chapter, the preliminary TBMetapopPy model
effectively models the primary and latency stages of TB. However, almost
all transmission and the majority of mortality of disease (80%) occurs in
the post-primary stage [125], typically localised to the apices of the lung
and displaying cavitation - which greatly increases the chance of disease
transmission [250].
In this chapter, we present an upgraded model of TBMetapopPy that
incorporates a post-primary stage of disease in order to study how and
where cavities form in the lung during infection. We first overview some
important concepts for post-primary disease and cavitation and the struc-
ture of the human bronchial tree, then describe how the model has been
amended to incorporate these factors into a new, more-granular envir-
onment and detail other dynamics changes. We outline an algorithm to
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create a space-filling tree inside any 2-dimensional shape, and show how
this was used to create an approximation of the bronchial tree for the
second iteration of our TBMetapopPy model. We then present the results
of experiments run using this iteration of the model, paying attention to
the overall bacterial load of the system, as well as the size and location of
lesions, showing that our model favours the apical localisation of larger
lesions during the latent stage of disease, creating a preferential region
just below the apex whereby conditions are ideal for bacterial growth.
We incorporated a paradigm of post-primary disease, and show how
a weakening of the immune system in the models leads to the apical
lesions reaching bacterial loads seen in the initial lesion during primary
infection.
5.2 Methods
5.2.1 Background
The human lungs are supplied by a single branching structure, the
tracheobronchial tree (for a comprehensive review of the structure of the
human tracheobronchial tree, see [191]). Air breathed in passes down
the trachea, which splits into two main bronchi, one for each lung. This
split is dichotomous, and almost all subsequent divisions in the bronchi
are also dichotomous, although an occasional trichotomous split may be
witnessed [112]. The main bronchi then divide into lobar bronchi, with
each one supplying a lobe of the lung. The right lung contains 3 lobes,
and the main bronchus divides once to supply the upper lobe, then again
to supply the middle and lower lobes. The left lung has 2 lobes (upper
and lower), and the left main bronchus divides in two to supply each.
These lobar bronchi then divide to supply the various bronchopulmonary
segment (as described in 4.2.1).
Subsequently, the airways divide, with about 20 to 28 divisions occur-
ring[112, 166]. As the branches divide, the branching angle, diameter
and length of child branches decreases [112]. Thus the bronchial tree is a
self-similar structure, a fractal, with divisions in lower branches reflecting
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divisions further up the tree [149], and the bronchial tree can be modelled
using fractal techniques [91, 177]. Computational models of the human
airway have been previously created using these fractal methods and fit
to real-world data [60, 203].
At the termini of these branches are the terminal bronchioles, which
are the last branches in the conducting zone. There are estimated to be
approximately 25,000 terminal bronchioles in a single lung [113]. These
then branch into respiratory bronchioles, and the surfaces of these respir-
atory bronchioles are interrupted by alveoli, where oxygen exchange and
TB disease occurs.
5.2.2 Aims
In order to create a model that could better inform us of the specific areas
within the lung affected during different stages of disease, a number of
further developments were made to the initial TBMetapopPy model. This
demonstrates the iterative nature of mechanistic model development as
described in section 1.1.3 of this thesis: an initial model is made that
conforms to our knowledge of the real-world dynamics, and this model
is then refined as either our knowledge changes or we wish to explore
the subject matter in more detail. In this section, we outline the various
changes made to create the next version of the TBMetapopPy model.
The model presented in chapter 4 can be seen as model of primary
and latent infection: an initial infection is seeded in the lower regions of
the lung and the presence of this triggers and adaptive immune response.
The increased immune activity brings the infection level down and con-
tains it (but does not eradicate it), such that the disease never reaches the
bacterial levels during the initial infection (albeit with oscillating bacterial
levels).
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Symbol Parameter Description
P Perimeter A series of (x,y) coordinates com-
posing the external perimeter of the
model environment
a Branching start
point
An (x,y) point, on P, where the
branching process originates from
f Branch length di-
visor
The length of the new branch as
a fraction of the line dividing the
perimeter in two
z Minimum area The minimum area needed to stop
the branching process
SV Ventilation skew The scale of differential of V
SQ Perfusion skew The scale of differential of Q
Table 5.1: New required environmental parameters for the second itera-
tion of TBMetapopPy
5.2.3 Environmental changes
The largest changes to the model were made to alter the underlying
environment of the system within the PulmonaryEnvironment class.
Rather than a hard-coded network as had previously been used, the
model dynamically constructs the network based on parameters that are
provided at the start of simulation. The new required parameters are
listed in Table 5.1.
The process creates a 2D space-filling tree. A perimeter, P, is provided
which forms the 2D reference space for the model. A single point on this
perimeter, a, is also provided and the branching process begins at this
point. An recursive process then occurs, an example of which is shown
in Figure 5.1, which proceeds as follows.
a) An initial perimeter, P∗, for a shape is provided, as is a starting
point, a∗ on the perimeter.
b) A second point, b∗∗, on P∗ is chosen such that the line between a∗
and b∗ divides the shape created by P∗ exactly in two1. The length,
a∗b∗ is calculated.
1All polygon areas are calculated using a Python implementation of the Shoelace
formula, whereby a shape of co-ordinates [(x1,y1), (x2,y2),...,(xn,yn)] has area
A = 12 |x1y2 − x2y1 + x2y3 − x3y2 + ... + xn−1yn − xnyn−1 + xny1 − x1yn|
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c) A point, c∗, on the line is calculated such that the length of the line
from a∗ to c∗ is a∗b∗f
d) A branch is created from a∗ to c∗. The resulting shapes formed by
bisection of P∗ by the line from a∗ to b∗ then form the areas for
the next child branches. The process continues recursively from a)
using these two shapes.
Figure 5.1: Example of the branching algorithm used to generate the
environment within the second TBMetapopPy model.
Once the area of the child shapes drops below the threshold for the
minimum area, z, then the branching process terminates. At this point,
a patch is placed at the location that the final branch terminates. Thus
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an abstraction of the bronchial tree is created, with a branching structure
that fills the available space and ultimately terminates at each patch of
the network, with each patch represents all the alveolar tissue that would
be present at the end of that particular branch.
The values for environmental variables were also modified. Rather than
using attributes set to arbitrary values as had occurred in the original
model, the values were chosen to more accurately reflect the vertical
position in the lung. It was decided that all V and Q values should sum
to 1, thus meaning that the V and Q values at each patch represent the
proportion of ventilation and blood perfusion from the whole lung that
is directed to that patch. This simplifies the calculations for immune cell
recruitment: the recruitment rate can be set to reflect the total numbers
of cells found in the human lung (which data exists for) and the V and
Q values then scale the number of cells at a given patch based on the
number of patches and their vertical position. In order to achieve this,
two new parameters, SV and SQ, were introduced to skew the differen-
tials of V and Q respectively. Once the network is constructed, scales are
created such a patch at very apex of the lung would have both V and Q
values set to 1, whilst a patch at the very base of the lung would have
a V value of SV and Q value of SQ. Patches are then assigned values
according to these scales and based on their vertical position, as shown in
equations 5.1 and 5.2, where y is the vertical position of the patch, ymax
is y-coordinate of the highest vertical point of the area and ymin is the
y-coordinate of the lowest vertical point.
V = 1 + (ymax − y) ∗ SV − 1ymax − ymin (5.1)
Q = 1 + (ymax − y) ∗ SQ − 1ymax − ymin (5.2)
Once every patch in the lung has been assigned these values, the sums of
all values for V and Q are calculated and each patch’s values are divided
by these totals in order to normalise them and make them all sum to 1.
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5.2.4 Event dynamics changes
Further changes were made to dynamics of the events within the TBMeta-
popPy model, to either conform to the new network dynamics, to improve
the performance or to better match the known pathophysiology of TB.
These changes are detailed below:
• In order to simplify the model, contact between members of the
model was standardised, whereby each event that involves contact
between members uses a half-sat formulation for its state variable.
Furthermore, the dynamics of contact between bacteria and immune
cells was altered: whereas in the previous model there existed two
events for each extracellular bacteria and macrophage combination
(one for bacterial destruction and one for macrophage infection),
the second model uses a single event: bacterial ingestion. We
assume macrophages ingest any bacteria they come into contact
with. There is then a probability associated with the chance of
infection: a macrophage internally destroy the bacteria or may fail
to do so and thus become infected. This allows us to include a
saturation dynamics for bacterial destruction: the destruction of
bacteria by macrophages is reduced when the numbers are very
high as crowding effects within the lesion prevent physical access
to bacteria.
• Bacterial dissemination from the lymph into the lung is amended.
In the new model, we assume that bacteria in the lymph will be
constrained from dissemination as a lesion forms: the granuloma
is intended to physically ’wall-off’ bacteria and stop the spread to
other regions. In order to model this, we use a new compartment,
caseum , as an indicator of the development of a lesion - the greater
the caseum, the less likely a bacteria will be to escape the lymphatics
and disseminate elsewhere. In our model, the caesium compartment
increases when an infected macrophage dies - either naturally or
through bacterial mechanisms or immune mechanisms. Thus, there
is a brief window after the bacteria have entered the lymphatics but
before a solid lesion forms there, wherein bacteria can disseminate
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and form lesions elsewhere.
• T cell dissemination from the lymphatics was amended. In the ori-
ginal model, all activated T cells disseminated from the lymphatics
to the lung to fight infection. In the new model, not all areas of the
lung become infected, and a more nuanced dynamics was needed
to allow some T cells to remain in the lymphatics in order to fight
infection there. Chemotaxis of T cells to specific areas through the
detection of chemokines is well-known [9, 135, 155], and we repres-
ent this by directing migration of T cells based on MI numbers: a
"chemokine" attribute, K, is added to each edge, which is updated
when the number of MI in the adjacent lung patch changes. Migra-
tion of T cells then follows Equation 5.3, where KL is the sum of all
K values on the edges from the lymphatics to the lung (i.e. the total
amount of infection in the lung) and MI is the number of infected
macrophages within the lymph. KL
σT
KLσT+MIσT
is a scaling term that
will have values between 0 and 1: as KL gets larger compared to MI
(i.e. the infection in the lung outweighs the infection in the lymph),
the term tends to 1 and the rate increases. As MI outweighs KL
(i.e. the infection in the lymphatics outweighs the infection in the
lung), the term tends to zero and thus the rate of T cell migration
decreases. A power term, σT, allows us to control how the change
in infection affects the change in T cell translocation - if σT tends
to infinity, the rate becomes a simple switch: if MI exceeds KL, the
term is zero and no translocation occurs, whilst if MI is less than
KL, the term equals one and all T cells migrate.
TA ∗ KL
σT
KLσT + MIσT
(5.3)
• Greater T cells numbers were required to contribute to the larger
number of lesions present in this model. We therefore implement a
mechanism that was not included in the previous iteration of the
model: T cell replication. Once activated, T cells can proliferate
into many clones [9], increasing the availability of T cells. This only
occurs shortly after activation: to model this, we allow TA members
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to create new TA members, but restrict this event to only occur
within the lymph patches (at rate λT).
5.3 Results
5.3.1 Environment
For our simulations, we created a simple lung environment: a 2D rect-
angle whose height is twice its width: this is a rough approximation of
the dimensions seen in human lungs [134]. Thus, we initialise the model
with P = [(0,0), (0,100), (50,100), (50,0)], and we set the initial branching
point a = (50,50), a point mid-way up the right edge of the rectangle,
approximating the entry of the main bronchus into the right lung. We set
the minimum area z = 0.05 and length divisor f = 2. Using these values,
the algorithm creates a H-tree-like structure, with 65,536 terminal nodes.
For the environmental variables, we use SV = 2 and SQ = 3 [237].
5.3.2 Experiment
The second iteration of the MetapopPy model is computationally intensive
- the larger number of nodes combined with the increased, more accurate,
number of immune cells being modelled results in a greater number of
computations per experiment. Therefore, it was necessary to delegate the
computation of the simulation repetitions to a dedicated computer server
with 8 cores. As MetapopPy was built upon the epyc library, we were
able to use the ClusterLab class of that library in conjunction with an
ipyparallel computer cluster running on the 8-core machine to improve
the speed at which results were obtained from each simulation run.
We ran 32 simulations in total using the parameters as specified in the
tables in Appendix A.
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Figure 5.2: Total bacterial load of all patches over time within the TBMeta-
popPy system, showing individual counts for each of 32 repetitions
5.3.3 Total bacterial load and lesion size
We first examined the total bacterial load of the system over time. Fig-
ure 5.2 shows the results of the total bacterial load for each of the 32
repetitions over time. In the initial phase, a primary infection begins
and reaches its peak between 25 and 45 days in all simulations. This
is brought under control by the introduction of the adaptive immune
response with low bacterial levels in all simulations by about day 55.
Whilst all simulations are relatively consistent to the point where the
infection has been brought under control, with only minor variations in
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the height and time of the peak of initial infection, the results vary much
greater in the response after this point. Whilst many simulations tend
to keep bacteria numbers at a low level, for those that do not, the total
number present has a large amount of variation. But it is impossible from
this Figure to accurately understand the whole situation: a high bacterial
load may be a result of a single large lesion, or multiple small lesions. It is
important to make the distinction between these two scenarios: multiple
small lesions can be interpreted as being stable: the immune system
is able to keep these lesions at a low level and stop bacterial growth;
whereas a large lesion can be interpreted as a failure of the immune
system to control bacterial growth at that location: this may lead to tissue
damage, and then cavitation. Therefore, it is preferable for the host to
keep the lesion size small, and it is important for us to understand the
size of the lesions created.
We investigated the notion of bacteria distribution by tracking the average
size of all lesions for each simulation, with the results shown in In Figure
5.3. Here, we see that the average lesion size after day 60 is much lower:
indicating that while there are a high number of bacteria, they are often
being contained in multiple smaller lesions than fewer, tissue-damaging
large lesions.
5.3.4 Spatial distribution of lesions and lesion size
We then explored which spatial areas of the lung were being affected by
the disease over the course of the infection, by looking at the average le-
sion size for each horizontal slice of alveolar tissue (i.e. we group patches
together that fall within the same given vertical position boundaries).
Figure 5.4 shows the correlation of average lesion size to vertical position
in the lung during the primary stages of infection. The initial lesion (in
the very lowest region) grows and peaks at around 30 days - this was the
largest average lesion size seen over the whole course of the simulation
time-frame. By day 50, the lesion has stabilised but bacteria have spread
to over regions of the lung. At this point, these lesions are all at a very
small average size and we see almost complete heterogeneity in size
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Figure 5.3: Average size (measured as number of bacteria) of all lesions
over time within the TBMetapopPy system, showing individual averages
for each of 32 repetitions
across the lung.
Figure 5.5 shows the average lesion size during the following stages
of infection, from day 60 to day 150. We witnessed that whilst lesion
starts homogeneous across the lung, as time progresses the lesions at the
apical region start to expand at a greater rate than those towards the base.
This is in stark contrast to the lesions during the primary stage, which are
typically completely homogeneous in terms of bacterial load. The size of
these lesions during latency fluctuates in a sinusoidal manner (see Figure
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Figure 5.4: Vertical distribution of lesion sizes with TBMetapopPy sim-
ulations during the primary infection stage. Colour shows the average
lesion size at each of 20 evenly sized horizontal slices of lung taken from
32 simulations.
5.3), but these average lesions sizes never reach the size seen during the
primary infection. We further explored the numbers of lesions during
infection, again stratifying the lesions based on their vertical position. Fig-
ure 5.6 shows the average number of lesions in each horizontal division
of the lung per simulation. Here, we only counted patches where there
was a bacterial presence - i.e. any lesions that were healed (no bacteria
remaining) were not counted. In the primary stages, there is always a
lesion present in the lowest basal region (the initial lesion where infection
begins). By day 50, other lesions have begun to form across the lung, with
a fairly even spread across the vertical dimension. Figure 5.7 shows the
average number of lesions per horizontal section per simulation for later
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Figure 5.5: Vertical distribution of average lesion sizes with TBMetapopPy
simulations during the latent infection stage
timesteps. At the very bottom section, the number of lesions decreases
and reaches a level comparable to the rest of the lung. This occurs due
to healing: the original lesion is, in many simulations, being completely
healed of bacteria and thus is no longer counted. For the remainder of
the lung, we witnessed some heterogeneity in the number of the lesions.
By day 120, there appear to be two distinct regions with greater lesion
counts: one at the very bottom of the lung, at one in the second quadrant
from the top of the lung (marked A and B respectively on Figure 5.7).
5.3.5 Post-primary disease
Having established that our model permits a higher bacterial load to-
wards the apices during latent infection, we then proceeded to model
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Figure 5.6: Vertical distribution of the number of lesions with TBMeta-
popPy simulations during the primary infection stage
the post-primary stage of the disease. As the actual causes of the change
from latency to post-primary are unclear, and may not be the same for
every individual case, we chose to model one case: a weakening of the
immune system. In order to model this, we introduced a static event,
which is set at the beginning of simulation and will always occur at the
set time-point2. This event drops the T cell recruitment rate, αT, by half,
and is set to occur at 250 days, well after latency has been established.
We again ran 32 simulations, this time running for 500 days.
2In order to implement this, we amended the event loop of MetapopPy to also check
for static events. If a time-step, τ, is chosen that would increment the time beyond the
next static event, the τ value is discarded and instead time is incremented to the time of
the next static event. The loop then proceeds as normal. This may introduce a slight
inaccuracy in the one event that would have been chosen.
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Figure 5.7: Vertical distribution of the number of lesions with TBMeta-
popPy simulations during the latent infection stage. Colour shows the
average number of lesions present at each of 20 evenly sized horizontal
slices of lung, with average taken from 32 simulations.
Figure 5.8 shows the distribution of the average lesion size for each of
the 32 simulations. We see the same pattern as before for primary and
latency disease. At the time of the T cell recruitment drop, the lesion
sizes increase again, in many cases reaching levels similar to those seen
at primary disease. We determine these to be a post-primary form of
disease. We also note that not all replications reach this level: in some
cases, where the average lesion size was low during latency, the aver-
age lesion size after the T cell recruitment drop increases but does not
reach these high levels. In Figure 5.8 we show the spatial distribution
of average lesion sizes within the lung. Again, the lesion size is large at
base during primary infection (t=30), and this levels out at the end of
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Figure 5.8: Average size (measured as number of bacteria) of all le-
sions over time within the TBMetapopPy system incorporating a T cell
recruitment drop (black line), showing individual averages for each of 32
repetitions
primary infection and the beginning of the latent phase (t=60), with a
slightly greater lesion size at the apex during latency (t=150). After the T
cell recruitment drop, the average lesion sizes increase, with the largest,
most damaging lesions appearing at the apex of the lung (t=400).
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Figure 5.9: Vertical distribution of average lesion sizes with TBMetapopPy
simulations during the primary (t=30), early latency (t=60), latency (t=150)
and post-primary (t=400) infection stages.
5.4 Analysis
With this second iteration of the TBMetapopPy model, we are better able
to understand the spread and size of lesions that occur during different
stages of infection. Our findings show that after the establishment of
a latent form of infection, the lesions that develop within the lung are
heterogeneous in size. The conditions towards the apex favour bacterial
growth, either through the availability of oxygen, the reduced immune
response towards the apex or a combination of these and other environ-
mental factors, resulting in larger sized lesions. This isn’t a completely
linear scale however, the areas with the largest sized lesion on average
lie just below the apex (as seen in Figure 5.5). The very apex of the
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lung is perhaps too poorly perfused to permit bacterial translocation
in order to establish lesions. Therefore, there exists a location (about
6-10% of the total lung height from the apex) where the conditions are
ideal from the point of view of the bacteria: the perfusion is just high
enough to permit bacterial dissemination to the region but not so high as
to allow a sufficient immune presence to keep bacteria levels very low.
It is reasonable to assume that these higher bacterial levels at the apex
during latent infection are what contribute to apical localisation during
post-primary disease: they serve as larger reservoirs for bacterial growth
if the immune system is compromised, and thus they are the areas we
would most expect cavitation to occur as the immune system battles to
contain a ever-growing infection. We would expect future iterations of
the model to incorporate this concept of cavitation and the effect it would
have on bacterial growth (e.g. providing more access to oxygen as cavities
rupture into airways).
We also see a differential with the number of lesions (Figures 5.6 and 5.7).
Once latency is established, the lesions predominantly form in 2 main
regions: at the very base, and approximately 25% to 50% of the lung
height from the apex. The reasons for this clustering are unclear: the
lower region can be explained by the increased perfusion there, as more
bacteria seed this region more lesions form there. The average number of
lesions decreases moving up the lung, until a sudden increase signifying
the start of the second region. It is possible that this also forms due
to the perfusion values: as perfusion decreases up the lung the chance
of bacterial seeding likewise decreases, by the immune response also
decreases, meaning the likelihood of lesion sterilisation (removal of all
bacteria) drops. This may reach a tipping point, where the reduced im-
mune response becomes too low to sterilise lesions and thus more lesions
occur as no sterilisation now occurs. These concepts could be explored
by experimentation with a greater range of lung sizes and topologies.
A common occurrence in our findings (both in this model and the first
iteration in Chapter 4) is an oscillating level of bacteria (as seen in the
individual runs in Figure 5.2). Whilst there is evidence of some oscillating
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bacterial levels during infection [198], as well oscillations in numbers of
immune cells for animal models challenged with mycobacteria [221], the
amplitude of these oscillations witnessed is much lower than those seen
in our model.
We have created a full-lifecycle model in incorporating one possible
mechanism of the reactivation of TB after latency is established: a weak-
ening of the immune system. Our findings show that in such a scenario,
the lesions throughout the lung will increase in size, with those at the top
of the lung reaching levels similar to those present during the primary
stage. If we interpret bacterial size as the main driving factor behind
cavitation, then this would support the notion of the environmental het-
erogeneities within the lung being the driving force behind the apical
localisation of post-primary disease.
5.4.1 Limitations
This second iteration of the TBMetapopPy model is an improvement on
the first as it allows us to analyse in greater detail the spatial locations
of bacteria within the lung, but it still has limitations as an effective
simulation of TB within the human lungs. Both the environment and
dynamics of the model can be modified to improve the model and we
discuss both of these factors in turn here.
This iteration of the model simulates TB over a static, two-dimensional,
rectangular-shaped lung topology. Whilst this is a useful abstraction
for the purposes of demonstrating how environmental heterogeneity
affects the disease pathophysiology, it is obviously simplistic compared
to the real-world three dimensional anatomy of the human lungs. A
three-dimensional could have profound impacts, particularly if a future
iteration of the model were to also account for differential orientation of
the subject: the environmental heterogeneities of the lung are believed
to be caused by gravity, so changes in posture or orientation (e.g. lying
down) would alter these environmental conditions and create preferential
regions for bacteria in other dimensions. This could be explored if the
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model was expanded to a third dimension.
In this iteration, we included environmental impacts upon TB but have
not included the reverse: how the disease affects the environment. This oc-
curs during TB through a variety of mechanisms, the clearest of which is
cavitation: whereby the disease triggers erosion of the alveolar structure,
allowing bacteria to access new regions of the bronchial tree. Incorporat-
ing this would require changes to both the dynamics and environments
of the model: new events would be needed to cause cavitation to happen
and these events would need to alter the structure of the network, pos-
sibly adding edges between patches.
Cavitation does not occur in every TB infected person, and its pres-
ence is known to be associated with higher bacterial loads in sputum
[187], and thus understanding the causes of cavity formation is of great
importance. Whilst the exact mechanisms by which this occurs remain
controversial, it is believed that the cause is actually due to the host im-
mune system, as evidenced by the fact that patients with HIV were shown
to have less cavitary disease than those who were HIV-negative [28], and
that treatment with immunosuppressive drugs prevented the formation
of cavities in rabbits [248]. Therefore, using just bacteria numbers as a
surrogate for cavitation may be too simplistic, and rather this may be a
result of excessive levels of activated macrophages attempting to control
larger bacteria numbers towards the apex. Future models should explore
these aspects.
5.5 Conclusion
In this chapter, we have presented a second iteration of our TBMetapopPy
model. This iteration expands on the original by introducing a more
granular environment, with the environmental attributes attached to
each patch now coming as direct result of the patch’s vertical location
within the lung. We have also extended our model to simulate the entire
life-cycle of TB, introducing an external event that drives the system from
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a latent form of disease into post-primary, reactivation, TB.
With our model, we were able to produce some of the significant phenom-
ena seen during TB infection, particularly a greater lesion size towards
the apex during latent and post-primary infection. But as well as reprodu-
cing these phenomena, it is important to be able to explain the causes of
these as well: specifically, determining exactly which parameters within
the model contribute to the behaviours we see in the outcomes of the
model. In order to create better treatments for TB, we need to understand
which environmental, immunological and bacterial factors are most influ-
encing the bacterial growth, lesion formation and degradation and cavity
formation. This concept is explored in the following chapter.
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In which we overview the role of uncertainty and sensitivity analysis in
mechanistic model development, detail the creation of a framework to perform
these analyses, and present our results of applying these analyses to our
TBMetapopPy model.
6.1 Introduction
It is important to remember that models are abstractions of real-world
scenarios and not exact replications. Every model requires some form of
abstraction of the complete set of dynamics, and ideally, models should
be as parsimonious as possible - only including the events that are abso-
lute required to investigate the specific problem [150]. The more complex
a model is, the more information needs to be provided to it, and with
many real-world scenarios this information is very often not well-known
[210]. This is particularly true with regards to TB research, where a lack
of knowledge about the underlying dynamics occurring during infec-
tion leaves much uncertainty about the values of parameters used when
modelling within-host TB dynamics. However, this complexity and the
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uncertainty it generates is sometimes unavoidable if a useful model is to
be created.
As seen in the previous chapter, the model we created to study TB
across the whole lung is relatively complex and involves a large number
of parameters, thus introducing greater uncertainty in the model output.
Therefore, it is important to understand how uncertainty in the model
parameters propagates through to impact the model outputs. In this
chapter, we explore techniques to determine how uncertainty in a mod-
els output is generated from uncertainty in the model parameters, and
methods apportion variance in the model output to specific individual
parameters. We outline the development of a Python framework that
allows these techniques to be applied to a model, which has been built to
allow for the model simulations to be run concurrently across an ipython
cluster, thus reducing computation time (which can be particularly heavy
for these analyses as a wide parameter space is explored). We then use
this framework to perform analyses on the model described in the pre-
vious chapter, with our results presented here. We show that perfusion
is significant sensitivity for lesion size - indicating that this may be the
most dominant environmental aspect that drives localisation towards the
apex. We also show the importance of t-cells to the model, with many
t-cell parameters having significant sensitivities.
6.2 Background
6.2.1 Definitions
In this chapter, we will review two important concepts, which we firstly
define:
• Uncertainty Analysis (UA) is used to determine how uncertainty in
the model predictions creates uncertainty in the model outputs [150].
It is important to note that at this stage, UA does not determine
which of the uncertain inputs are more or less responsible - it is
only concerned with the overall output uncertainty [210].
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• Sensitivity Analysis (SA) intends to apportion the uncertainty in
model outputs to uncertainty in individual model inputs [209].
Thus, UA should precede SA - uncertainty is estimated by UA and then
apportioned to the inputs via SA (although this may not occur for cases
of model calibration or optimisation where uncertainty does not need to
be quantified [210]).
6.2.2 Uncertainty Analysis
6.2.2.1 Types and sources of uncertainty
Any model created is the combination of many parts, including but not
limited to [210]:
• Mechanics - the coded events which define the interpretation of the
real-world
• Model parameters - the parameters that define the rates at which
events occur
• Initial conditions - the starting state of the model
• Resolution - the granularity at which a model operates
Each of these inputs can contain a level of uncertainty, and further un-
certainty can be introduced through the computational costs (which can
limit the number of simulations) and coding errors [85]. In practical
terms, it is not always possible to vary all of these factors during UA
(varying the mechanics would require the development of multiple dif-
ferent models which may be too time-consuming) and thus only a subset
of these can be analysed, termed "input factors".
For mechanistic models, the input factors which we are able to ana-
lyse through UA typically consist of the model parameters and the initial
conditions, which may be uncertain due to a variety of factors, such
as natural variation (e.g. the size difference between human lungs in
different people), errors in measurement or an inability to measure [150].
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This type of uncertainty is termed ’epistemic uncertainty’, where uncer-
tainty of output arises from uncertainty of inputs. Conversely, ’aleatory
uncertainty’ is where the output of the model is uncertain due to inherent
randomness within the model [108]. For deterministic models, all output
uncertainty arises from epistemic uncertainty, whereas for stochastic
models, both epistemic and aleatory contribute.
In order to perform UA, the k-dimensional parameter space needs to be
explored, where k is the number of uncertain input factors. Exploring
the full space can be impractical, due to the computational overheads
of running the complete cross-product of all parameter values, or even
impossible, as input ranges are often continuous and thus generate an
infinite number of possible values. Therefore, sampling methods are
needed to generate a finite number of samples which nevertheless suffi-
ciently sample the entire parameter space.
6.2.2.2 Latin hypercube sampling
A variety of sampling methods exist, with one of the most commonly
used being Latin Hypercube Sampling (LHS), a Monte Carlo technique
favoured for its efficiency [107]. As with all Monte Carlo techniques,
LHS requires each of the K uncertain inputs to define values in terms
of a probability density function (pdf). Common choices for a pdf are
a normal distribution (where evidence suggests a more common value
for an input) or uniform distribution (where no a priori information on
values exists) [150]. We then execute the following procedure:
1. We define a sample number, NS. This will be the number of unique
input parameter samples generated.
2. We stratify each input range into NS parts, with each part containing
an equal probability. For uniform distributions, this results in evenly
sized stratifications; for normal distributions, the stratification size
is smaller closer to the mean.
3. We construct an LHS matrix (of size NS rows by K columns) by
selecting one stratification (without replacement) at random for
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each of the inputs. This forms the model input samples.
4. We use the LHS matrix to parameterise the model, with each row
corresponding to the input values for a simulation. We run the
model, generating an output matrix, Y, consisting of NS rows 1.
6.2.3 Sensitivity analysis
Once the uncertainty within the model outputs has been established,
the next step is to apportion this uncertainty to the uncertainty with the
model inputs. This is the purpose of SA, and in performing this analysis,
it allows a researcher to identify parameters and inputs that are critical to
the model output [150], and conversely, to determine those inputs which
have little impact on the output and thus can be ’fixed’ to a single value
[210].
SA techniques can be classified into two distinct groups [208, 211]:
• Local: these techniques involve determining the sensitivity of the
model output to a single input. They involve fixing all inputs
(except the input of interest) to nominal values, and varying the
input of interest to determine the variation in the model outputs.
• Global: these techniques vary all inputs. They aim to determine
the global influence of a factor on the model’s output variance,
including the effects of interactions between inputs [210].
Local techniques are very efficient - the number of input samples required
is much lower than those needed for global techniques (especially when
there are a large number of parameters) [211]. But local techniques are
limited, only exploring a small amount of the k-dimensional parameter
space, and are not appropriate for situations where there are a large
number of uncertain parameters, or there are parameters with large
ranges of values [150]. In these cases, global techniques should be used.
1The output matrix Y can be one dimensional when only one model output exists,
or may have multiple columns for multiple outputs. Where multiple outputs occur,
analysis should be performed on each output independently.
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Two such examples of global techniques are discussed in the following
text.
6.2.3.1 Partial rank correlation coefficient
Partial rank correlation coefficients (PRCCs) provide a measure of mono-
tonicity between an output and an input after the removal of the linear
effects of all inputs except the input of interest [150]. PRCC can be
combined with LHS as follows 2:
1. Parameter samples, X (of size NS samples by K parameters), are
generated and the model is run to create an output matrix, Y (of
size NS samples by R results), using the method of LHS described
in section 6.2.2.2.
2. Each input Xi (i=1...K) in X is rank-transformed, as is each result Yj
(j=1...R) in Y, with the highest value given rank NS, and the lowest
given rank 1.
3. Linear regression models are fitted to each input (xˆi, equation 6.1)
and each output (yˆj, equation 6.2).
xˆi = c0 +
K
∑
p=1,p 6=j
cpxp (6.1)
yˆj = b0 +
K
∑
p=1,p 6=j
bpxp (6.2)
4. The PRCC value between input xi and output yj is then calculated
as the correlation co-efficient between the residuals (ri = xi - xˆi) and
(qj = yj - yˆj), as per equation 6.3, where r¯i and q¯j are the respective
means of ri and qj.
PRCCxi,yj =
∑NSv=1(riv − r¯i)(qjv − q¯j)√
∑NSv=1(riv − r¯i)2∑NSv=1(qjv − q¯j)2
(6.3)
Statistical significance tests can then be performed to determine if a PRCC
value is significantly different from zero, or whether two PRCC values
are significantly different from each other [150].
2For an illustrated example of the process of an LHS-PRCC scheme, see [150].
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6.2.3.2 Extended Fourier amplitude sensitivity test
In contrast to PRCC, the extended Fourier amplitude sensitivity test
(eFAST) is a variance-based method [208], and is more suitable than
PRCC for input-output trends that are non-linear and non-monotonic
[150]. eFAST works by varying the parameters, causing variation in the
outputs of the model, and then partitioning the variance, determining
what fraction of the total output variance can be explained by individual
inputs. The power of eFAST lies in how the inputs are varied: inputs are
varied at different frequencies, and the strength of the input frequency
on the output frequency is measured using Fourier analysis3.
We now outline the procedure for performing eFAST. The original eFAST
procedure was described in [208], and an amended procedure was de-
tailed in [150]. The sampling process listed here is derived from both of
these sources:
1. Each of the K uncertain inputs must be defined with a distribution
type (e.g. uniform, normal, etc.) and appropriate values. For
inputs where no a priori information exists, a uniform distribution is
appropriate, whereas for parameters where a more frequent value
is known, a normal distribution would be more suitable [150].
2. We add an additional ‘dummy’ parameter (the distribution here is
irrelevant), giving a total of K+1 inputs.
3. In order to generate the input samples, we analyse each input, xi,
in turn.
4. We assign parameter xi a high frequency, ωi, as per equation 6.4,
where NS is the number of samples required per run and M is the
number interference factor4 (usually 4).
ωi =
Ns − 1
2M
(6.4)
3Fourier analysis is used to study how a function can be approximated by a combin-
ation of simpler functions. A classic example of this is in sound waves - whereby an
overall sound wave can be decomposed into its constituent pure frequencies
4This is the maximum number of Fourier coefficients that may be retained in
calculating the partial variances without interferences between the assigned frequencies
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5. We assign a low frequency to all other inputs. In order to do this,
we calculate a maximum complimentary frequency, ω(−i), as per
equation 6.5.
ω(−i) =
1/M
ωi/2
(6.5)
6. Frequencies are then chosen to satisfy the following conditions: a)
the step between each frequency must be as large as possible and b)
the number of inputs to which the same frequency is applied must
be as low as possible.
7. Thus each parameter, xq, has a frequency and a vector of values,
gq, in the range (0,1) are calculated for all parameters using the
respective frequency, ωq, as per equation 6.6, where s is a vector
(of length NS) that varies between −pi2 and pi2 , and φw is a random
phase-shift in the range [0, 2pi)5.
gq =
1
2
+
1
pi
arcsin(sinωws + φw) (6.6)
This function, defined in [208], creates an approximate uniform dis-
tribution of values between 0 and 1 across the range of s (see Figure
6.1). The values in gq can then be converted into the appropriate
values for the required distribution of xq.
8. Each parameter therefore generates NS values, and NS samples are
created. We then repeat this NR times, with NR representing the
number of resamples. With each resample, we create a new phiw
for every parameter, thus exploring more of the parameter space.
9. We repeat steps 3 to 8, taking a different input as the input of
interest.
10. Once all parameters have been processed, we pass the samples into
the model to produce the required outputs. Therefore, the total
number of samples is NS ∗ NR ∗ (K + 1).
5The random phase-shift φw ensures that the search curve does not repeat itself and
thus covers the whole parameter space.
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Figure 6.1: The sinusoidal function of eFAST. a) shows how as s varies
between −pi2 and
pi
2 , gw values are generated between 0 and 1. These
values are evenly distributed, as shown in b) which plots the histogram
of density for values of gw. Recreated from [208].
Having generated the full sample and produced the results, Y, these can
then be analysed. This is done through Fourier analysis: for each input
of interest and each resample curve, the output is Fourier transformed
and the variance calculated from the Fourier coefficients at the frequency
of interest. The first-order variance, Si, represents the fraction of the
variance of the model output that can be attributed to input xi, whilst the
total-order variance, STi, includes the first-order variance and the variance
due to higher-order interactions between inputs. eFAST produces non-
zero sensitivity indices for parameters which the model is independent
from: to counteract this, [150] proposed a scheme to introduce a negative-
control dummy variable (step 2 above) and then compare input sensitivity
indices against this known independent variable, to establish where the
indices are significantly different from those of the dummy variable.
6.3 Methodology
In [150], the authors outline a methodology for performing UA and SA
on a systems biology problem, with examples relating to within-host
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modelling of TB dynamics, and we chose to follow this methodology due
to its high relevance to our particular problem. Based one experiments
with a variety of example models, the methodology described there sug-
gests running both PRCC and eFAST analysis tests (as covered in the
previous section) to understand model uncertainty and sensitivity, as
each test measures a different output. Therefore, to perform UA and SA
on our TBMetapopPy model, we implemented Python-based versions of
both of these analyses.
One major issue, particularly with eFAST, is computation time: in order
to fully explore the parameter space, a large number of samples will
be needed, with this number increasing exponentially as the number
of uncertain parameters grows. This is even more of a problem for a
stochastic model: as samples from the same parameter set will generate
different results, multiple repetitions need to be performed and averaged
(as described in [150]) in order to reduce the influence of the aleatory
uncertainty present in any model that contains random-based actions.
6.3.1 Existing software
In order to overcome the issue of high computational costs, we required a
framework that could be run on a compute cluster. As we were unaware
of any existing software that can perform UA and SA, we decided to
develop our own framework, combining existing software to perform
experiments on a cluster with existing software to generate relevant
samples and perform analysis on the model results.
epyc, as previously described in Chapter 3, is a Python software lib-
rary designed to handle experiment creation and running. The Lab class
within epyc takes a series of parameters and possible values for each para-
meter. When an experiment is run in the lab, a parameter space is created
based on the cross-product of all values of all parameters, and each
parameter sample within the created space is sent to the model as the
parameters with which the model is run. This process can be over-ridden,
allowing for different user-defined parameter sampling mechanisms to be
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implemented and create parameter spaces unique to the problem being
researched. Results are saved within an instance of the LabNotebook
class, and from here further analysis can be performed. Furthermore,
epyc contains a subclass of the Lab class, ClusterLab, designed to run
an experiment with multiple parameter samples over a defined compute
cluster. These factors, combined with the fact that TBMetapopPy model is
already an extension of the Lab class, made epyc an ideal starting point
for our UA and SA framework.
The authors of [150] also provide MATLAB code with which to run
PRCC and eFAST analyses6 and we used this as reference guide. In
Python, few libraries exist to perform UA and SA, with SALib [109] being
one of the most prominent. This library provides the means to both create
samples and analyse results for a variety of methods, including LHS and
eFAST. The implementation of eFAST present in SALib is similar to that
outlined in [150], but does not include the notion of resampling or of a
dummy parameter. We chose to use the SALib implementation of eFAST,
but amend them to conform with the [150] methodology. We also utilised
the statistical methods of the scipy Python library, as this allowed us to
calculate correlation coefficients and their associated p-values with ease.
6.3.2 Architecture
Our UA and SA framework subclasses two main classes of epyc:
• ClusterLab: to create parameter samples, and run each sample
against the model, with multiple runs being distributed across a
compute cluster.
• JSONLabNotebook: to store results and analyse them.7
Each of these classes was extended for each sensitivity test (PRCC and
eFAST).
6http://malthus.micro.med.umich.edu/lab/usanalysis.html
7JSONLabNotebook is an extension of the LabNotebook class, where results are
persisted within a JSON file. As the model would be run on a compute cluster on
a remote machine, this was chosen in order to avoid any possible data loss during
simulations.
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6.3.3 Aggregating results
epyc allows for multiple repetitions to be run of every parameter sample
created by the Lab instance. However, when recorded to an instance
of the LabNotebook class, these values are stored in their full form
- no aggregation of data across repetition occurs. In order to test for
sensitivities (both PRCC and eFAST) across a stochastic model such
as TBMetapopPy, averaging of results across multiple repetitions was
required. Thus, a new class AggregationNotebook was created, as an
extension of JSONLabNotebook, which contained functions to create a
new data set from the experiment results, whereby results recorded across
multiple repetitions were averaged together. This is then subclassed for
specific sensitivity tests.
6.3.4 PRCC
For PRCC tests, the ClusterLab class was extended to create a new
class of LatinHypercubeLab. Firstly, this class provides a function to
add a parameter with a minimum value, a maximum value and a given
number of stratifications. The parameter is added and the value range
is calculated by dividing the range into the number of stratifications
(based on the defined distribution). The parameterSpace function is
overridden so that, rather than creating a cross-product of all parameter
values, each uncertain parameter has its possible values shuffled (after
a check to ensure all uncertain parameters have the same number of
values/stratifications). Then, the first value is chosen from each shuffled
parameter range and combined with the values for all certain parameters
(those with only one value) to create a sample. Then the second value
is chosen from each, and so on until all values have been chosen. Thus,
the number of samples generated equals the number of stratifications
specified.
In order to analyse results, the AggregationNotebook class is exten-
ded to create the new class of LatinHypercubeJSONNotebook, with
a function calculate_prcc. This function takes a parameter and a
result key, from which a PRCC value and a p-value are created. Firstly,
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the aggregated parameter samples and aggregated results are ranked
(using the pandas package). Then two linear regression models (equations
6.1 and 6.2) are fit (using the sklearn library): one between the parameter
of interest and the remaining parameters, and on between the output
of interest and the remaining parameters. The residuals of these are
calculated, and then a Pearson correlation co-efficient is calculated from
these two sets of residuals (using the pearsonr function of the stats
module of scipy library). This returns two values: a PRCC value of the
correlation and an associated p-value.
6.3.5 eFAST
For PRCC tests, the ClusterLab class was extended to create a new
class of EFASTClusterLab. Similarly to LatinHypercubeLab, each
uncertain parameter is defined with 3 values, one of which specifies
the distribution type (normal/uniform etc.) and the other two to define
the range (minimum and maximum or mean and standard deviation).
The parameterSpace function is also overridden here. In this case, the
uncertain parameters are determined and a new parameter, dummy is
also added8. A frequency list (of length K + 1, K = number of uncertain
parameters) is created, with the first value being the ωi value defined in
equation 6.4, and the remaining values are calculated as per steps 5 and
6 of the eFAST algorithm (section 6.2.3.2). A numpy array of length NS is
created, ranging from 0 to 2pi.
Each parameter is processed in turn as the parameter of interest, and is
assigned the ωi value, with other parameters assigned values from ω(−i).
Then, for each resample (NR), values between 0 and 1 are constructed
for each parameter using the s array and the frequencies as per equation
6.6. Once these have been calculated (resulting in a k by NSNR sized
matrix), the 0-1 values are converted into values within the ranges of the
parameters (using the scale_samples function from SALib).
8dummy is given a uniform distribution between 0 and 10, but the values are
irrelevant as this parameter should have no bearing on the model result
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Additional parameters are added to the parameter samples generated:
these indicate which parameter is the parameter of interest and which
resample number the sample belongs to and which run number it is
within the resample. By default epyc shuffles the order in which samples
are processed: however, the analysis of eFAST uses a Fourier transform
and thus this requires the data to be ordered. Adding these additional
parameters allows the data to be re-ordered later.
The AggregationNotebook class is extended to create the new class
of EFASTJSONNotebook. M, NR and NS values are set during the run-
ning of experiments, and these are persisted within the JSON file. A
generate_sensitivity_indices function returns values of Si and
STi for each parameter and result combination. This function is adapted
from the eFAST analyze function of SALib, and modified to accommod-
ate the resampling introduced. Firstly, the aggregated data is re-ordered
by parameter of interest, resample and run number (in that order). Then
for each parameter of interest and each resample, the Si and STi are
calculated as per the SALib function. This function returns a dictionary
of parameter and results as keys, with each having a value consisting of
two lists: one for Si values (of length NR) and one for STi values (also
length NR). These values can be averaged to generate values for each
combination of result and parameter.
6.4 Verification
Having developed this framework, it was necessary to run some verific-
ation tests to ensure that the output generated was correct. In order to
do this, we attempted to duplicate some previously published results in
SA. As the methodology present in [150] had been followed to create this
framework, we chose the examples from within this work as a suitable
means of comparison.
The papers defines a predator-prey (Lotka-Volterra) model which tracks
two populations over time, prey (QLV(t)) and predators (PLV(t)), using
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Parameter Mean Standard deviation
αLV 1.5 0.01
βLV 1 0.2
σLV 3 0.2
δLV 1 0.01
Table 6.1: Parameter values used to verify the UA and SA framework.
All parameters are normally distributed.
equations 6.7 and 6.89.
dQLV
dt
= αLVQLV − βLVQLV PLV (6.7)
dPLV
dt
=−σLV PLV + δLVQLV PLV (6.8)
We created a model (an extension of epyc.Experiment) and used the
parameters values in Table 6.1 as the distributions for our framework of
LHS and eFAST.
6.4.1 PRCC verification
Figure 6.2 shows the comparison of results between a) PRCC results
generated from MATLAB code supplied with [150] and b) our UA and
SA framework. It was necessary to use the MATLAB to generate PRCC
values as we believe the paper contains an erratum: parameter αLV is
shown as having a positive correlation (and not being significant), whilst
the actual code provided with the paper gives the opposite result: the
parameter has a negative PRCC value and is significant. The significance
factor is also contrary to the data supplied within the paper: Table 1
states αLV is significant whilst the graph shows it is not. We see that the
PRCC values generated by our code are very close to those generated
from the MATLAB code (see Table 6.2 for results).
6.4.2 EFAST verification
Figure 6.3 shows the comparison of results between our framework (B)
and the results presented in the paper (A). Whilst we see strong agree-
9In order to differentiate the parameters and populations used for verification from
those used for our TB model, we subscript the verification components with LV
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Figure 6.2: Comparison of PRCC results for a Lotka-Volterra model from
a) [150] and b) our UA and SA framework.
Parameter PRCC p value Significant?
αLV -0.14597746 3.564e-6 Yes
βLV 0.544 5.750e-78 Yes
σLV -0.742 1.378e-175 Yes
δLV 0.0516 0.102 No
dummy 0.0175 0.581 No
Table 6.2: Lotka-Volterra model PRCC values of parameters for output Q
at time t=9, with associated p-values (significant when p<0.01).
ment between the two results in terms of the sensitivity indices created
(for both first-order Si and total-order ST), there is some discrepancy with
the standard deviations. The results in [150] have much higher standard
deviations than the range produced through our repetitions for αLV , δLV
and the dummy parameter. The reasons for this are unclear: they may
be due to errors in the published paper or because of the differences
between the random number generator processes used in the original
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Parameter Index Value T-test (p value) Significant?
αLV Si 0.00276 0.897 (p=0.396) No
αLV ST 0.0684 -1.782 (p=0.113) No
βLV Si 0.175 100.865, (p=1.042e-13) Yes
βLV ST 0.630 68.377 (p=2.329e-12) Yes
σLV Si 0.338 30.850, (p=1.325e-09) Yes
σLV ST 0.805 72.932 (p=1.392e-12) Yes
δLV Si 0.00281 0.998 (p=0.348) No
δLV ST 0.0676 -2.003 (p=0.080) No
Table 6.3: Lotka-Volterra model eFAST sensitivity indices of parameters
for output QLV at time t=9, with significance checks of t-tests run between
resamples of each parameter and compared to the dummy variable
(significant when p<0.01).
paper and our Python code. These differences do not affect our signific-
ance checks in comparison to the Marino model: we find βLV and σLV
are significantly different from the dummy parameter for both first- and
total-order indices (i.e. p<0.01) whilst αLV and δLV are not significantly
different for either (i.e. 0.01<=p) (see Table 6.3).
Figure 6.3: Comparison of eFAST results for a Lotka-Volterra model from
a) [150] and b) our UA and SA framework. Error bars indicate 2 standard
deviations above and below the mean.
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6.5 Results
6.5.1 Parameters and outputs
In order to perform a comprehensive analysis of the second iteration
of the TBMetapopPy model, we applied a range and/or distribution to
every network-building parameter and event parameter (see Appendix
B for the full list of parameter values and distributions used). Where
an appropriate value could be derived from the literature or existing
models, we applied a normal distribution using the derived value as the
mean, with a reasonable standard deviation added (e.g. replication rate
standard deviation values were chosen to ensure positive non-zero values
were produced). For values where no existing value could be determined
(i.e. rates and half-saturation values for contact between cells), uniform
distributions were chosen, and given large ranges to allow for a wider
range of possible values.
There exists a large number of possible outputs from the model: at
each time-step, the entire state of the network is output and these values
could be aggregated in great many possible ways to produce summary
statistics. For the purposes of our SA, we examined three outputs, as
listed in Table 6.4. These values vary over time, as the system moves
between different stages of infection. Therefore, we track the SA values
of each parameter and output combination over a time period, chosen as
being day 1 of infection to day 120 (by which time the primary infection
has been contained and a latent infection established).
We chose to only perform sensitivity analyses on the primary and latency
stages of infection: our model of post-primary disease requires one of
the parameters (αT) to be changed during simulation. The sensitivity
analyses we have outlined in this chapter are unable to account for
changing parameter values so would not generate accurate results for a
post-primary stage.
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Output Description
ΩT The total number of bacteria (of all
states) present within the system
ΩN The total number of lesions present
within the system (i.e. patches where
bacteria count > 0, does not include
lesions which have been sterilised)
ΩS The average size of all lesions within
the system (i.e. the average number
of bacteria per patch, includes patches
where the lesion has been sterilised)
Table 6.4: Outputs from TBMetapopPy used for sensitivity analysis
6.5.2 PRCC
As per the recommended methodology published in [150], we began by
first calculating PRCC values for all parameters against all output vari-
ables over the time-span of 120 days. We chose to use 100 stratifications of
the input parameter ranges, and used the average results of 20 repetitions
in order to reduce the contribution of aleatory uncertainty. As noted in
section 6.3.1, the use of parallel computing reduces the computational
time required for running this type of analysis: our simulations were run
upon an 8-core machine.
Figure 6.4: Uncertainty analysis plot of each output over time from each
of the 100 averages (of 20 repetitions) for each parameter sample
We first plotted the results of our three outcomes in order to perform our
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Figure 6.5: Uncertainty analysis summary statistics plot of all outputs
over time from each of the 100 averages (of 20 repetitions) for each
parameter sample.
UA and understand how uncertain our outcomes were. These are shown
in Figure 6.4, which shows the plots of each of the 100 aggregations of 20
repetitions for each parameter sample generated by the LHS method, and
summarised in Figure 6.5, which shows the mean and standard deviation
over time of these outputs.
From these plots, we note that there is a high degree of uncertainty in our
output variables, particularly in the later stages of infection (as seen by
the large errors present for all three outputs in Figure 6.5. From Figure
6.4, we see the effects of aleatory and epistemic uncertainty: changes in
the model parameters can lead to different scenarios in the outcomes
(evidenced by the grouping of results at time t=120.0, particularly for ΩS
and ΩT), while aleatory uncertainty creates minor fluctuations within
these outcomes.
Having established the uncertainty within our model outcomes, we
then generated PRCC values for each parameter and output combination
over the time-scale of the simulations. The full set of plots and significant
sensitivities are presented in Appendix C, and in this section we overview
some of these results.
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6.5.2.1 The influence of environmental parameters
The three environmental parameters, SV , SQ and SG, all exhibit differing
sensitivities upon the outputs (see Figure 6.6). For these variables, an
increases indicates a increase in the heterogeneity within the lung; for
example, a greater SV value results in more ventilation being directed
towards the base of the lung and less towards the apex, and similarly
for SQ and SG. For the number of lesions, the environmental parameters
show little sensitivity, with increased drainage at the base showing a
slight negative PRCC value during the early stage of infection, imply-
ing better movement of immune cells to the lymphatics can reduce the
number of lesions during the primary stage, but this reduces as latency
is established. The sensitivity of the SQ and SV have little impact on the
number of lesions throughout the infection.
After a period of around 30 days, the PRCC values for SQ against
Figure 6.6: Sensitivity plots for environmental parameters within TB-
MetapopPy, plotting the PRCC value of each parameter against one of
the three outputs over time. Grey shaded area shows non-significance
(p<0.01).
both the total number of bacteria and the average lesion size become
significant. This implies that the differential in perfusion across the lung
has little impact on the primary infection, but does impact the conditions
present during latent infection, with a greater differential increasing both
the total bacteria present within the patient and the size of the lesions
they have developed.
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6.5.2.2 The importance of T cells
Figure 6.7 shows a selection of the sensitivities of parameters related
to T cells against the outputs of the model. We note that the model
is highly sensitive to many of these parameters, indicating that T cells
play a very important role in the course of infection. For the number of
lesions, the sensitivities for most parameters remain in the insignificant
range, but for most these values become significant after the primary
stage of infection. T cell activation is very important, with eT having
negative values (as greater rates of activation decrease the number of
lesions) and θeT having negative values (as an increased half-sat reduces
the rate of contact between T cells and APCs). This trend for T cell
activation also occurs for the other two outputs. The speed at which T
cells destroy macrophages and the contact rates allowing this to occur
have high sensitivities for all three outputs, indicating this is an important
process to maintain control over infection. Establishing a sufficient T
cell presence is also an important factor, with T cell replication have a
strongly negative PRCC value, as the proliferation of T cells is necessary
in the model to fight bacterial growth.
6.5.2.3 Bacterial replication
Our PRCC results show contrasting findings for the replication of intra-
cellular and extracellular bacteria on the outputs, as shown in Figure
6.8. Intracellular replication (λI) has a positive PRCC value for all three
outputs during the initial primary infection (albeit with non-significance
for ΩN). This value becomes negative and remains non-significant until
briefly becoming significant for all three outcomes at around 30 days.
This is in contrast to the two extracellular replication rates, which at 60
days are both positive. This suggests there may be some benefit to bac-
teria by growing slower when intracellular, possibly due to slower growth
reducing the rate of cell death of the macrophage, and thus keeping the
bacteria in an environment where they cannot be harmed for a longer
period of time.
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Figure 6.7: Sensitivity plots for T cell related parameters within TBMeta-
popPy, plotting the PRCC value of each parameter against one of the three
outputs over time. Grey shaded area shows non-significance (p<0.01).
Only parameters with sustained significant PRCC values against one
output are displayed.
6.5.2.4 Translocation of macrophages is more important than
translocation of dendritic cells
One perhaps surprising result is that the translocation of macrophages
(τM) had higher PRCC value than translocation of dendritic cells (τD) for
most of the time-frame of infection, as shown in Figure 6.9. τM occurs
at a much lower rate than τD in our model (1e-4 - 1e-1 compared to 0.1 -
1.0 ranges respectively), indicating that this process is an important part
bacterial containment within our model, possibly as the macrophages
carry a larger quantity of bacteria than the dendritic cells, and thus
draining more of them to the lymph nodes and exposing them to activated
T cells faster is a suitable mechanism to improve the fight against the
bacteria proliferation.
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Figure 6.8: Sensitivity plots for bacterial replication parameters within
TBMetapopPy, plotting the PRCC value of each parameter against one of
the three outputs over time. Grey shaded area shows non-significance
(p<0.01).
Figure 6.9: Sensitivity plots for immune cell migration parameters within
TBMetapopPy, plotting the PRCC value of each parameter against one of
the three outputs over time. Grey shaded area shows non-significance
(p<0.01).
6.5.2.5 Parameters affecting different stages
As noted, many parameters within TBMetapopPy change significance over
time, with some of these corresponding to different stages of infection.
Tables C.1, C.2 and C.3 show the effects of all parameters with a significant
PRCC against each outcome, stratified into 10 days periods. We see
that some parameters that are significant during the first 30 days (i.e.
the primary stage of infection) lose significance at later stages. And
conversely, parameters that are insignificant during the early stages
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gain significance later in the simulated time. Examples of this include
the rate of death of naïve T cells (µTN), where increased T cell death
results in great bacterial numbers, but only during the primary infection,
and enhanced recruitment of macrophages to the lymph nodes (βMY),
whereby increased cell recruitment there decreases the average size of
lesions and the total number of bacteria within the model, but only from
day 51 onwards.
6.5.3 eFAST
Whilst PRCC is an effective method of analysing model and parameter
sensitivity for monotonic relationships between input parameters and
model outputs, it is of limited use for cases where a non-monotonic
relationship exists. In these cases of non-monotonic parameter/output
combinations, non-significant PRCC values may be obtained despite
the input parameter having influence on the model output [150]. Com-
plex models with many parameters and many interacting compartment,
such as TBMetapopPy, have a higher probability of introducing such non-
monotonic relationships, and therefore it is advisable to perform further
sensitivity analyses with methods such as eFAST which can handle these
issues.
Whilst the eFAST method has significant utility, this comes at a cost: the
number of simulations required in order to generate the necessary data
is far higher than is needed for PRCC. The PRCC methodology is able to
generate results for all parameters from every simulation, eFAST requires
each parameter to be analysed in turn. The minimum number of runs for
each parameter is 65 [208], and the resampling method requires this to
be multiplied by NR (the resample number). Furthermore, repeated sim-
ulations are needed to alleviate the aleatory uncertainty present within a
stochastic model. The total number of simulations required (C) is shown
in equation 6.9, where Rep is the number of repetitions of the parameter
sample.
C = k ∗ NS ∗ NR ∗ Rep (6.9)
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The computational cost of running eFAST was deemed to be too high for
TBMetapopPy. With k = 40 (number of parameters) and taking NS = 65,
NR = 5 and Rep = 5, this would result in 65,000 simulations - more than
32 times as many simulations as were performed for the PRCC analysis.
6.6 Conclusion
In this chapter, we have explored the role of UA and SA in model de-
velopment, showing that as models become more and more complex,
the risk of uncertainty from a variety of sources increases. In order to
draw any significant conclusions from a model, it is of utmost import-
ance that a modeller understands how uncertainties within the inputs
of the model impact on the outputs of the model. We have described
in detail two methods of performing SA on mechanistic models and
have presented our framework designed to perform these on a model
using parallel computation in order the time cost associated with these
intensive analyses. We have verified our framework by comparing the
results generated by it using an existing, deterministic model against
previously published results for the same model, showing that we can
achieve similar results. The benefit of our framework is the compatibility
with an existing computational experiment control library, epyc, allowing
for the separation of model definition and experiment procedure, mean-
ing any model generated by a user have sensitivity analyses conducted
on a remote, multi-core machine. This is particular important for SA
tests, as fully exploring the possible parameter space involves a great
many simulations, and running these in serial comes with a significantly
large time-cost.
We have used our framework to perform sensitivity analyses on our
TBMetapopPy model, the understand how the uncertainty present in the
total number of bacteria, the number of lesions and the average lesion
size can be attributed to uncertainty in the various parameters of the
model. This is an important process for analysing our model: there exists
a large amount of uncertainty within the parameters of our model, either
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due to known heterogeneity in the natural systems (e.g. the large vari-
ation in macrophage numbers seen in different people [218]) or due to an
incomplete mechanistic knowledge knowledge of the system (e.g. there
are no published values concerning the rate of contact between individual
cells with the body during a TB infection). Before trying to overcome
this uncertainty, possibly through additional laboratory experiments or
clinical trials focusing on these parameters, it is important to know which
of the parameters affects the model outputs most. If a large amount of
variation in the output can be attributed to an uncertain parameter, then
this parameter should be prioritised in terms of further research which
would aim the uncertainty in its value range.
Our results show that environmental attributes do contribute to the
bacterial proliferation during an infection. The differential in perfusion
from the apex to the base in particular has a large effect on both the total
bacteria numbers and the average lesion size. The ventilation differential
was not shown to have a significant effect on bacterial numbers, lesion
numbers or lesion size during latency. This suggests that the apical
localisation is less about oxygen availability and more about immune cell
availability: the reduced perfusion at the apex of the lungs means the
immune presence is weaker there, and thus presents bacteria with a more
sheltered location in which to proliferate.
Furthermore, our results show the set of parameters with significant
PRCC values differs during different stages of infection, lending credence
to the notion that the immunological events that occur during primary
and latency stages of infection are very different [67].
6.6.1 Limitations
The results presented in this chapter provide insight into the factors
that are influential to the progression and scale of an infection within
TBMetapopPy, but they are limited. As discussed, PRCC is incapable of
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determining the sensitivity of an output due to a specific input in the
case where a non-monotonic relationship exists between the variables.
Within the context of a TB infection, it is reasonable to assume such non-
monotonic relationships exist. Consider the case of inflammation: the nat-
ural response of the immune system to infection is to cause inflammation,
usually to restrict the invading pathogen from accessing further areas of
tissue. TB is no exception to this, with inflammation being an important
part of granuloma control [77, 176]. However, inflammation is only useful
to the host when carefully balanced [224]: excessive inflammation can
lead to tissue destruction, and in the case of TB, might cause cavitation
and thus afford bacteria access to highly-oxygenated airways [65]. Thus,
the existence of non-monotonic relationships between host immune re-
sponses and bacterial outcomes necessitates the need of SA techniques
which can handle such scenarios. However, as described in section 6.5.3,
eFAST, a statistical test designed to handle non-monotonicities, comes
at an exponentially greater computational cost. Whilst appropriate for
smaller models of limited parameter numbers, running a complete eFAST
analysis of a highly-parametrised model such as TBMetapopPy comes at
too high a cost in terms of computation time. One solution would be to
run simulations on multi-core machines or utilise cloud computing, but
these are not always available to a modeller.
It is worth noting that what we present in this chapter is the determin-
ation of sensitivities within the model: we do not make the claim that
these are definitively the contributing factors to infection within the real-
world. Rather, they highlight possible avenues of research to explore in a
laboratory setting; by performing SA to understand which parameters
our model is most sensitive to, these parameters can then form the basis
of in vitro and possible in vivo experiments which will help refine the
parameter ranges, thus reducing the uncertainty of the model. This
demonstrates the iterative nature of in silico model development and the
need for collaboration between modellers and experimental scientists.
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In which we discuss the findings of this thesis, detail the contributions, outline
the limitations of our work and suggest possible future work based on this thesis.
7.1 Discussion
In this thesis, we have studied an emerging field within the wider of
TB research: computational mechanistic modelling. Current efforts to
reduce TB treatment duration (and thus improve adherence and reduce
the threat of antibiotic resistance) have been unsuccessful, hampered by
a lack of understanding of the complete set of complex dynamics that oc-
curs during infection, even in spite of the disease having been present in
society since antiquity. This lack of understanding is compounded by the
lack of any animal model that completely mimics the pathophysiology
seen in humans. Computational models offer a solution to this issue: by
using a synthetic human lung, we can replicate the dynamics as seen
in human disease, with recent advancement in computing power and
techniques now allowing us to build more complex models.
In chapter 2, we reviewed the literature on TB infection within humans,
looking at the series of complex interactions between host and pathogen
that lead to a disease with varying stages: from primary infection arising
after initial bacterial deposition, to the establishment of a latent form of
disease whereby the bacteria are contained but are typically not eradic-
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ated, with the host remaining in an asymptomatic and non-contagious
state for years or decades, through to the degradation of containment
leading to the emergence of a post-primary form of disease. In particu-
lar, we noted that the localisations within the lung differ these different
stages, with primary infection typically starting in the lower regions of
the lung, and post-primary disease occurring in the apices of the lung.
As post-primary disease is the stage where the vast amount of disease
transmission occurs, and which makes up the majority of clinical cases,
understanding how and why bacteria move to the apices during a TB
infection is of paramount importance. In particular, creating novel treat-
ments that will be effective against the bacteria requires an understanding
of the environments in which the bacteria reside. It is believed that en-
vironmental heterogeneities such as differentials in oxygen tension and
blood perfusion contribute to creating a micro-environment within the
apex of a lung that benefits bacterial proliferation, but it remains unclear
as to what extent each of these environmental heterogeneities impacts
the disease.
Previously, in silico mechanistic models of TB have focused on modelling
the disease at a microscopic level, typically to investigate the factors that
contribute to the formation, stabilisation and/or degradation of a single
granuloma. This work plays a vital part in improving the understanding
of TB, but comes with a limitation: modelling a TB life-cycle whereby the
breakdown of the initial lesion is the contributing factor of post-primary
disease ignores the evidence that the entry lesion and exit lesion are in
two distinct locations in the lung, implying that some form of bacterial
dissemination must occur, and that the heterogeneity of conditions within
the lung induces bacterial growth at the apex. Prior to this thesis, very
few existing computational models of the disease had examined TB as
it occurs over the whole lung, and of those that had, none had included
these environmental heterogeneity phenomena.
On this basis, we framed our research questions as:
• To what extent can we use computational models of whole organ
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scale to provide insight into the dynamics that occur during TB
infection within the lungs?
• What environmental factors within the lung contribute to the spe-
cific localisations of TB during different stages of the disease?
7.2 Contributions
In order to answer the research questions above, this thesis makes a
number of contributions, which we discuss in greater detail here:
7.2.1 A framework for the creation of networked
metapopulation models which incorporate
environmental heterogeneity
The main premise of our research was to build the first computational
model of TB to incorporate environmental heterogeneity in order to study
its impact on the disease pathophysiology. In chapter 3, we laid the
groundwork for this model by first introducing a modelling framework,
MetapopPy, that allows a modeller to create a networked metapopulation
model that incorporates environmental heterogeneity. This is achieved
by taking a network and attaching environmental attributes to each indi-
vidual node. Then, a series of events can be programmed to occur, some
of which may be dependent on the environmental attributes, thus creat-
ing a heterogeneous system of dynamics whereby the rates of occurrence
of events may differ depending on where in the network they are occur-
ring. This framework removes any responsibility of change propagation
from the user: when a change is made that affects the environment or
population at each patch of the metapopulation, the changes are auto-
matically propagated through to the rate calculations, only requiring the
user to define how event rates should be calculated from a patch. This
framework is abstract in its nature and can be applied to a wide variety of
fields; we demonstrate through our validation, creating epidemic models
of disease using the framework and comparing the results retrieved from
them against previously published results.
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7.2.2 A whole organ model of a pulmonary TB
infection that incorporates the environmental
heterogeneity found within the lung to determine
the role it plays upon disease progression
In chapter 4, we then outlined how this framework was utilised to create
TBMetapopPy, the first TB computational model including environmental
heterogeneity within the lung. A network of patches, representing the
bronchopulmonary segment of the lung and the associated lymph nodes,
was created and the lung patches were assigned environmental variables
corresponding to known differentials in the lung that are believed to
affect to TB. Nodes where connected to indicate the possibilities of bac-
terial and immune cell dissemination. On top of this network, a set of
events simulating the various translocations and interactions of both and
immune cells between each other and the environment, allowing the
differentials in the environment to impact on factors such as immune cell
recruitment and bacterial state change.
Our results showed that the introduction of heterogeneity had profound
impacts on the bacterial loads present during infection, whereby creating
regions within the network of reduced perfusion and increased oxygen
allowed for overall bacterial proliferation at a rate far higher than in
a similar model with a homogeneous environment. In doing so, we
showed that in order to fully appreciate the scale of disease within a host
during TB infection, environmental heterogeneity must be accounted for
in simulation models.
Building on this initial model, we developed a secondary model with a
more granular network, as noted in chapter 5. We devised a space-filling
tree algorithm that creates a branching structure similar to that seen in
the human bronchial tree. This algorithm then formed the basis of our
new network, where each end point of the tree corresponded to a single
division of the total alveolar tissue within the lung. This granular net-
work allowed us to more accurately reflect the differentials of ventilation
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and perfusion as linear scales (and subsequently oxygen tension as an
exponential scale) running across the height of the lung, and we therefore
applied environmental attributes based on the vertical position of each
patch. The events present and the parameters used for the model were
then adjusted to this paradigm.
Our results showed further proof of how environmental heterogeneity
can impact disease progression: with the initial infection in the lower
regions spreading to patches across the lung environment, but at latency
establishing different bacterial loads in different locations. Our findings
show an ideal region of the lung exists, approximately one quarter of
the height of the whole lung from the apex, whereby perfusion is high
enough to permit bacterial dissemination but the environmental condi-
tions lead to establishment of larger lesions than in any other region. We
therefore establish a heterogeneity of lesion size, and show that have
shown that a drop in t-cell recruitment will lead to the lesions at the apex
reaching similar levels to those seen during the primary stage, effectively
establishing a post-primary form of disease.
7.2.3 A software framework to efficiently perform
sensitivity and uncertainty analysis
In chapter 6, we outline the importance of uncertainty and sensitivity
analysis in understanding how uncertainty within the inputs of the model
propagates to create uncertainty in the output, and outline some existing
statistical techniques that have previously been used in published articles
to apportion the output uncertainty to the various uncertain inputs of a
system. This is of particular importance for TB models, where the lack
of a complete mechanistic knowledge and the unavailability of relevant
data to some of the dynamics of infection can lead to large numbers
of uncertain parameters. Only by understanding how this uncertainty
affects the model can we draw any valid conclusions. Performing these
sensitivity analyses requires a wide sample of the parameter space to
be explored, sometimes using a complex algorithm, and thus a large
number of simulations need to be run. Performing these in serial can be
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at best time-consuming and at worst completely unfeasible. Therefore, we
developed a framework, using an existing experiment control library, to
automatically create the parameter samples of two established sensitivity
tests and to distribute these samples across a parallel compute server
to improve performance. We again verified our code against previously
published results.
7.2.4 Insight into biological factors that contribute to
TB progression
We then used this framework to perform sensitivity analyses on our
TBMetapopPy model, in order to determine which of our parameters and
dynamics were contributing to the variety of disease outcomes that were
shown in our results (in terms of lesion size and total bacteria).
Whereas many sources have attributed the apical localisation of TB solely
to the increased oxygen tension at the apices, we have shown that of all
the environmental heterogeneities within our model, it is perfusion that
has the greatest impact on the lesion size. This affects both the oxygen
availability and the immune response throughout the lung.
T cell functions have long been known to be critical in controlling TB
infection [47, 78], and our sensitivity results corroborate this, showing
the importance of T cells in containing infection, with most T cell-related
parameters have a significant PRCC value against our outputs.
Understanding where bacteria reside during infection is critical to the
creation of new treatment regimens, as different drugs have different
efficacies in different locations. Our sensitivity results show that during
latency, it is extracellular replication that has more of an impact on our
disease results than intracellular replication, indicating that the killing of
extracellular bacteria may be of more importance than killing those that
are intracellular.
It is already known that bacteria disseminate across the lung and lymph-
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atics during infection, but the mechanisms by which they do this are
unclear. Macrophage migration to the lymphatics is rarely considered as
a contributing factor, due to the low rate at which it occurs, but our sens-
itivity results indicate that this is a significant factor in disease outcomes,
far more so than the migration of dendritic cells. But our results suggest
that the transfer of macrophages can improve disease outcome, leading
to smaller lesions and less total bacteria, possibly due to the draining of
bacteria away from areas of pathology in the lung and into the lymphatics
where a stronger T cell response can be formed. Our research suggests
that this mechanism should be explored in greater detail, perhaps in a
laboratory setting.
Our findings show not just the factors which affect disease outcomes, but
also the times during infection at which they are significant. If we are able
to determine the complete set of significant parameters during each stage
of infection, we can develop a regimen which specifically targets these
parameters at each stage, focusing on the areas that accelerate bacteria
growth at each point to better reduce the chance of a negative outcome
and thus improve the speed at which bacteria are destroyed.
7.3 Limitations
Systems biology approaches, of the kind utilised throughout this thesis,
aim to replicate the real world and as such they are built upon our current
understanding of the systems, which raises an important question:
Will our models not be inherently flawed from the outset if
our current knowledge is wrong?
Indeed, all models are ‘wrong’: they are abstractions of the real world
designed to help us make sense of it. But this does not preclude them
from being useful, so long as we understand why they are ‘wrong’. This
requires verification and validation: verification ensures that the model
that has been built matches our design specifications (i.e. our current
understand of the disease dynamics) correctly, whilst validation of a
model checks that the model produces results that reflect the real world
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[223]. If our model is well-verified, but we are unable to validate our
model predictions against real-world data, then this suggests that our
current understanding is incorrect. The model can be refined, moving
it away from the currently accepted paradigm and towards one that
better reflects available evidence. The discrepancies between the new
model and the current understanding can then provide the basis for in
vitro and in vivo investigation. In this sense, modelling allows us to gain
insight into disease and treatment dynamics and provides evidence in
support (or in opposition) of our beliefs about disease mechanics. Close
collaboration with experimentalists and trialists is needed for this, as all
model outcomes must be viewed through the lens of clinical disease to
test the plausibility of predictions.
The relative paucity of knowledge regarding the processes of a disease
such as TB presents a challenge when developing mechanistic models:
If we don’t know how the disease develops in the body, how
do we determine realistic parameter values for the model?
All parameters used within a model will be based on biological or clinical
experiments that are inherently variable and can have wide confidence
intervals - it is challenging to understand the impact of different ex-
perimental definitions and methods on the results produced. This can
make reliable parameter values hard to assign and further highlights the
importance of working closely with experimentalist collaborators. In our
model, a wide number of parameters had no existing values we could
derive from the literature, requiring us to estimate possible values and
thus introducing greater uncertainty. One way to mitigate this difficulty
is through sensitivity analysis, as we have demonstrated in Chapter 6.
However, these analyses can be computational intensive, even when
run in parallel, as we showed with regards to running eFAST analyses
to account for non-monotonic relationships. This represent the classic
trade-off encountered when modelling: the model must be complex
enough to represent as much of the dynamics of the real-world system
as needed for the problem being investigated, but not so complex as
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to become impossible to draw any meaningful conclusions from, either
due to extensive computational costs when running simulations or the
introduction of complex interactions between parameters. Our model is
relatively complex and yet does not incorporate many factors that may
play a large role in bacterial dissemination, including local transmission
along the bronchial tree. These events are not particularly relevant to our
investigations, but may need to be included in future work.
Compounding the issue of choosing an appropriate level of model com-
plexity is the fact that, currently, the MetapopPy framework is not efficient
when run on networks with large numbers of nodes and/or events due
to the large number of rate calculations needed, limiting the number of
repetitions permissible and thus retaining aleatory uncertainty. There-
fore, future iterations of the framework should look to improve the data
structures used to store rates and the mechanisms by which changes are
propagated.
The aim of this thesis is not the development of a model that can be
used to predict patient outcomes from novel treatments. Doing so would
require a complete knowledge of the underlying dynamics and, as is
discussed throughout this thesis (particularly in Chapter 2), our current
understanding of TB is not nearly comprehensive enough to permit this.
Instead, the intention of this thesis is to provide insight: to improve
our current understanding by simulating those events that we are un-
certain about, either providing an explanation for currently unexplained
dynamics, or to highlight the direction that further research (either com-
putational or in a laboratory or clinical trial) should progress in.
7.4 Future work
The results presented in this thesis are interesting in their own right, but
are necessarily incomplete due to the limitations listed in this chapter
and in the previous chapters. In this section, we extrapolate possible
future avenues of research which build upon the work presented here.
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7.4.1 Validation of results
We have shown that environmental heterogeneities within the lung cause
an apical localisation of lesions that occur slightly below the extreme
apex. Whilst this agrees with the general consensus of the localisation of
post-primary TB [11, 67, 94, 173], further validation should be performed
to match the results shown here to patient x-rays for untreated TB, to
determine the accuracy of predictions in terms of the exact distance of
the major lesions from the very apex of the lung.
7.4.2 Enhancements to the current TBMetapopPy
Here, we list possible factors that could be incorporated into new itera-
tions of the TBMetapopPy model and further experiments that can be run
using the model.
7.4.2.1 Lung anatomy and morphology
The current network topology used to model the lungs is simplistic: we
have represented the lung as a series of two-dimensional points built
upon a space filling-tree that fills a rectangle. The reality is that the
lungs have a non-uniform shape, with the apex of the lung being much
more rounded and narrower than the wide base of the lung. This could
have significant impact on the pathophysiology of TB: if the apices also
have less space available than the basal regions this could present a
greater challenge to M. tuberculosis bacteria in finding a preferential niche.
Shape is also significantly different between left and right lungs, with
the left lung being smaller to accommodate the heart in that side of the
chest cavity. Incorporating a second lung, with a different topology, and
performing analyses to understand how the differences between lungs
impacts disease will be an important avenue of research.
TB disease obviously occurs in three-dimensions. Our current model
only accounts for two-dimensional environmental changes across the
lung as these are the most common concepts that affect disease in the TB
literature. A three-dimensional model could show interesting dynamics,
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particularly in instances where the lung orientation does not remain
constant (see section 7.4.2.2).
In our model, we have made the assumption that all disease that occurs
within the lung does so at the alveolar tissue. Whilst a useful abstraction,
this may be simplistic, particularly when trying to understand the means
by which bacteria disseminate across the organ. Endobronchial TB (TB
disease of the bronchial tree) is known to occur [215], and it has been
hypothesised that bronchial obstruction can be a crucial factor in the
pathogenesis of cavities in TB [120].
7.4.2.2 Dynamic lung environment
Our lung model contains a single, static lung, but the reality is that no
lung is ever static. Various different factors influence the shape of the
lung at a given time and the environmental heterogeneities that occur
there.
The environmental heterogeneities within our lung model are based
on those exhibited in the human lung due to gravity when the lung is
upright (i.e. the person is stood/sat straight up). But changes in posi-
tion can affect the scale and/or direction of differentials in ventilation,
perfusion and thus also oxygen tension: when lying down in a supine
position, more blood is sent to the entire posterior region of the lung, thus
increasing the blood at (part of) the apices. This may explain the evidence
that bed rest (which would necessarily involve the patient spending more
time lying down) had previously been prescribed as a cure for TB [173].
Exercise and changes in altitude also alter the blood distribution within
the lungs, increasing the blood flow to the apices in order to improve
oxygen exchange when it is most needed [234, 235]. As human beings
are never constantly static (particularly not for the long periods of time a
TB infection takes place), models that display dynamic changes in their
environmental heterogeneities would better reflect the real-world, and
could test the effects of bed rest when combined with pharmacological
treatment.
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7.4.2.3 Between-person heterogeneity
Lung morphology and physiology are affected by a number of factors,
including height and body size [48], and sex [18, 45, 222]. Differences
by sex may be of particular interest to TB researchers, as there has
been shown to be gender differences in responses to treatment: an
analysis of the REMoxTB clinical trial (see section 2.10.3) showed men
with cavitation responded poorer to treatment than women with or
without cavitation [172]. These differentials in disease outcome between
genders may be caused by biological sex differences between male and
female lung morphologies [45, 179], although the causes may also be
socio-economic or cultural [118]. Further experiments using TBMetapopPy
should focus on investigating how differentials between people influence
clinical outcomes in order to determine the patients who will be at greater
risk of relapse.
7.4.2.4 Immune cell enhancements
The interactions that occur between immune cells and bacteria during a
TB infection are many and various, and in order to keep TBMetapopPy
parsimonious we have necessarily had to make restrictions on the number
and type of immune cells we include, but we acknowledge that there
are more complexities to the human immune system that should also be
included in any future iterations of the model.
In TBMetapopPy, we include just two states for T cells: naïve and ac-
tivated. In fact, T cells populations contain a variety of phenotypes. One
major distinction that is not included in the current iteration of the model
is the difference between CD4 (effector) T cells and CD8 (cytotoxic) T cells.
In our model, all activated T cells perform actions of both of these pheno-
types, but in order to get a better understanding of how environmental
differentials impact distinct sub-populations of cells, future iterations
of the model could incorporate this and other distinctions within the
existing model compartments.
The phagocytes we have included with TBMetapopPy are limited to
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macrophages and dendritic cells, based on previousin silico models of
within-host TB dynamics. However, as previously stated, it is known
that neutrophils play a major role in the disease pathology as they are
often the first cells to encounter bacteria [145]. Whilst the roles that
neutrophils play during infection are largely covered by the current pha-
gocytes within the model, separating neutrophils out into a separate
compartment may allow for a more accurate representation of the real
world dynamics, and to better understand cell-to-cell interactions and
the impact the environment has on these, as neutrophils have strong
interactions with macrophages [145].
Whilst classically the role of humoral immunity in TB was thought to
be limited [40], B cells and antibodies have been re-appraised to better
understand how they might influence disease outcomes [1, 146]. TBMeta-
popPy could be a useful tool to model the humoral and cell mediated
immune systems and understand their interactions and how they might
be targeted to improve patient response to disease and treatment.
7.4.2.5 Bacterial heterogeneities
TB exists in a variety of different strains, with some patients being co-
infected with more than one strain [19, 230]. It is reasonable to assume
these strains may behave differently (different replications rates, differen-
tial probability of destruction by immune cells, differential resistance to
antibiotics, etc.), and thus TBMetapopPy could be a useful tool to under-
stand how differences in the mycobacteria affect the pathology over the
whole organ. Another bacterial heterogeneity that could be incorporated
into different compartments of bacteria is that of drug resistance, with
different compartments having differing levels of resistance to certain
drugs (see 7.4.3 for further discussion on the causes and implications of
a model with drug resistance).
7.4.2.6 Impacts of the disease on the lung
Our current iteration of TBMetapopPy has focused on how the environ-
ment impacts the disease, but has not yet investigated the reverse: how
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TB pathology can alter the lung environment. This can occur during
infection in many ways, from obstruction of the bronchi caused by a
pneumonia creating an abundance of foamy macrophages and thus a
dysregulation of the immune response in the region [120], to cavitation,
where large destruction of the bronchial tissue affords bacteria access to
regions of greater oxygenation. In the latter event, this may require a
restructuring of the TBMetapopPy network, where cavitation causes new
patches (which are close-by in physical space but perhaps a long distance
via the bronchial tree) to be connected.
7.4.3 Pharmacology modelling
Understanding how treatment of TB is affected by the environment re-
quires us to understand how the disease exists differently in different
regions within the lung. As such, our model has been confined to study-
ing just an untreated version of TB, but having made such a model,
a logical next step would be to introduce a treatment component to
understand how the heterogeneities of the environment impact the phar-
macology of TB, either by the environment creating different populations
and conditions for bacteria which cause heterogeneities of treatment, or
through the environment directly impacting the way chemotherapy is
delivered to the areas of infection.
All chemotherapy for TB enters the lung through the blood (after having
been digested), and therefore it is reasonable to assume that the deliv-
ery of the drugs to the alveolar tissue is impacted by heterogeneities in
the lung, in particular by the differential in blood perfusion. We have
shown how the apex of the lung is preferential in an untreated case of
TB, by reduced access of immune cells, but the same may also be true
for treatment, with reduced perfusion resulting in levels of drugs that do
not reach the MIC levels necessary to suppress and/or eliminate bacteria.
Therefore, a future iteration of our model could investigate if environ-
mental heterogeneities in the lung can lead to inadequate treatment and
possibly even allow for prediction of drug levels that would be sufficient.
It is also possible that differences in the environment may impact of the
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PD of the drugs, with different drugs having different activity depending
the environment which they reach (i.e. the differentials of oxygen and
ventilation, or other heterogeneities know to exist in the lung such as pH,
may alter the effectiveness of each drug), and this could investigated by
our model.
7.4.3.1 Emergence of drug resistance
Exposure to insufficient quantities of drugs can lead to development of
drug resistance in the remaining bacteria that are not destroyed, and this
presents a global danger through the emergence of MDR-TB and XDR-TB.
This could be incorporated into our model, by including drug-susceptible
and drug-resistant compartments of bacteria, and allowing movement
between these based on the exposure levels of bacteria.
7.4.4 Virtual clinical trials
By extending our model to include:
• the ability to create a heterogeneous population of varying lung
environments,
• pharmacological components, including drug activity and differen-
tial treatment regimens and adherences,
then these components combined effectively create a ‘virtual clinical trial’,
whereby a synthetic population of different demographics (representative
of the demographics found in real life) could be created, and possible new
treatment regimens could be created and trialled over this population. If
achieved, this would be a major benefit to the TB research community: the
ability to predict how likely a novel regimen would be to succeed when
put to clinical trial would allow for better prioritisation of many possible
new regimens, reducing the risk of clinical trial failure and saving both
time and money and the hastening our search for an improved, shorter
treatment. Whilst this may be a long way off, we believe the work
presented in this thesis is an important step on the road towards this goal
of a virtual clinical trial.
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7.4.5 Enhancements to the current sensitivity analysis
framework
The scope of the sensitivity analysis framework we presented here was
limited by time and the requirements of the sensitivity analysis required
for the TBMetapopPy model. There are many more advancements that
could be made to this framework to enable users to quickly and conveni-
ently perform their own analyses, without requiring a comprehensive
understanding of the mathematical processes involved in creating the
samples and analysing the results1. The first of these would be to in-
corporate the framework directly into the epyc library: epyc currently
only allows for the creation and running of experiments. Incorporating
our sensitivity analyses into this would make the entire analysis process
seamless, requiring only one library to run everything. Secondly, further
methods of sensitivity analysis should also be included, allowing the
user to run different analyses dependent of the type of simulation they
are investigating.
1This is most evident in eFAST - the processes required to derive the samples
(sampling each parameter at various frequencies including resamples and random
phase shifts), would be difficult for researchers without a mathematical background to
comprehend. Making these processes simpler and only requiring the user to specify
parameters and their ranges would be a significant benefit.
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A. Secondary model parameters
Parameter Description Value Ref
λR BER replication rate 0.814 [26]
λD BED replication rate 0.26 [26]
λI BIM replication rate 0.26 E
σλ Sigmoid for BIM replica-
tion
2.0 [153]
φ Carrying capacity of mac-
rophages
50 [153]
ξ Rate of conversion between
bacterial states
1 E
θξ Half-saturation for con-
version between bacterial
states
1 E
σξ Sigmoid for conversion
between bacterial states
2 E
τBY Rate of translocation of bac-
teria from the lymphatics
to the lung
1e-3 E
θτBY Half-sat of caseum prevent-
ing translocation of bac-
teria from the lymphatics
into the lung
500 E
Table A.1: Bacterial event parameters within TBMetapopPy (E = estimated)
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Parameter Description Value Ref
αD Rate of standard recruit-
ment of DI into the lung
599e4 E
βD Rate of enhanced recruit-
ment of DI into the lung
5000.05 E
θβD Half-saturation value for
enhanced recruitment of
DI into the lung
5500 E
µDI Death rate of DI 0.01 [153]
µDM Death rate of DM 0.3 [153]
γD Rate at which DI encoun-
ters bacteria
0.3 E
θγD Half-saturation value for
contact between DI and
bacteria
5500 E
τD Rate of translocation of DM
from lung to lymphatics
0.55 [154, 202]
Table A.2: Dendritic cell event parameters within TBMetapopPy (E =
estimated)
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Parameter Description Value Ref
αML Rate of standard recruit-
ment of MR into the lung
599e5 [218]
βML Rate of enhanced recruit-
ment of MR into the lung
50000.05 E
θβML Half-saturation value for
enhanced recruitment of
MR into the lung
5e3 E
αMY Rate of standard recruit-
ment of MR into the lymph-
atics
53.465 [154]
βMY Rate of enhanced recruit-
ment of MR into the lymph
750 E
θβMY Half-saturation value for
enhanced recruitment of
MR into the lymph
5500 E
ω Weighting value for
chemokine release by MI
to MA
0.55 E
µMR Death rate of MR 0.01 [153]
µMA Death rate of MA 0.01 [153]
µMI Death rate of MI 0.01 [153]
ψµ Percentage of bacteria
destroyed during natural
death of MI
0 E
ζ Rate of bursting of MI 0.275 [153]
ψζ Percentage of bacteria des-
troyed during bursting of
MI
0 E
τM Rate of translocation of MI
from the lung to the lymph-
atics
0.001 E
Table A.3: Macrophage event parameters within TBMetapopPy (E = estim-
ated)
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Parameter Description Value Ref
eMB Rate of activation of MR by
extracellular bacteria
0.01 E
θeMB Half-saturation for activa-
tion of MR by extracellular
bacteria
5500 E
eMT Rate of activation of MR by
TA
0.3 [153]
θeMT Half-saturation for activa-
tion of MR by TA
5500 E
κM Rate at which TA destroy
MI
1.35 [153]
θκM Half-saturation value for
TA destruction of MI
1e3 E
ψκM Percentage of bacteria des-
troyed when MI is des-
troyed by TA
0.5 E
γR Rate at which MR ingest
bacteria
0.3 [153]
θγR Half-sat for contact
between MR and bacteria
5500 E
η Probability MR becomes in-
fected when ingesting bac-
teria
0.75 E
γA Rate at which MA ingest
bacteria
0.8 E
θγA Half-sat for contact
between MA and bacteria
5500 E
Table A.4: Parameters for events involving macrophages coming into
contact with other cells within TBMetapopPy (E = estimated)
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Parameter Description Value Ref
αT Rate of standard recruit-
ment of TN into the lymph-
atics
1000 [153]
βT Rate of enhanced recruit-
ment of TN into the lymph-
atics
1000 E
θβT Half-saturation value for
enhanced recruitment of
TN into the lymphatics
1e3 E
eT Rate of activation of t-cells 0.4 [153]
θeT Half-saturation value for
activation of t-cells
1e3 E
τT Rate of translocation of t-
cells from lymphatics into
the lung
0.625 [153]
σT Sigmoid for translocation
of t-cells from lymphatics
into the lung
0.25 E
µTN Rate of death for TN 0.102 [153]
µTA Rate of death for TA 0.333 [153]
λT Rate of replication for TA 0.15 E
Table A.5: T-cell event parameters within TBMetapopPy (E = estimated)
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BAppendix BModel parametersfor sensitivityanalysis
Parameter Range Distribution
SV 2.0 (0.1) N
SQ 3.0 (0.1) N
SG 1.0-5.0 U
Table B.1: Environmental parameters within TBMetapopPy for sensitivity
analysis. In Distribution, U = Uniform, N = Normal. For uniform, a
range is given, for normal, mean and standard deviation are given.
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B. Model parameters for sensitivity analysis
Parameter Range Distribution
λR 0.814 (0.03) N
λD 0.256 (0.01) N
λI 0.256 (0.01) N
σλ 2.0 (0.01) N
φ 50 (10) N
ξ 0.01 - 2.0 U
θξ 0.01 - 2.0 U
σξ 1.0 - 3.0 U
τBY 5e-4 - 2e-3 U
θτBY 250 - 750 U
Table B.2: Bacterial event parameters within TBMetapopPy for sensitivity
analysis. In Distribution, U = Uniform, N = Normal. For uniform, a
range is given, for normal, mean and standard deviation are given.
Parameter Range Distribution
αD 599e4 (75e4) N
βD 1e-1 - 1e5 U
θβD 1e3 - 1e4 U
µDI 0.01 (4e-3) N
µDM 0.3 (0.1) N
γD 0.2 - 0.4 U
θγD 1e3 - 1e4 U
τD 0.1 - 1.0 U
Table B.3: Dendritic cell event parameters within TBMetapopPy for sensit-
ivity analysis. In Distribution, U = Uniform, N = Normal. For uniform, a
range is given, for normal, mean and standard deviation are given.
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Parameter Range Distribution
αML 599e5 (75e5) N
αMY 53.465 (3.0) N
βML 1e-1 - 1e5 U
θβML 1 - 1e4 U
βMY 600 - 900 U
θβMY 1e3 - 1e4 U
ω 1e-2 - 1 U
eMB 1e-4 - 0.1 U
θeMB 1e3 - 1e4 U
eMT 0.1 - 0.5 U
θeMT 1e3 - 1e4 U
µMR 0.01 (4e-3) N
µMA 0.01 (4e-3) N
µMI 0.01 (4e-3) N
ζ 0.25 (0.05) N
κM 0.7 - 2 U
θκM 1e1 - 2e3 U
ψκM 0.5 - 1 U
γR 0.3 (0.01) N
θγR 1e3 - 1e4 U
η 0.5 - 1.0 U
γA 0.2 - 1.4 U
θγA 1e3 - 8e3 U
τM 1e-4 - 1e-1 U
Table B.4: Macrophage event parameters within TBMetapopPy for sensit-
ivity analysis. In Distribution, U = Uniform, N = Normal. For uniform, a
range is given, for normal, mean and standard deviation are given.
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B. Model parameters for sensitivity analysis
Parameter Range Distribution
αT 1000 (3) N
βT 900 - 4000 U
θβT 1 - 2e3 U
eT 0.1 - 0.7 U
θeT 10 - 2e3 U
τT 0.3 - 0.95 U
σT 1e-3 - 3 U
λT 1e-3 - 0.3 U
µTN 0.102 (1e-2) N
µTA 0.333 (1e-2) N
Table B.5: T-cell event parameters within TBMetapopPy for sensitivity
analysis. In Distribution, U = Uniform, N = Normal. For uniform, a
range is given, for normal, mean and standard deviation are given.
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Figure C.1: Sensitivity plots for various parameters within TBMetapopPy,
plotting the PRCC value of the parameter against the three outputs over
time. Grey shaded area shows non-significance (p<0.01).
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Figure C.2: Sensitivity plots for various parameters within TBMetapopPy,
plotting the PRCC value of the parameter against the three outputs over
time. Grey shaded area shows non-significance (p<0.01).
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Figure C.3: Sensitivity plots for various parameters within TBMetapopPy,
plotting the PRCC value of the parameter against the three outputs over
time. Grey shaded area shows non-significance (p<0.01).
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Figure C.4: Sensitivity plots for various parameters within TBMetapopPy,
plotting the PRCC value of the parameter against the three outputs over
time. Grey shaded area shows non-significance (p<0.01).
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Figure C.5: Sensitivity plots for various parameters within TBMetapopPy,
plotting the PRCC value of the parameter against the three outputs over
time. Grey shaded area shows non-significance (p<0.01).172
Days after initial infection
1-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 91-100 101-110 111-120
SV -
SQ + + + + + + + + + + +
λR + + + + + + + + + + + +
λD + + + + + + + + +
λI + + - - -
σλ - - - -
φ -
ξ + +
θξ - -
σξ - -
τBY + + +
αD - - - - - - - -
βD + + + + +
θβD -
µDI + +
τD + - - -
αMY + +
βMY - - - - - - -
ω + +
θeMB - - -
θeMT + + + + + + + + + + + +
µMR + +
µMA + +
κM - - - - - - - - - - -
θκM + + + + + + + + + + + +
ψκM +
γR + + +
θγR +
η + + +
γA - - - -
θγA +
τM - - - - - - - - - - - -
βT + + + + + + + + + + +
θβT -
eT - - - - - - - - - - - -
eT + + + + + + + + + + + +
τT - - - - - - - - -
λT - - - - - - - - - - -
µTN + + +
µTA + + + + + +
Table C.1: Parameter effects on average lesion size over the course of
infection. + denotes the parameter has a significant, positive PRCC value
for the lesion size in the 10 day period, whilst - denotes the parameter has
a significant, negative PRCC value for the lesion size. Where no symbol
is present, the PRCC value is non-significant.
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Days after initial infection
1-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 91-100 101-110 111-120
SQ + + + +
SG +/- - -
λR + + + + + + + + + +
λI - -
σλ - -
φ + + + + + + + +
ξ - -
θξ + +
θξ -
λD - + + +
θτBY + -
αD - - - - - - - -
βD + +
θβD + +
µDI - + +
µDM + +
γD +
θγD -
τD +
βML + + +
βMY - - - -
θβMY -
θeMB +
eMT - -
θeMT + + + + + + + + + +
µMR + + + + + + + + +
ζ -
κM - - - - - -
θκM - + + + + + + + + + +
ψκM - - - - -
θγR + + + + + + + +
η +
γA + - - - - - - - - - -
θγA -
τM + - - - - - - - - - - -
αT +
βT - -
θβT -
eT - - - - - - - - - -
θeT + + + + + + + + + + + +
τT - - - - - - - -
σT + + + + + + + + +
λT - - - - - - - - - -
µTN + + + + +
µTA - +
Table C.2: Parameter effects on number of lesions over the course of
infection. + denotes the parameter has a significant, positive PRCC value
for the number of lesions in the 10 day period, - denotes the parameter
has a significant, negative PRCC value for the number of lesions, and +/-
denotes both positive and negative PRCC values exist. Where no symbol
is present, the PRCC value is non-significant.
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Days after initial infection
1-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 91-100 101-110 111-120
SV -
SQ + + + + + + + + + + +
SG +
λR + + + + + + + + + + + +
λD + + + + + + + +
λI + + - - -
σλ - - - - -
φ - + + + + +
ξ + + +
θξ - -
σξ - -
τBY + + + + + +
θτBY - -
αD - - - - - - -
βD + + + + + + +
θβD - -
µDI + + +
µDM - -
τD + - - - - -
αMY + +
βMY - - - - - - - -
θeMB - -
θeMT + + + + + + + + + + + +
µMR + + + + + + + +
µMA + + +
κM - - - - - - - - - - -
θκM + + + + + + + + + + + +
ψκM + -
γR + +
θγR + + + +
η + + +
γA - - - - - - - - - - -
τM - - - - - - - - - - - -
βT + + + + + + + + + +
θβT -
eT - - - - - - - - - - - -
θeT + + + + + + + + + + + +
τT - - - - - - - - -
λT - - - - - - - - - - -
µTN + + + + +
µTA + + + + +
Table C.3: Parameter effects on total number of bacteria over the course of
infection. + denotes the parameter has a significant, positive PRCC value
for the total bacteria numbers in the 10 day period, whilst - denotes the
parameter has a significant, negative PRCC value for the total bacteria
numbers. Where no symbol is present, the PRCC value is non-significant.
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